EP0778821B1 - Ortho-substituted aromatic ether compounds and their use in pharmaceutical compositions for pain relief - Google Patents

Ortho-substituted aromatic ether compounds and their use in pharmaceutical compositions for pain relief Download PDF

Info

Publication number
EP0778821B1
EP0778821B1 EP95929969A EP95929969A EP0778821B1 EP 0778821 B1 EP0778821 B1 EP 0778821B1 EP 95929969 A EP95929969 A EP 95929969A EP 95929969 A EP95929969 A EP 95929969A EP 0778821 B1 EP0778821 B1 EP 0778821B1
Authority
EP
European Patent Office
Prior art keywords
phenethyl
phenoxymethyl
alkyl
formula
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP95929969A
Other languages
German (de)
French (fr)
Other versions
EP0778821A1 (en
Inventor
Gloria Anne Breault
John Oldfield
Howard Tucker
Peter Warner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of EP0778821A1 publication Critical patent/EP0778821A1/en
Application granted granted Critical
Publication of EP0778821B1 publication Critical patent/EP0778821B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/20—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/21—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C205/22—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring having one nitro groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/76—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • C07C45/298—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups with manganese derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/41—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrogenolysis or reduction of carboxylic groups or functional derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
    • C07C45/511—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups
    • C07C45/513—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups the singly bound functional group being an etherified hydroxyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/562—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with nitrogen as the only hetero atom
    • C07C45/565—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with nitrogen as the only hetero atom by reaction with hexamethylene-tetramine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
    • C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/83—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to novel, aromatic compounds and pharmaceutically-acceptable salts thereof which possess useful pharmacological properties. More particularly the compounds of the invention are antagonists of the pain enhancing effects of E-type prostaglandins. The invention also relates to processes for the manufacture of the aromatic compounds and pharmaceutically-acceptable salts thereof; to novel pharmaceutical compositions containing them; and to use of the compounds in pain relief.
  • the compounds of the invention are useful in the treatment of pain such as the pain associated with joint conditions (such as rheumatoid arthritis and osteoarthritis), postoperative pain, post-partum pain, the pain associated with dental conditions (such as dental caries and gingivitis), the pain associated with burns (including sunburn), the treatment of bone disorders (such as osteoporosis, hypercalcaemia of malignancy and Paget's disease), the pain associated with sports injuries and sprains and all other painful conditions in which E-type prostaglandins wholly or in part play a pathophysiological role.
  • pain such as the pain associated with joint conditions (such as rheumatoid arthritis and osteoarthritis), postoperative pain, post-partum pain, the pain associated with dental conditions (such as dental caries and gingivitis), the pain associated with burns (including sunburn), the treatment of bone disorders (such as osteoporosis, hypercalcaemia of malignancy and Paget's disease), the pain associated with sports injuries and spra
  • Non-steroidal anti-inflammatory drugs and opiates are the main classes of drugs in pain relief. However both possess undesireable side effects. NSAIDS are known to cause gastrointestinal irritation and opiates are known to be addictive.
  • the compounds of the invention may also possess anti-inflammatory, anti-pyretic and anti-diarrhoeal properties and be effective in other conditions in which prostaglandin E 2 (PGE 2 ) wholly or in part plays a pathophysiological role.
  • PGE 2 prostaglandin E 2
  • An 8 to 10 membered bicyclic heteroaryl ring system is a bicyclic aryl ring system having from 8 to 10 ring atoms wherein 1, 2, 3, 4 or 5 of the ring atoms are selected from nitrogen, oxygen and sulphur.
  • a 5- or 6-membered heteroaryl ring system is a monocyclic aryl ring system having 5 or 6 ring atoms wherein 1, 2 or 3 ring atoms are selected from nitrogen, oxygen and sulphur.
  • a 5- or 6-membered saturated or partially saturated heterocyclic ring is a ring system having 5 or 6 ring atoms wherein 1, 2 or 3 of the ring atoms are selected from nitrogen, oxygen and sulphur.
  • Particular 8 to 10 membered bicyclic heteroaryl ring systems include benzofuryl, indolizinyl, isoindolyl, indolyl, indazolyl, benzothienyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl and phthalazinyl.
  • Particular 5- or 6-membered heteroaryl rings include pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazolyl, thiadiazolyl, thienyl, furyl and oxazolyl.
  • Particular 5- or 6-membered saturated or partially saturated heterocyclic ring ring systems include pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl and morpholinyl.
  • Particular substituents for ring carbon atoms in A include halo, trifluoromethyl, nitro, hydroxy, amino, C 1-4 alkylamino, diC 1-4 alkylamino, cyano, C 1-6 alkoxy, C 1-6 alkylS(O) p - (p is 0, 1 or 2), phenylS(O) p - (p is 0, 1 or 2), C 1-6 alkyl (optionally substituted by hydroxy, amino, halo, nitro, C 1-4 alkylS(O) p - (p is 0, 1 or 2), C 1-4 alkoxy, phenylS(O) p - (p is 0, 1 or 2) or cyano), carbamoyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-3 alkyl, C 3-7 cycloalkylC 2-3 alkenyl, C 3-7 cycloalky
  • Particular substituents for ring carbon atoms in B include halo, trifluoromethyl, nitro, hydroxy, C 1-6 alkoxy, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-3 alkyl, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, cyano, -S(O)pC 1-6 alkyl (p is 0, 1 or 2), carbamoyl, C 1-4 alkylcarbamoyl and di(C 1-4 alkyl)carbamoyl.
  • Particular substituents for D include halo, trifluoromethyl, nitro, hydroxy, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, cyano, C 1-6 alkoxy, -S(O) p C 1-4 alkyl, -S(O) p phenyl (p is 0, 1 or 2), C 1-4 alkanoyl and C 1-4 alkyl optionally substituted by hydroxy, halo, nitro, cyano or amino.
  • Particular substituents for ring carbon atoms in phenyl, heteroaryl and 5- and 6-membered saturated or partially saturated heterocyclyl groups in R a1 and R b include halo, trifluoromethyl, nitro, hydroxy, amino, C 1-4 alkylamino, diC 1-4 alkylamino, cyano, C 1-6 alkoxy, carboxy, C 1-6 alkylS(O) p - (p is 0, 1 or 2), phenylS(O) p - (p is 0, 1 or 2), C 1-6 alkyl (optionally substituted by hydroxy, amino, halo, nitro, C 1-4 alkylS(O) p - (p is 0, 1 or 2), C 1-4 alkoxy, phenylS(O) p - (p is 0, 1 or 2) or cyano), carbamoyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-7 cycl
  • a ring nitrogen atom in A or B can be substituted without becoming quaternised, it can be unsubstituted or substituted by C 1-4 alkyl.
  • alkyl' when used herein includes straight chain and branched chain substituents for example methyl, ethyl, n-propyl, isopropyl, n-butyl and isobutyl.
  • hydroxyiminoC 1-4 alkyl includes 1-(hydroximino)ethyl and 2-(hydroxyimino)ethyl.
  • Amino acid residues formed from R a and R a1 together with the amide nitrogen to which they are attached and esters thereof include for example radicals of the formula -NH-CH(R c )-COOR d wherein R c is hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, phenylC 1-3 alkyl, 5- or 6-membered heteroaryl or 5- or 6-membered heteroarylC 1-3 alkyl and R d is hydrogen or C 1-6 alkyl, wherein alkyl, alkenyl, alkynyl, phenyl and heteroaryl groups are optionally substituted. Examples of substituents include those mentioned above for ring A; in particular hydroxy.
  • alkenyl or alkynyl group when directly linked to the nitrogen of a primary or secondary amine, the double or triple bond may not be in the 1-position.
  • alkyl groups which are substituted by halo, hydroxy or an amine may not be substituted by these substituents in the 1-position when the alkyl group is directly linked to the nitrogen of a primary or secondary amine.
  • Examples of C 1-6 alkoxycarbonyl are methoxycarbonyl, ethoxycarbonyl and t-butoxycarbonyl; examples of carboxyC 1-3 alkyl are carboxymethyl, 2-carboxyethyl, 1-carboxyethyl and 3-carboxypropyl; examples of C 1-6 alkoxycarbonylC 1-3 alkyl are methoxycarbonylmethyl, ethoxycarbonylmethyl and methoxycarbonylethyl; examples of tetrazolylC 1-3 alkyl are tetrazolylmethyl and 2-tetrazolylethyl; examples of C 1-4 alkoxy are methoxy, ethoxy, propoxy and isopropoxy; examples of C 2-6 alkenyl are vinyl and allyl; examples of C 2-6 alkynyl are ethynyl and propynyl; examples of C 3-7 cycloalkyl are cyclopropyl, cyclobutyl and cyclo
  • A is optionally substituted: phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thienyl, 1,2,3-thiadiazolyl, oxazolyl, naphthyl or of the formula: wherein E is nitrogen or CH, F is nitrogen or CH, G is sulphur or oxygen and I is nitrogen or CH 3 .
  • B is optionally substituted: phenyl, pyridyl, thiazolyl, thienyl, thiadiazolyl, pyrazinyl, pyridazinyl, pyrimidyl, oxazolyl or imidazolyl.
  • D is optionally substituted: thienyl or phenyl.
  • A is optionally substituted: phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thienyl or 1,2,3-thiadiazolyl.
  • B is optionally substituted: phenyl, pyridyl, thiazolyl, thienyl, thiadiazolyl, pyrazinyl, pyridazinyl or pyrimidyl.
  • D is optionally substituted phenyl.
  • A is optionally substituted: phenyl, pyridyl, thienyl or pyrimidyl.
  • B is optionally substituted: pyridyl, phenyl, thiazolyl, thienyl or pyridazinyl.
  • A is optionally substituted: phenyl or thienyl.
  • B is optionally substituted phenyl, thiazolyl or pyridyl.
  • A is optionally substituted phenyl.
  • B is phenyl
  • Preferred optional substituents for ring carbon atoms in A are halo, nitro, trifluoromethyl, cyano, hydroxy, amino, C 1-6 alkoxy, C 1-4 alkanoylamino, C 1-4 alkylS(O)p-, C 1-6 alkyl (optionally substituted by cyano, phenylS(O)p- or C 1-4 alkylS(O)p-), C 1-4 alkanesulphonamido, benzenesulphonamido, C 1-6 alkanoyl, phenyl, C 1-4 alkoxyiminoC 1-4 alkyl and hydroxyiminoC 1-4 alkyl.
  • substituents for ring carbon atoms in A include fluoro, chloro, bromo, nitro, trifluoromethyl, cyano, amino, methoxy, methyl, isopropyl, hexyl, methylthio, benzensulphonyl, phenyl, acetyl, formyl, benzenesulphonamido, hydroxyiminomethyl, 1-(hydroxyimino)ethyl, cyanomethyl and benzensulphonylmethyl.
  • A when A is a 6-membered ring, it is unsubstituted, or substituted in the 4, 5 or 6-position (when the ring is numbered such that the ring carbon bearing the -OCH(R 3 )- group is in the 1-position and the ring carbon bearing the -X-D group is in the 2-position).
  • A is a 6-membered ring
  • A is unsubstituted, or substituted in the 4 or 6-position using the above numbering system.
  • A is a 6-membered ring
  • A is unsubstituted, or substituted in the 4-position using the above numbering system.
  • a preferred optional substituent for ring carbon atoms in B is hydroxy.
  • the aryl group in -X-D is unsubstituted or substituted by one or two substituents.
  • optional substituents for the aryl group in -X-D are selected from halo, nitro, hydroxy, cyano, C 1-4 alkyl, amino, C 1-4 alkoxy and carbamoyl.
  • aryl group in -X-D is unsubstituted.
  • A is unsubstituted or substituted by one or two substituents.
  • B is unsubstituted or substituted by one substituent.
  • R 1 is carboxy, tetrazolyl or of the formula -CONHR a1 or -CONHSO 2 R b .
  • R a is optionally substituted: C 1-6 alkyl, tetrazolyl or pyridylC 1-3 alkyl.
  • R b is C 1-4 alkyl (optionally substituted by hydroxy, nitro, cyano, amino, C 1-4 alkylamino, di-C 1-4 alkylamino, C 1-4 alkanoylamino, C 1-4 alkyl-N-C 1-4 alkanoylamino, carbamoyl, C 1-4 alkylcarbamoyl, di-C 1-4 alkanoylcarbamoyl, halo, C 1-4 alkoxy) or optionally substituted: phenylC 1-3 alkyl, pyridylC 1-3 alkyl, phenyl, thienyl, thiadiazolyl, oxazolyl, isoxazolyl, pyrazolyl or 1,1-dioxidotetrahydrothienyl.
  • R b is C 1-4 alkyl, hydroxyC 1-4 alkyl, C 1-4 alkoxyC 1-4 alkyl, phenyl (optionally substituted by halo, cyano, nitro, carbamoyl, C 1-4 alkylcarbamoyl, di-C 1-4 alkylcarbamoyl, hydroxy, amino, C 1-4 alkanoylamino, N-C 1-4 alkanoyl-N-C 1-4 alkylamino, C 1-4 alkylamino or di-(C 1-4 alkyl)amino), benzyl (optionally substituted by halo, cyano, nitro, carbamoyl, C 1-4 alkylcarbamoyl, di-C 1-4 alkylcarbamoyl, hydroxy, amino, C 1-4 alkanoylamino, N-C 1-4 alkanoyl-N-C 1-4 alkylamino, C 1-4 alkylamino or di-(
  • R 1 is carboxy or tetrazolyl or R 1 is of the formula -CONHR a1 wherein R a1 is tetrazolyl, pyridylC 1-3 alkyl or C 1-6 alkyl (optionally substituted by hydroxy, amino, cyano or C 2-4 alkanoyloxy), or R 1 is of the formula -CONHSO 2 R b wherein R b is C 1-6 alkyl or phenyl (wherein the alkyl and the phenyl group are optionally substituted by hydroxy, halo, cyano, C 1-4 alkyl, nitro, amino, carbamoyl, C 1-4 alkoxy, or C 1-4 alkylS(O)p- (p is 0, 1 or 2)).
  • R 1 is carboxy, tetrazolyl or of the formula -CONHR a wherein R a is tetrazolyl, pyridylmethyl or C 1-6 alkyl (optionally substituted by hydroxy or cyano), or R 1 is of the formula -CONHSO 2 R b wherein R b is C 1-6 alkyl or phenyl (wherein the alkyl and phenyl group are optionally substituted by hydroxy, halo, cyano or C 1-4 alkyl).
  • R 1 is carboxy, carboxyC 1-3 alkyl, tetrazolyl, tetrazolylC 1-3 alkyl, tetronic acid, hydroxamic acid, sulphonic acid, or R 1 is of the formula -CONR a R a1 wherein R a is hydrogen or C 1-6 alkyl and R a1 is hydrogen, C 1-6 alkyl (optionally substituted by halo, hydroxy, nitro, cyano, trifluoromethyl, C 1-4 alkoxy or C 1-4 alkoxycarbonyl), C 2-6 alkenyl, C 2-6 alkynyl, C 1-3 alkyl substituted by a 5- or 6-membered saturated or partially saturated heterocyclic ring, 5- or 6-membered heteroaryl C 1-3 alkyl, 5- or 6-membered saturated or partially saturated heterocyclic ring, or 5- or 6-membered heteroaryl or R 1 is of the formula -CONHSO 2 R b wherein R b
  • X is of the formula -CH 2 -CH 2 -.
  • R 3 is hydrogen or methyl.
  • R 3 is hydrogen.
  • R 4 is hydrogen or methyl.
  • R 4 is hydrogen.
  • a preferred class of compounds is that of the formula (V): wherein R 1 and R 3 are as hereinabove defined, R 6 is hydrogen, halo, trifluoromethyl, nitro, hydroxy, amino, cyano, C 1-6 alkoxy, C 1-6 alkylS(O) p (p is 0, 1 or 2), phenylS(O) p (p is 0, 1 or 2), C 1-6 alkyl (optionally substituted by hydroxy, amino, halo, nitro or cyano), C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-3 alkyl, carbamoyl, C 1-4 alkylcarbamoyl, di(C 1-4 alkyl)carbamoyl, C 2-6 alkenyl C 2-6 alkynyl, C 1-4 alkoxycarbonylamino, C 1-4 alkanoylamino, C 1-4 alkanoyl(N-C 1-4 alkyl)amino, C 1-4
  • the invention includes in its definition of active ingredient any such optically active or racemic form which possesses anti-hyperalgesic properties.
  • the synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form.
  • the pain relieving effects may be evaluated using the standard laboratory techniques referred to hereinafter.
  • An in vivo hydrolysable ester of a compound of the formula (I) containing carboxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid, for example, a pharmaceutically acceptable ester formed with a (1-6C)alcohol such as methanol, ethanol, ethylene glycol, propranol or butanol, or with a phenol or benzyl alcohol such as phenol or benzyl alcohol or a substituted phenol or benzyl alcohol wherein the substituent is, for example, a halo (such as fluoro or chloro), (1-4C)alkyl (such as methyl) or (1-4C)alkoxy (such as methoxy) group.
  • a halo such as fluoro or chloro
  • (1-4C)alkyl such as methyl
  • (1-4C)alkoxy such as methoxy
  • a suitable value for an in vivo hydrolysable amide of a compound of the formula I containing a carboxy group is, for example, a N-(1-6C)alkyl or N,N-di-(1-6C)alkyl amide such as N-methyl, N-ethyl, N-propyl, N,N-dimethyl, N-ethyl-N-methyl or N,N-diethyl amide.
  • a suitable pharmaceutically-acceptable salt of a compound of the formula (I) is, for example, an acid-addition salt of a compound of the formula (I) which is sufficiently basic, for example an acid-addition salt with an inorganic or organic acid such as hydrochloric, hydrobromic, sulphuric, trifluoroacetic, citric or maleic acid; or, for example a salt of a compound of the formula (I) which is sufficiently acidic, for example an alkali or alkaline earth metal salt such as a calcium or magnesium salt, or an ammonium salt, or a salt with an organic base such as methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
  • an acid-addition salt of a compound of the formula (I) which is sufficiently basic for example an acid-addition salt with an inorganic or organic acid such as hydrochloric, hydrobromic, sulphuric, trifluoroacetic, cit
  • the invention provides a process for preparing compounds of the formula (I) or pharmaceutically acceptable salts or in vivo hydrolysable amides or ester thereof, which comprises deprotecting a compound of the formula (VI): wherein R 7 is R 1 or protected R 1 ; and R 3 , X, A, B and D are as hereinabove defined, and any optional substituents are optionally protected and at least one protecting group is present; and thereafter if necessary:
  • Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question, and may be introduced by conventional methods.
  • Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.
  • a suitable protecting group for a hydroxy group is, for example, an arylmethyl group (especially benzyl), a tri-(1-4C)alkylsilyl group (especially trimethylsilyl or tert -butyldimethylsilyl), an aryldi-(1-4C)alkylsilyl group (especially dimethylphenylsilyl), a diaryl-(1-4C)alkylsilyl group (especially tert -butyldiphenylsilyl), a (1-4C)alkyl group (especially methyl), a (2-4C)alkenyl group (especially allyl), a (1-4C)alkoxymethyl group (especially methoxymethyl) or a tetrahydropyranyl group (especially tetrahydroyran-2-yl).
  • an arylmethyl group especially benzyl
  • a tri-(1-4C)alkylsilyl group especially trimethylsilyl or tert -butyldi
  • an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-charcoal.
  • a trialkylsilyl or an aryldialkylsilyl group such as a tert-butyldimethylsilyl or a dimethylphenylsilyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric, phosphoric or trifluoroacetic acid, or with an alkali metal or ammonium fluoride such as sodium fluoride or, preferably, tetrabutylammonium fluoride.
  • a suitable acid such as hydrochloric, sulphuric, phosphoric or trifluoroacetic acid
  • an alkali metal or ammonium fluoride such as sodium fluoride or, preferably, tetrabutylammonium fluoride.
  • an alkyl group may be removed, for example, by treatment with an alkali metal (1-4C)alkylsulphide such as sodium thioethoxide or, for example, by treatment with an alkali metal diarylphosphide such as lithium diphenylphosphide or, for example, by treatment with a boron or aluminium trihalide such as boron tribromide.
  • an alkali metal (1-4C)alkylsulphide such as sodium thioethoxide
  • an alkali metal diarylphosphide such as lithium diphenylphosphide
  • a boron or aluminium trihalide such as boron tribromide.
  • a (1-4C)alkoxymethyl group or tetrahydropyranyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric or trifluoroacetic acid.
  • a suitable protecting group for a hydroxy group is, for example, an acyl group, for example a (2-4C)alkanoyl group (especially acetyl) or an aroyl group (especially benzoyl).
  • the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable protecting group for an amino, imino or alkylamino group is, for example, an acyl group, for example a (2-4C)alkanoyl group (especially acetyl), a (1-4C)alkoxycarbonyl group (especially methoxycarbonyl, ethoxycarbonyl or tert -butoxycarbonyl), an arylmethoxycarbonyl group (especially benzyloxycarbonyl) or an aroyl group (especially benzoyl).
  • the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl, alkoxycarbonyl or aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an acyl group such as a tert -butoxycarbonyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid, and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-charcoal.
  • a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a (1-4C)alkyl group (especially methyl or ethyl) which may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide; or, for example, a tert-butyl group which may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide
  • a tert-butyl group which may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid.
  • the cyano group may be converted into a tetrazole ring by reacting, for example, with ammonium or tin azide in an aprotic solvent such as DMF, in a temperature range of 100°C to 130°C.
  • an aprotic solvent such as DMF
  • Alkoxycarbonyl may be converted into a carboxy group by acid or base hydrolysis.
  • base hydrolysis may be carried out in an organic solvent such as methanol or THF in a temperature range of ambient to 100°C, in the presence of sodium hydroxide or potassium hydroxide.
  • Acid hydrolysis may, for example, be carried out or in neat formic acid or neat trifluoroacetic acid optionally in an organic solvent such as dichloromethane.
  • An alkoxycarbonyl or an activated carboxy group, such as an acid chloride or activated ester, or an acyl group such as an alkanoyl group may be converted to an amide group by reacting with the appropriate amine in an inert solvent such as DMF or dichloromethane, in a temperature range of 0°C to 150°C, preferably around ambient temperature, in the presence of a base such as triethylamine.
  • an inert solvent such as DMF or dichloromethane
  • the compounds of the formula (VII) may be prepared using processes b), c), d) or e) from the appropriate starting materials wherein R 7 is replaced with R 10 .
  • the compounds of the formula (VIII) may be reduced under standard conditions known in the art for the reduction of olefins, for example, catalytic hydrogenation using Raney nickel, platinum metal or its oxide, rhodium, zinc oxide, palladium-on-charcoal or Wilkinson's catalyst [RhCl(Ph 3 P) 3 as the catalyst.
  • Catalyst hydrogenation is conveniently carried out in the temperature range 0°C to 150°C, but preferably at ambient temperature at slightly above atmospheric pressure, unless the double bond is highly substituted in which case higher temperatures and pressure may be required, or Wilkinson's catalyst in which case a temperature of approximately 50°C and pressure of approximately 50 atmospheres are preferable.
  • R 11 -R 13 are independently alkyl or aryl (such as phenyl or substituted phenyl) L 1 is a leaving group and P is a hydroxy protecting group.
  • P, A, D, R 4 and q are as hereinabove defined, and n is 2 or 3 and R 15 is bromo or iodo.
  • A, D, and R 4 are as hereinabove defined and L 11 is a leaving group.
  • the compounds of the formula (XX) may be converted to compounds of the formula (VIII) by removing the hydroxy protecting group thus forming a compound of the formula (XXa), and reacting the compound of the formula (XXa) with a compound of the formula (X) in an ether forming reaction.
  • Suitable conditions in the ether forming step are similar to those described for the reaction between compounds of the formulae (IX) and (X) below.
  • the compounds of the formula (XX) are conveniently prepared by reacting a compound of the formula (XXI) with a compound of the formula (XXII) (Scheme I) under conditions known for the Wittig reaction.
  • a compound of the formula (XXI) with a compound of the formula (XXII) (Scheme I) under conditions known for the Wittig reaction.
  • an inert solvent such as hexane, tetrahydrofuran, or diethyl ether in a temperature range of -78°C to ambient.
  • R 11 , R 12 and R 13 are all the same.
  • R 11 -R 13 are all phenyl.
  • the compounds of the formula (XXII) are rarely isolatable and usually prepared in situ by deprotonating a compound of the formula (XXIII). Deprotonation is usually carried out in an inert solvent such as tetrahydrofruan or diethyl ether, in a temperature range of -78°C to ambient, in the presence of a strong base.
  • strong bases are lithium hexamethyldisilylamide (LiHMS), CH 3 SOCH 2 - Na + and butyl lithium.
  • a compound of the formula (XXIII) may be prepared by reacting a compound of the formula (XXIV) with a compound of the formula (XXV) (scheme I).
  • Suitable values for L 1 include halogen, such as chloro, bromo or iodo.
  • an inert solvent such as acetonitrile, diethyl ether, tetrahydrofuran or toluene is used and a temperature range of 50°C or 120°C.
  • the Horner-Emmons reaction may be used in which case the compound of the formula (XXIII) is replaced with the appropriate Horner-Emmons reagent.
  • the Horner-Emmons reaction is conveniently carried out in an inert solvent such as diethyl ether, THF or toluene, in a temperature range of ambient to 65°C.
  • inert solvent such as diethyl ether, THF or toluene
  • bases which may be used in the deprotonation include sodium hydride, butyl lithium and LiHMS.
  • the compounds of the formula (XXIV) may be known or prepared from another compound of the formula (XXIV) or a compound of the formula (XXVI): wherein R 4 , D, q and optional substituents on D are as hereinabove defined.
  • the compound of the formula (XXVI) may be reduced to a compound of the formula (XXIV), wherein L 1 is hydroxy.
  • a compound of the formula (XXIV) wherein L 1 is hydroxy may then be converted to a compound of the formula (XXIV) wherein L 1 is bromo by, for example, by bromonating with phosphorous tribromide.
  • compounds of the formula (XX) may be formed by reacting a compound of the formula (XXVII) with a compound of the formula (XXVIII) in the presence of acetic anhydride or a Lewis acid such as titanium tetrachloride or zinc chloride.
  • the reaction is conveniently perfomed in an inert solvent such as dichloromethane in a temperature range of ambient to 100°C.
  • Compounds of the formula (XX) may also be prepared by dehydrating a compound of the formula (XXIX) using standard methods known in the art for dehydration. For example with sulphuric or phosphoric acid at an elevated temperature or aluminium oxide at an elevated temperature.
  • Compounds of the formula (XXIX) may be prepared by reacting a compound of the formula (XXX) and a compound of the formula (XXVIII) in a Grignard reaction.
  • the compound of the formula (XXX) may be formed by reacting a compound of the formula (XXXI) with magnesium, in an etherial solvent such as diethyl ether optionally with warming to initiate the reaction.
  • the compound of the formula (XXX) may be reacted, in situ , with the compound of the formula (XXVIII) in a temperature range of -78°C to reflux.
  • compounds of the formula (XXIX) may be prepared by deprotonating a compound of the formula (XXVII) with a base and reacting with a compound of the formula (XXVIII).
  • A is not electron-withdrawing, for example when A is phenyl, a strong base may be necessary, for example tert-butyl lithium.
  • the reaction is conveniently carried out in an etherial solvent such as tetrahydrofuran or diethyl ether or, depending on the nature of the base, hexane, in a temperature range of -78°C to ambient.
  • the ether forming reaction between compounds of the formulae (IX) and (X) is typically performed in an inert solvent such as acetone or DMF, in a temperature range of ambient to 60°C, in the presence of a mild base.
  • Suitable values for L include tosylate, mesylate, triflate and halo, for example chloro or bromo.
  • compounds of the formulae (IX) and (X) may, for example, be reacted together in DMF, at ambient temperature in the presence of a base such as potassium carbonate.
  • the Mitsunobu reaction may be used (O. Synthesis, 1981, 1). For example reacting in tetrahydrofuran or toluene in the presence of diethyl azodicarboxylate and triphenylphosphine.
  • the compounds of the formula (IX) and (X) may alternatively be reacted together using a phase transfer system.
  • Compounds of the formula (IX) may be prepared as indicated in Schemes II and III. For example, by removing P from a compound of the formula (IXa). Compounds of the formula (IXa), when n is 2 or 3, may be prepared by reducing a compound of the formula (XX) using standard methods such as those described for the reduction of compounds of the formula (VIII).
  • compounds of the formula (IXa) may be prepared by reducing a compound of the formula (XXXII) using standard methods known for the reduction of alkynes to alkanes, such as catalytic hydrogenation using palladium-on-carbon or Wilkinson's catalyst as the catalyst.
  • Compounds of the formula (XXXII) may be prepared by reacting a compound of the formula (XXXIII) with a compound of the formula (XXXIV), for example in a trialkylamine solvent such as triethylamine or in dimethylformamide (DMF) or in a DMF/trialkylamine mixture, in the presence of a catalyst such as palladium and preferably also in the presence of copper (I) idodide, in a temperature range of ambient to 100°C.
  • a trialkylamine solvent such as triethylamine or in dimethylformamide (DMF) or in a DMF/trialkylamine mixture
  • a catalyst such as palladium and preferably also in the presence of copper (I) idodide, in a temperature range of ambient to 100°C.
  • Compounds of the formula (XXXV) are conveniently prepared by deprotonating a compound of the formula (XXXVII) with a base, such as butyl lithium, and reacting with a compound of the formula (XXXVI).
  • a base such as butyl lithium
  • L 11 is bromo, chloro, tosylate or mesylate. Most commonly L 11 is bromo.
  • the reaction is usually carried out in an etherial solvent such as ether or THF in a temperature range of -78°C to ambient temperature.
  • Compounds of the formula (IX), wherein n is 1, may be prepared by reacting together compounds of the formulae (XXXVIII) and (XXXIX).
  • the compounds of the formulae (XXXVIII) and (XXXIX) are reacted together in the presence of PhB(OH) 2 and trichloroacetic acid (CCl 3 CO 2 H) (or propanoic acid), in an inert hydrocarbon solvent such as toluene, in a temperature range of 60°C to reflux.
  • PhB(OH) 2 and trichloroacetic acid (CCl 3 CO 2 H) (or propanoic acid) in an inert hydrocarbon solvent such as toluene, in a temperature range of 60°C to reflux.
  • the boronic acid complex intermediate thus formed may be isolated and used in the subsequent step without further purification.
  • This intermediate is converted to a compound of the formula (IX) by reacting with aluminium trichloride (AlCl 3 ) and borane- tert -butylamine complex ( tert -butyl NH 2 .BH 3 ) in an inert solvent, for example a chlorinated hydrocarbon such as dichloromethane, in a temperature range of 0°C to reflux.
  • AlCl 3 aluminium trichloride
  • tert -butylamine complex tert -butyl NH 2 .BH 3
  • an inert solvent for example a chlorinated hydrocarbon such as dichloromethane
  • compounds of the formula (IX), wherein n is 1, may be prepared by reducing a compound of the formula (XXXX). Reaction conditions for the reduction of a carbonyl group to methylene are known in the art, for example the Clemmensen and Wolff-Kischner reactions.
  • the compounds of the formula (XXXXI) may be prepared by reacting a compound of the formula (XXXVIII) with a compound of the formula (XXXXII) in the presence of a base such as triethylamine and optionally also in the presence of dimethylaminopyridine (DMAP). Conveniently the reaction is carried out in an etherial solvent such as diethyl ether, in a temperature range of 0°C to 100°C, preferably at ambient temperature.
  • a base such as triethylamine
  • DMAP dimethylaminopyridine
  • reaction between compounds of the formulae (XI) and (XII) is most suitable when A is an 'activated' heterocycle for example when A is pyridine, pyrimidine, pyrazine or pyridazine and in compounds of the formula (XI) the chloro group is in the 2- or 4-position of the pyridine, 2- or 4- position of the pyrimidine, 2-position of the pyrazine and 3-position of the pyridazine ring.
  • Such ring systems being optionally further substituted.
  • compounds of the formulae (XI) and (XII) are reacted together in the presence of a base, such as sodium hydride, potassium tert-butoxide and lithium hexamethyldisilylamide.
  • a base such as sodium hydride, potassium tert-butoxide and lithium hexamethyldisilylamide.
  • the reaction may, for example be carried out in an etherial solvent such as diethyl ether or tetrahydrofuran in a temperature range of 0° to 60°C.
  • Compounds of the formula (XI) may be prepared from compounds of the formula (IX), which in one tautomeric form may contain an oxo group.
  • This oxo group may be converted to a chloro group by reacting the compound of the formula (IX) with a chlorinating agent such as sulphonyl chloride, phosphorous trichloride, phosphorous pentachloride or P(O)Cl 3 .
  • a chlorinating agent such as sulphonyl chloride, phosphorous trichloride, phosphorous pentachloride or P(O)Cl 3 .
  • the reaction is often carried out in the absence of a solvent, although N,N-dimethylaniline may be used if acid-sensitive groups are present. Alternatively an inert organic solvent may be used.
  • Optional substituents may be converted into other optional substituents.
  • an alkylthio group may be oxidised to an alkylsulphinyl or alkysulphonyl group, a nitro group reduced to an amino group, a hydroxy group alkylated to a methoxy group, or a bromo group converted to an alkylthio group.
  • an acyl group or alkyl group may be introduced into an activated benzene ring using Friedel-Crafts reactions, a formyl group by formylation with titanium tetrachloride and dichloromethyl ethyl ether, a nitro group by nitration with concentrated nitric acid concentrated sulphuirc acid and bromination with bromine or tetra(n-butyl)ammonium tribromide.
  • compounds of the formula (I) are antagonists of the pain enhancing effects of E-type prostaglandins and of value in the relief of mild to moderate pain which, for example, accompanies inflammatory conditions such as rheumatoid arthritis and osteoarthritis. Certain properties of the compounds may be demonstrated using the test procedures set out below:-
  • Test (b) No overt toxicity or other untoward effects were noted in Test (b) when compounds of the formula I are administered at several multiples of their minimum inhibitory dose.
  • Prostaglandin receptors and in particular receptors for PGE 2 have been tentatively characterised by Kennedy et al. (Advances in Prostaglandin, Thromboxane and Leukotriene Research, 1983, 11 , 327).
  • the known PGE 2 antagonist SC-19220 blocks the effect of PGE 2 on some tissues such as guinea pig ileum or dog fundus but not on other tissues such as the cat trachea or chick ileum. Those tissues which did possess SC-19220 sensitive mediated effects were said to possess EP 1 receptors. Based on this compounds of the present invention, possessing activity in Test (a), are EP 1 antagonists.
  • a pharmaceutical composition which comprises a compound of the formula (I) or an in-vivo hydrolysable ester thereof or an amide thereof, or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier.
  • the composition may be in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use, for example a cream, ointment, gel, spray or aqueous or oily solution or suspension; for nasal use, for example a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example a suppository or rectal spray; for administration by inhalation, for example as a finely divided powder or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oily solution or suspension.
  • the above compositions may be prepared in a conventional manner using conventional excipients.
  • the amount of active ingredient (that is a compound of the formula (I) or a pharmaceutically-acceptable salt thereof) that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration.
  • a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
  • a compound of the formula (1) or an in-vivo hydrolysable ester or amide or a pharmaceutically-acceptable salt thereof for use in a method of treatment of the animal (including human) body by therapy.
  • a compound of the formula I or an in-vivo hydrolysable ester or amide or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for use in the relief of pain in the animal (including human) body.
  • a compound of the formula (I) is useful in treating the pain which, for example, accompanies inflammatory conditions such as rheumatoid arthritis and osteoarthritis.
  • a daily dose in the range for example, 0.1 mg to 75 mg per kg body weight is received, given if required in divided doses.
  • lower doses will be administered when a parenteral route is employed.
  • a dose in the range for example, 0.05 mg to 30 mg per kg body weight will generally be used.
  • a dose in the range for example, 0.05 mg to 25 mg per kg body weight will be used.
  • the compounds of the formula (I) are primarily of value as therapeutic agents for use in warm-blooded animals (including man), they are also useful whenever it is required to antagonise the effects of PGE 2 at the EP 1 receptor, based on test a). Thus, they are useful as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents.
  • the compounds of the formula I are of value in the treatment of certain inflammatory and non-inflammatory conditions which are currently treated with a cyclooxygenase-inhibitory non-steroidal anti-inflammatory drug (NSAID) such as indomethacin, ketorolac, acetylsalicyclic acid, ibuprofen, sulindac, tolmetin and piroxicam or other analgesics such as paracetamol, tramadol, Codein or in some circumstances morphine.
  • NSAID cyclooxygenase-inhibitory non-steroidal anti-inflammatory drug
  • Co-administration of a compound of the formula I with a NSAID can result in a reduction of the quantity of the latter agent needed to produce a therapeutic effect.
  • a pharmaceutical composition which comprises a compound of the formula (I), or an in-vivo hydrolysable ester or amide or pharmaceutically-acceptable salt thereof, in conjunction or admixture with a cyclooxygenase inhibitory non-steroidal anti-inflammatory agent, and a pharmaceutically-acceptable diluent or carrier.
  • the compounds of the invention may also be used with other anti-inflammatory agents such as an inhibitor of the enzyme 5-lipoxygenase (such as those disclosed in European Patent Applications Nos. 0351194, 0375368, 0375404, 0375452, 037547, 0381375, 0385662, 0385663, 0385679, 0385680).
  • an inhibitor of the enzyme 5-lipoxygenase such as those disclosed in European Patent Applications Nos. 0351194, 0375368, 0375404, 0375452, 037547, 0381375, 0385662, 0385663, 0385679, 0385680).
  • the compounds of the formula (I) may also be used in the treatment of conditions such as rheumatoid arthritis in combination with antiarthritic agents such as gold, methotrexate, steroids and penicillinamine, and in conditions such as osteoarthritis in combination with steroids.
  • antiarthritic agents such as gold, methotrexate, steroids and penicillinamine
  • the compounds of the present invention may also be administered in degradative diseases, for example osteoarthritis, with chondroprotective, anti-degradative and/or reparative agents such as Diacerhein, hyaluronic acid formulations such as Hyalan, Rumalon, Arteparon and glucosamine salts such as Antril.
  • degradative diseases for example osteoarthritis
  • chondroprotective, anti-degradative and/or reparative agents such as Diacerhein, hyaluronic acid formulations such as Hyalan, Rumalon, Arteparon and glucosamine salts such as Antril.
  • compositions of the invention may in addition contain one or more other therapeutic or prophylactic agents known to be of value for the treatment of pain.
  • a known opiate pain-killer such as dextropropoxyphene, dehydrocodeine or codeine
  • an antagonist of other pain or inflammation mediators such as bradykinin, neurokinin and calcitonin gene related peptides (CGRP), or an alpha 2 -adrenoceptor agonist, a GABA B receptor agonist, a calcium channel blocker, a sodium channel blocker, a CCK B receptor antagonist, or an antagonist or modulator of the action of glutamate at the NMDA receptor may usefully also be present in a pharmaceutical composition of the invention.
  • the compounds of the present invention may also be administered in bone diseases such as osteoporosis alone or in combination with calcitonin and bisphosphonates and estrogens.
  • the solid was purified by subjecting to chromatography on silica, eluting with a mixture of methanol and dichloromethane (1:9 v/v) to give 5-[4-(4-bromo-2-(2-phenethyl)phenoxymethyl)phenyl]-1H-tetrazole 1.8 g (78%) m.p. 183-5°C.
  • Triethylamine (0.24 ml) was added to a solution of 4-(6-methoxy-2-(2-phenethyl)phenoxymethyl)benzoic acid (0.6 g) and 2-aminomethylpyridine (0.20 ml) in DMF (20 ml) maintained at 5°C.
  • Diphenylphosphoryl azide (0.37 ml) was added to this mixture and the solution was allowed to warm to ambient temperature and was stirred at this temperature for 16 hours. Water (50 ml) was added to the reaction mixture. This mixture was extracted with ethyl acetate (2 x 50 ml) and the ethyl acetate extracts washed with water (50 ml) and dried (MgSO 4 ).
  • the starting material was prepared as follows:
  • the starting material was prepared as follows:
  • Triethylamine (5 ml) was added to a stirred suspension of 2,4-dihydroxybenzaldehyde (12 g) in dichloromethane (50 ml) at -8°C. To this mixture was added t-butylcarbonyl chloride (4.4 ml) and the mixture was allowed to warm to ambient temperature and was stirred at this temperature for 16 hours. The reaction mixture was washed consecutively with aqueous 1N hydrochloric acid (20 ml), water (20 ml) and saturated aqueous sodium bicarbonate solution (20 ml) and then dried (MgSO 4 ).
  • the 5-(t-butylcarbonyloxy)-2-(2-phenethenyl)phenol was prepared by reaction of 4-(t-butylcarbonyloxy)-2-hydroxybenzaldehyde with benzyltriphenylphosphonium bromide using a similar method to that described in Reference Example 12.
  • the 5-(t-butylcarbonyloxy)-2-(2-phenethyl)phenol was prepared by hydrogenation of 5-(t-butylcarbonyloxy)-2-(2-phenethenyl)phenol as described in Reference Example 8.
  • the 4-[4-bromo-2-(2-phenethyl)benzonitrile used as starting material in Example 5 was prepared by reacting 4-bromo-2-(2-phenethyl)phenol and 4-bromomethylbenzonitrile under similar conditions to those described in Reference Example 1.
  • t-butyl esters used as starting material in Examples 3 and 4 were prepared from the appropriately substituted 2-(2-phenethyl)phenols and t-butyl 4-bromomethylbenzoate (Tilley et al J Med Chem 34 1125-36 (1991)) using a similar method to that described in Reference Example 1.
  • Benzyl 6-bromo-2-(2-phenethyl)phenyl ether (10.57 g, 28.8 mmol) was dissolved in DMF (100 ml). Cuprous cyanide (6.72 g, 75 mmol) was added and the reaction heated to 150°C for 18 hours. The reaction was poured in ethylene diamine (440 ml) and water (1.5 l) and the product was extracted with ethyl acetate (3x). The organic extracts were combined, dried (MgSO 4 ) and evaporated.
  • Tetrabutylammonium tribromide (10.00 g) was added to a solution of 2-(2-phenethyl)phenol (3.77 g) in dichloromethane (140 ml at ambient temperature and the mixture stirred for 2 hours. The reaction mixture was washed consecutively with aqueous sodium thiosulphate solution (2 x 100 ml), water (3 x 100 ml) and brine (100 ml) and then dried (MgSO 4 ).
  • the 2-(2-phenethyl)phenol was prepared according to the route described in the literature JACS, 81 , 2795, (1959).
  • reaction temperature rose to -50°C and was allowed to warm to ambient temperature.
  • the reaction mixture was partitioned between ethyl acetate/dilute aqueous HCl, the organic phase was dried (MgSO 4 ) and evaporated and the residue purified by chromatography (eluant ethyl ether/hexane) to give a 1:1 mixture of 6-bromo and 6-methylthio-2-(2-phenylethyl)phenol. (1.29 g, 98%).
  • reaction was heated at reflux for 3 hours, then allowed to cool to ambient temperature and to stand for 18 hours.
  • the reaction was diluted with toluene (28 ml) and washed with 2M aqueous H 2 SO 4 (27 ml).
  • the organic phase was washed with water until a neutral pH was achieved. After drying (MgSO 4 ) the solution was evaporated and the residue purified by chromatography (eluant: ethyl ether/hexane) to give the title product (3.11 g, 54%).
  • Methyl 4-(4-hydroxymethyl-2-(2-phenethyl)phenoxymethyl)benzoate (0.5 g, 1.33 mmol) was dissolved in pyridine (3 ml), cooled to 0°C (under argon) and treated with PhSSPh (0.87 g, 4 mmol) and tributyl phosphine (0.8 g, 4 mmol). The mixture was allowed to warm to ambient temperature and stirred at ambient temperture overnight. The reaction was partitioned between ethyl ether and water and the etherial layer washed with water (2X), 1N HCl (2X), and brine (1X). The organic phase was dried (MgSO 4 ) and evaporated.
  • Methyl 4-(4-formyl-2-(2-phenethyl)phenoxymethyl)benzoate (0.18 g, 0.48 mMol) was dissolved in ethanol (3 ml) and treated with hydroxylamine hydrochloride (0.040g, 0.57 mMol) and pyridine (0.1 ml). The reaction mixture was refluxed on a steam bath for 3 hours, then allowed to cool to ambient temperature. The resulting precipitate was dissolved in ethyl ether and the organic solution washed with 2N aqueous HCl (2x), water (1x) and brine (1x). The etherial layer was dried (MgSO4) and evaporated to give the title product as white solid (0.19 g, quantitative).

Abstract

PCT No. PCT/GB95/02030 Sec. 371 Date Feb. 21, 1997 Sec. 102(e) Date Feb. 21, 1997 PCT Filed Aug. 29, 1995 PCT Pub. No. WO96/06822 PCT Pub. Date Mar. 7, 1996The invention provides compounds of formula I: wherein A, B, D, X, R1, and R3 have any of the values defined in the specification, as well as N-oxides thereof, S-oxides thereof, pharmaceutically acceptable salts thereof, and in vivo hydrolizable esters and amides thereof, that are useful to relieve pain. The invention also provides pharmaceutical compositions as well as synthetic and therapeutic methods relating to such compounds.

Description

  • This invention relates to novel, aromatic compounds and pharmaceutically-acceptable salts thereof which possess useful pharmacological properties. More particularly the compounds of the invention are antagonists of the pain enhancing effects of E-type prostaglandins. The invention also relates to processes for the manufacture of the aromatic compounds and pharmaceutically-acceptable salts thereof; to novel pharmaceutical compositions containing them; and to use of the compounds in pain relief.
  • The compounds of the invention are useful in the treatment of pain such as the pain associated with joint conditions (such as rheumatoid arthritis and osteoarthritis), postoperative pain, post-partum pain, the pain associated with dental conditions (such as dental caries and gingivitis), the pain associated with burns (including sunburn), the treatment of bone disorders (such as osteoporosis, hypercalcaemia of malignancy and Paget's disease), the pain associated with sports injuries and sprains and all other painful conditions in which E-type prostaglandins wholly or in part play a pathophysiological role.
  • Non-steroidal anti-inflammatory drugs (NSAIDS) and opiates are the main classes of drugs in pain relief. However both possess undesireable side effects. NSAIDS are known to cause gastrointestinal irritation and opiates are known to be addictive.
  • We have now found a class of compounds structurally different to NSAIDS and opiates, and useful in relief of pain.
  • The compounds of the invention may also possess anti-inflammatory, anti-pyretic and anti-diarrhoeal properties and be effective in other conditions in which prostaglandin E2 (PGE2) wholly or in part plays a pathophysiological role.
  • According to the invention there is provided a compound of the formula I;
    Figure 00020001
    wherein:
  • A is an optionally substituted: 8- to 10-membered bicyclic heteroaryl, 5- or 6-membered heteroaryl, naphthyl or phenyl; provided that the -OCH(R3)- and -X- linking groups are positioned in a 1,2 relationship to one another on ring carbon atoms;
  • B is an optionally substituted 5- or 6-membered heteroaryl ring system or optionally substituted phenyl;
  • D is optionally substituted: pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, thienyl, furyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl or phenyl;
  • X is of the formula -(CHR4)n- or -(CHR4)p CR4=CR4(CHR4)q- wherein n is 1 to 3 and p and q are either both 0 or one of p and q is 1 and the other is 0;
  • R1 is positioned on ring B in a 1,3 or 1,4 relationship with the -OCH(R3)- linking group in 6-membered rings and in a 1,3 relationship with the -OCH(R3)- linking group in 5-membered rings and is carboxy, carboxyC1-3alkyl, tetrazolyl, tetrazolylC1-3alkyl, tetronic acid, hydroxamic acid, sulphonic acid, or R1 is of the formula -CONRa Ra1 wherein Ra is hydrogen or C1-6alkyl and Ra1 is hydrogen or optionally substituted; C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl, C3-7cycloalkylC2-6alkenyl, C3-7cycloalkylC2-6alkynyl, C5-7cycloalkenyl, C3-7cycloalkenylC1-6alkyl, C5-7cycloalkenylC2-6alkenyl, C5-7cycloalkenylC2-6alkynyl, C1-3alkyl substituted by a 5- or 6-membered saturated or partially saturated heterocyclic ring, 5- or 6-membered heteroaryl C1-3alkyl, 5- or 6-membered saturated or partially saturated heterocyclic ring, or 5- or 6-membered heteroaryl; or wherein Ra and Ra1 together with the amide nitrogen to which they are attached (NRaRa1) form an amino acid residue or ester thereof; or R1 is of the formula -CONHSO2Rb wherein Rb is optionally substituted: C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl, C3-7cycloalkylC2-6alkenyl, C3-7cycloalkylC2-6alkynyl, C5-7cycloalkenyl, C5-7cycloalkenylC1-6alkyl, C5-7cycloalkenylC2-6alkenyl, C5-7cycloalkenylC2-6alkynyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroarylC1-6alkyl, phenyl, phenylC1-6alkyl, 5- or 6-membered saturated or partially saturated heterocyclyl or 5- or 6-membered saturated or partially saturated heterocyclylC1-6alkyl;
  • R3 is hydrogen or C1-4alkyl;
  • R4 is hydrogen or C1-4alkyl;
    • and N-oxides thereof where chemically possible;
    and S-oxides of sulphur containing rings where chemically possible;
    and pharmaceutically acceptable salts and in vivo hydrolysable esters and amides thereof; excluding 4-(2-benzyl-3-hydroxy-4-formylphenoxymethyl)-3-methoxybenzoic acid and 4-(2-(3-phenylprop-2-en-1-yl)-3-hydroxy-4-formyl phenoxymethyl)-3-methoxybenzoic acid.
  • An 8 to 10 membered bicyclic heteroaryl ring system is a bicyclic aryl ring system having from 8 to 10 ring atoms wherein 1, 2, 3, 4 or 5 of the ring atoms are selected from nitrogen, oxygen and sulphur.
  • A 5- or 6-membered heteroaryl ring system is a monocyclic aryl ring system having 5 or 6 ring atoms wherein 1, 2 or 3 ring atoms are selected from nitrogen, oxygen and sulphur.
  • A 5- or 6-membered saturated or partially saturated heterocyclic ring is a ring system having 5 or 6 ring atoms wherein 1, 2 or 3 of the ring atoms are selected from nitrogen, oxygen and sulphur.
  • Particular 8 to 10 membered bicyclic heteroaryl ring systems include benzofuryl, indolizinyl, isoindolyl, indolyl, indazolyl, benzothienyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl and phthalazinyl.
  • Particular 5- or 6-membered heteroaryl rings include pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazolyl, thiadiazolyl, thienyl, furyl and oxazolyl.
  • Particular 5- or 6-membered saturated or partially saturated heterocyclic ring ring systems include pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl and morpholinyl.
  • Particular substituents for ring carbon atoms in A include halo, trifluoromethyl, nitro, hydroxy, amino, C1-4alkylamino, diC1-4alkylamino, cyano, C1-6alkoxy, C1-6alkylS(O)p- (p is 0, 1 or 2), phenylS(O)p- (p is 0, 1 or 2), C1-6alkyl (optionally substituted by hydroxy, amino, halo, nitro, C1-4alkylS(O)p- (p is 0, 1 or 2), C1-4alkoxy, phenylS(O)p- (p is 0, 1 or 2) or cyano), carbamoyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-3alkyl, C3-7cycloalkylC2-3alkenyl, C3-7cycloalkylC2-3alkynyl, C1-4alkoxycarbonylamino, C1-4alkanoylamino, C1-4alkanoyl(N-C1-4alkyl)amino, C1-4alkanesulphonamido, benzenesulphonamido, aminosulphonyl, C1-4alkylaminosulphonyl, di(C1-4alkyl)aminosulphonyl, C1-4alkoxycarbonyl, C2-4alkanoyloxy, C1-6alkanoyl, formylC1-4alkyl, trifluoroC1-3alkylsulphonyl, hydroxyiminoC1-6alkyl, C1-4alkoxyiminoC1-6alkyl, C1-6 alkylcarbamoylamino, phenyl, C1-4alkylcarbamoyl and di(C1-4alkyl)carbamoyl.
  • Particular substituents for ring carbon atoms in B include halo, trifluoromethyl, nitro, hydroxy, C1-6alkoxy, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-3alkyl, amino, C1-4alkylamino, di(C1-4alkyl)amino, cyano, -S(O)pC1-6alkyl (p is 0, 1 or 2), carbamoyl, C1-4alkylcarbamoyl and di(C1-4alkyl)carbamoyl.
  • Particular substituents for D include halo, trifluoromethyl, nitro, hydroxy, amino, C1-4alkylamino, di(C1-4alkyl)amino, cyano, C1-6alkoxy, -S(O)pC1-4alkyl, -S(O)pphenyl (p is 0, 1 or 2), C1-4alkanoyl and C1-4alkyl optionally substituted by hydroxy, halo, nitro, cyano or amino.
  • Particular substituents for ring carbon atoms in phenyl, heteroaryl and 5- and 6-membered saturated or partially saturated heterocyclyl groups in Ra1 and Rb include halo, trifluoromethyl, nitro, hydroxy, amino, C1-4alkylamino, diC1-4alkylamino, cyano, C1-6alkoxy, carboxy, C1-6alkylS(O)p- (p is 0, 1 or 2), phenylS(O)p- (p is 0, 1 or 2), C1-6alkyl (optionally substituted by hydroxy, amino, halo, nitro, C1-4alkylS(O)p- (p is 0, 1 or 2), C1-4alkoxy, phenylS(O)p- (p is 0, 1 or 2) or cyano), carbamoyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-3alkyl, C3-7cycloalkylC2-3alkenyl C3-7cycloalkylC2-3alkynyl, C1-4alkoxycarbonylamino, C1-4alkanoylamino, C1-4alkanoyl(N-C1-4alkyl)amino, C1-4alkanesulphonamido, benzenesulphonamido, aminosulphonyl, C1-4alkylaminosulphonyl, di(C1-4alkyl)aminosulphonyl, C1-4alkoxycarbonyl, C2-4alkanoyloxy, C1-6alkanoyl, formylC1-4alkyl, trifluoroC1-3alkylsulphonyl, hydroxyiminoC1-6alkyl, C1-4alkoxyiminoC1-6alkyl, C1-6alkylcarbamoylamino, phenyl, C1-4alkylcarbamoyl and di(C1-4alkyl)carbamoyl.
  • Where a ring nitrogen atom in A or B can be substituted without becoming quaternised, it can be unsubstituted or substituted by C1-4alkyl.
  • The term 'alkyl' when used herein includes straight chain and branched chain substituents for example methyl, ethyl, n-propyl, isopropyl, n-butyl and isobutyl. The same convention applies to other radicals, for example hydroxyiminoC1-4alkyl includes 1-(hydroximino)ethyl and 2-(hydroxyimino)ethyl.
  • Amino acid residues formed from Ra and Ra1 together with the amide nitrogen to which they are attached and esters thereof include for example radicals of the formula -NH-CH(Rc)-COORd wherein Rc is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, phenyl, phenylC1-3alkyl, 5- or 6-membered heteroaryl or 5- or 6-membered heteroarylC1-3alkyl and Rd is hydrogen or C1-6alkyl, wherein alkyl, alkenyl, alkynyl, phenyl and heteroaryl groups are optionally substituted. Examples of substituents include those mentioned above for ring A; in particular hydroxy.
  • It will be appreciated that when an alkenyl or alkynyl group is directly linked to the nitrogen of a primary or secondary amine, the double or triple bond may not be in the 1-position. Similarly alkyl groups which are substituted by halo, hydroxy or an amine may not be substituted by these substituents in the 1-position when the alkyl group is directly linked to the nitrogen of a primary or secondary amine.
  • Examples of C1-6alkoxycarbonyl are methoxycarbonyl, ethoxycarbonyl and t-butoxycarbonyl; examples of carboxyC1-3alkyl are carboxymethyl, 2-carboxyethyl, 1-carboxyethyl and 3-carboxypropyl; examples of C1-6alkoxycarbonylC1-3alkyl are methoxycarbonylmethyl, ethoxycarbonylmethyl and methoxycarbonylethyl; examples of tetrazolylC1-3alkyl are tetrazolylmethyl and 2-tetrazolylethyl; examples of C1-4alkoxy are methoxy, ethoxy, propoxy and isopropoxy; examples of C2-6alkenyl are vinyl and allyl; examples of C2-6alkynyl are ethynyl and propynyl; examples of C3-7cycloalkyl are cyclopropyl, cyclobutyl and cyclohexyl; examples of C3-7cycloalkylC1-3alkyl are cyclopropylmethyl and cyclohexylmethyl; examples of C3-7cycloalkylC2-3alkenyl are cyclopropylethenyl and cyclopentylpropenyl; examples of C3-7cycloalkylC2-3alkynyl are cyclopropylethynyl and cyclopentylethynyl; examples of C5-7alkenyl are cyclopentenyl and cyclohexenyl; examples of C5-7cycloalkenylC1-3alkyl are cyclopentenylmethyl and cyclohexenylmethyl; examples of C5-7cycloalkenylC2-3alkenyl are cyclohexenylethenyl and cycloheptenylethenyl; examples of C5-7cycloalkenylC2-3alkynyl are cyclopentenylethynyl and cyclohexenylethynyl; examples of C1-4alkanoyl are formyl, acetyl, propionyl and butyryl; examples of halo are fluoro, chloro, bromo and iodo; examples of C1-4alkylamino are methylamino, ethylamino, propylamino and isopropylamino; examples of di(C1-4alkyl)amino are dimethylamino, diethylamino and ethylmethylamino; examples of -S(O)pC1-4alkyl are methylthio, methylsulphinyl and methylsulphonyl; examples of C1-4alkylcarbamoyl are methylcarbamoyl and ethylcarbamoyl; examples of di(C1-4alkyl)carbamoyl are dimethylcarbamoyl, diethylcarbamoyl and ethylmethylcarbamoyl; examples of C1-6alkyl are methyl, ethyl, propyl and isopropyl; examples of C1-4alkoxycarbonylamino are methoxycarbonylamino and ethoxycarbonylamino; examples of C1-4alkanoylamino are acetamido and propionamido; examples of C1-4alkanoyl(N-C1-4alkyl)amino are N-methylacetamido and N-methylpropionamido; examples of C1-4alkanesulphonamido are methanesulphonamido and ethanesulphonamido; examples of C1-4alkylaminosulphonyl are methylaminosulphonyl and ethylaminosulphonyl; examples of di(C1-4alkyl)aminosulphonyl are dimethylaminosulphonyl, diethylaminosulphonyl and ethylmethylaminosulphonyl; examples of C2-4alkanoyloxy are acetyloxy and propionyloxy; examples of formylC1-4alkyl are formylmethyl and 2-formylethyl; examples of hydroxyiminoC1-6alkyl are hydroxyiminomethyl, 1-(hydroxyimino)ethyl and 2-(hydroxyimino)ethyl and examples of C1-4alkoxyiminoC1-6alkyl are methoxyiminomethyl, ethoxyiminomethyl and 2-(methoxyimino)ethyl.
  • Preferably A is optionally substituted: phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thienyl, 1,2,3-thiadiazolyl, oxazolyl, naphthyl or of the formula:
    Figure 00070001
    wherein E is nitrogen or CH, F is nitrogen or CH, G is sulphur or oxygen and I is nitrogen or CH3.
  • Preferably B is optionally substituted: phenyl, pyridyl, thiazolyl, thienyl, thiadiazolyl, pyrazinyl, pyridazinyl, pyrimidyl, oxazolyl or imidazolyl.
  • Preferably D is optionally substituted: thienyl or phenyl.
  • More preferably A is optionally substituted: phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thienyl or 1,2,3-thiadiazolyl.
  • More preferably B is optionally substituted: phenyl, pyridyl, thiazolyl, thienyl, thiadiazolyl, pyrazinyl, pyridazinyl or pyrimidyl.
  • More preferably D is optionally substituted phenyl.
  • Yet more preferably A is optionally substituted: phenyl, pyridyl, thienyl or pyrimidyl.
  • Yet more preferably B is optionally substituted: pyridyl, phenyl, thiazolyl, thienyl or pyridazinyl.
  • Most preferably A is optionally substituted: phenyl or thienyl.
  • Most preferably B is optionally substituted phenyl, thiazolyl or pyridyl.
  • In particular A is optionally substituted phenyl.
  • In particular B is phenyl.
  • Preferred optional substituents for ring carbon atoms in A, are halo, nitro, trifluoromethyl, cyano, hydroxy, amino, C1-6alkoxy, C1-4alkanoylamino, C1-4alkylS(O)p-, C1-6alkyl (optionally substituted by cyano, phenylS(O)p- or C1-4alkylS(O)p-), C1-4alkanesulphonamido, benzenesulphonamido, C1-6alkanoyl, phenyl, C1-4alkoxyiminoC1-4alkyl and hydroxyiminoC1-4alkyl.
  • More preferably optional substituents for ring carbon atoms in A include fluoro, chloro, bromo, nitro, trifluoromethyl, cyano, amino, methoxy, methyl, isopropyl, hexyl, methylthio, benzensulphonyl, phenyl, acetyl, formyl, benzenesulphonamido, hydroxyiminomethyl, 1-(hydroxyimino)ethyl, cyanomethyl and benzensulphonylmethyl.
  • Preferably, when A is a 6-membered ring, it is unsubstituted, or substituted in the 4, 5 or 6-position (when the ring is numbered such that the ring carbon bearing the -OCH(R3)- group is in the 1-position and the ring carbon bearing the -X-D group is in the 2-position).
  • More preferably, when A is a 6-membered ring, A is unsubstituted, or substituted in the 4 or 6-position using the above numbering system. Most preferably, when A is a 6-membered ring, A is unsubstituted, or substituted in the 4-position using the above numbering system.
  • A preferred optional substituent for ring carbon atoms in B is hydroxy.
  • Preferably the aryl group in -X-D is unsubstituted or substituted by one or two substituents.
  • Preferably, optional substituents for the aryl group in -X-D are selected from halo, nitro, hydroxy, cyano, C1-4alkyl, amino, C1-4alkoxy and carbamoyl.
  • Most preferably the aryl group in -X-D is unsubstituted.
  • Preferably A is unsubstituted or substituted by one or two substituents.
  • Preferably B is unsubstituted or substituted by one substituent.
  • Preferably R1 is carboxy, tetrazolyl or of the formula -CONHRa1 or -CONHSO2Rb.
  • Preferably Ra is optionally substituted: C1-6alkyl, tetrazolyl or pyridylC1-3alkyl.
  • Preferably Rb is C1-4alkyl (optionally substituted by hydroxy, nitro, cyano, amino, C1-4alkylamino, di-C1-4alkylamino, C1-4alkanoylamino, C1-4alkyl-N-C1-4alkanoylamino, carbamoyl, C1-4alkylcarbamoyl, di-C1-4alkanoylcarbamoyl, halo, C1-4alkoxy) or optionally substituted: phenylC1-3alkyl, pyridylC1-3alkyl, phenyl, thienyl, thiadiazolyl, oxazolyl, isoxazolyl, pyrazolyl or 1,1-dioxidotetrahydrothienyl.
  • Most preferably Rb is C1-4alkyl, hydroxyC1-4alkyl, C1-4alkoxyC1-4alkyl, phenyl (optionally substituted by halo, cyano, nitro, carbamoyl, C1-4alkylcarbamoyl, di-C1-4alkylcarbamoyl, hydroxy, amino, C1-4alkanoylamino, N-C1-4alkanoyl-N-C1-4alkylamino, C1-4alkylamino or di-(C1-4alkyl)amino), benzyl (optionally substituted by halo, cyano, nitro, carbamoyl, C1-4alkylcarbamoyl, di-C1-4alkylcarbamoyl, hydroxy, amino, C1-4alkanoylamino, N-C1-4alkanoyl-N-C1-4alkylamino, C1-4alkylamino or di-(C1-4alkyl)amino), thiadiazolyl (optionally substituted by C1-4alkanoylamino, amino, C1-4alkylamino or di-C1-4alkylamino), thienyl (optionally substitued by halo or pyridyl), isoxazolyl (optionally substituted by C1-4alkyl or halo), pyrazolyl (optionally substituted by C1-4alkyl or halo) or 1,1-dioxidotetrahydro-2-thienyl.
  • More preferably R1 is carboxy or tetrazolyl or R1 is of the formula -CONHRa1 wherein Ra1 is tetrazolyl, pyridylC1-3alkyl or C1-6alkyl (optionally substituted by hydroxy, amino, cyano or C2-4alkanoyloxy), or R1 is of the formula -CONHSO2Rb wherein Rb is C1-6alkyl or phenyl (wherein the alkyl and the phenyl group are optionally substituted by hydroxy, halo, cyano, C1-4alkyl, nitro, amino, carbamoyl, C1-4alkoxy, or C1-4alkylS(O)p- (p is 0, 1 or 2)).
  • Most preferably, R1 is carboxy, tetrazolyl or of the formula -CONHRa wherein Ra is tetrazolyl, pyridylmethyl or C1-6alkyl (optionally substituted by hydroxy or cyano), or R1 is of the formula -CONHSO2Rb wherein Rb is C1-6alkyl or phenyl (wherein the alkyl and phenyl group are optionally substituted by hydroxy, halo, cyano or C1-4alkyl).
  • In a particular aspect R1 is carboxy, carboxyC1-3alkyl, tetrazolyl, tetrazolylC1-3alkyl, tetronic acid, hydroxamic acid, sulphonic acid, or R1 is of the formula -CONRa Ra1 wherein Ra is hydrogen or C1-6alkyl and Ra1 is hydrogen, C1-6alkyl (optionally substituted by halo, hydroxy, nitro, cyano, trifluoromethyl, C1-4alkoxy or C1-4alkoxycarbonyl), C2-6alkenyl, C2-6alkynyl, C1-3alkyl substituted by a 5- or 6-membered saturated or partially saturated heterocyclic ring, 5- or 6-membered heteroaryl C1-3alkyl, 5- or 6-membered saturated or partially saturated heterocyclic ring, or 5- or 6-membered heteroaryl or R1 is of the formula -CONHSO2Rb wherein Rb is hydrogen, C1-6alkyl (optionally substituted by halo, hydroxy, nitro, cyano, trifluoromethyl, C1-4alkoxy or C1-4alkoxycarbonyl), C2-6alkenyl, C2-6alkynyl, C1-3alkyl substituted by a 5- or 6-membered saturated or partially saturated heterocyclic ring, 5- or 6-membered heteroarylC1-3alkyl phenylC1-3alkyl, 5- or 6-membered saturated or partially saturated heterocyclic ring, 5- or 6-membered heteroaryl or phenyl;
    wherein any saturated or partially saturated heterocyclic ring or heteroaryl group in Ra1 is optionally substituted by halo, hydroxy, nitro, cyano, trifluoromethyl, C1-4alkoxy or C1-4alkoxycarbonyl and any phenyl, saturated or partially saturated heterocyclic ring and heteroaryl group in Rb is optionally substituted.
  • Preferably X is of the formula -CR4=CR4 or -CH(R4)-CH(R4)-.
  • Most preferably X is of the formula -CH=CH- or -CH2-CH2-.
  • In particular X is of the formula -CH2-CH2-.
  • Preferably R3 is hydrogen or methyl.
  • Most preferably R3 is hydrogen.
  • Preferably R4 is hydrogen or methyl.
  • Most preferably R4 is hydrogen.
  • A preferred class of compounds is that of the formula (V):
    Figure 00120001
    wherein
    R1 and R3 are as hereinabove defined, R6 is hydrogen, halo, trifluoromethyl, nitro, hydroxy, amino, cyano, C1-6alkoxy, C1-6alkylS(O)p (p is 0, 1 or 2), phenylS(O)p (p is 0, 1 or 2), C1-6alkyl (optionally substituted by hydroxy, amino, halo, nitro or cyano), C3-7cycloalkyl, C3-7cycloalkylC1-3alkyl, carbamoyl, C1-4alkylcarbamoyl, di(C1-4alkyl)carbamoyl, C2-6alkenyl C2-6alkynyl, C1-4alkoxycarbonylamino, C1-4alkanoylamino, C1-4alkanoyl(N-C1-4alkyl)amino, C1-4alkanesulphonamido, benzenesulphonamido, aminosulphonyl, C1-4alkylaminosulphonyl, di(C1-4alkyl)aminosulphonyl, C1-4alkoxycarbonyl, C2-4alkanoyloxy, C1-6alkanoyl, formylC1-4alkyl, trifluoroC1-3alkylsulphonyl, hydroxyiminoC1-6alkyl, C1-4alkoxyiminoC1-6alkyl or C1-6alkylcarbamoylamino, X is -(CH2)2- or -CH=CH- and B is phenyl, thiadiazolyl or pyridyl.
  • Particular compounds of the present invention are:
  • 4-[6-bromo-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[5-nitro-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[4-chloro-6-methyl-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[5-bromo-6-cyano-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[5-chloro-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[4-cyanomethyl-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[6-bromo-2-(phenethyl)phenoxymethyl]-2-hydroxybenzoic acid;
  • 4-[5-methyl-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[2-(phenethyl)-6-phenylphenoxymethyl]benzoic acid;
  • 4-[6-amino-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[6-methanethio-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[4-(1-(hydroxyimino)ethyl)-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[4-methyl-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[4-bromo-2-(phenethyl)phenoxymethyl]benzoid acid;
  • 4-[4-methoxy-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[6-cyano-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[6-cyano-4-methyl-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[4-chloro-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[6-benzenesulphonylmethyl-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[4-methanethio-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[5-bromo-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 4-[6-isopropyl-2-(phenethyl)phenoxymethyl]benzoic acid;
  • 5-[4-(2-(phenethyl)-6-phenylphenoxymethyl)phenyl]tetrazole;
  • 5-[4-(4-hydroxy-2-(phenethyl)phenoxymethyl)phenyl]tetrazole;
  • 5-[4-(4-methoxy-2-(phenethyl)phenoxymethyl)phenyl]tetrazole;
  • 5-[4-(2-(phenethyl)phenoxymethyl)phenyl]tetrazole;
  • 5-[4-(4-chloro-2-(phenethyl)phenoxymethyl)phenyl]tetrazole;
  • 5-[4-(4-bromo-2-(phenethyl)phenoxymethyl)phenyl]tetrazole;
  • 5-[4-(6-bromo-2-(phenethyl)phenoxymethyl)phenyl]tetrazole; and
  • 5-[4-(6-isopropyl-2-(phenethyl)phenoxymethyl)phenyl]tetrazole and pharmaceutically acceptable salts and in vivo hydrolysable esters and amides thereof.
  • It is to be understood that, insofar as certain of the compounds of formula (I) defined above may exist in optically active or racemic forms, by virtue of the compounds of the formula (I) containing an asymmetric carbon atom, the invention includes in its definition of active ingredient any such optically active or racemic form which possesses anti-hyperalgesic properties. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Similarly, the pain relieving effects may be evaluated using the standard laboratory techniques referred to hereinafter.
  • An in vivo hydrolysable ester of a compound of the formula (I) containing carboxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid, for example, a pharmaceutically acceptable ester formed with a (1-6C)alcohol such as methanol, ethanol, ethylene glycol, propranol or butanol, or with a phenol or benzyl alcohol such as phenol or benzyl alcohol or a substituted phenol or benzyl alcohol wherein the substituent is, for example, a halo (such as fluoro or chloro), (1-4C)alkyl (such as methyl) or (1-4C)alkoxy (such as methoxy) group.
  • A suitable value for an in vivo hydrolysable amide of a compound of the formula I containing a carboxy group is, for example, a N-(1-6C)alkyl or N,N-di-(1-6C)alkyl amide such as N-methyl, N-ethyl, N-propyl, N,N-dimethyl, N-ethyl-N-methyl or N,N-diethyl amide.
  • A suitable pharmaceutically-acceptable salt of a compound of the formula (I) is, for example, an acid-addition salt of a compound of the formula (I) which is sufficiently basic, for example an acid-addition salt with an inorganic or organic acid such as hydrochloric, hydrobromic, sulphuric, trifluoroacetic, citric or maleic acid; or, for example a salt of a compound of the formula (I) which is sufficiently acidic, for example an alkali or alkaline earth metal salt such as a calcium or magnesium salt, or an ammonium salt, or a salt with an organic base such as methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine. In a further aspect the invention provides a process for preparing compounds of the formula (I) or pharmaceutically acceptable salts or in vivo hydrolysable amides or ester thereof, which comprises deprotecting a compound of the formula (VI):
    Figure 00150001
    wherein R7 is R1 or protected R1; and R3, X, A, B and D are as hereinabove defined, and any optional substituents are optionally protected and at least one protecting group is present; and thereafter if necessary:
  • i) forming a pharmaceutically acceptable salt; and/or
  • ii) forming an in vivo hydrolysable ester or amide;
  • Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question, and may be introduced by conventional methods.
  • Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.
  • A suitable protecting group for a hydroxy group is, for example, an arylmethyl group (especially benzyl), a tri-(1-4C)alkylsilyl group (especially trimethylsilyl or tert-butyldimethylsilyl), an aryldi-(1-4C)alkylsilyl group (especially dimethylphenylsilyl), a diaryl-(1-4C)alkylsilyl group (especially tert-butyldiphenylsilyl), a (1-4C)alkyl group (especially methyl), a (2-4C)alkenyl group (especially allyl), a (1-4C)alkoxymethyl group (especially methoxymethyl) or a tetrahydropyranyl group (especially tetrahydroyran-2-yl). The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-charcoal. Alternatively a trialkylsilyl or an aryldialkylsilyl group such as a tert-butyldimethylsilyl or a dimethylphenylsilyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric, phosphoric or trifluoroacetic acid, or with an alkali metal or ammonium fluoride such as sodium fluoride or, preferably, tetrabutylammonium fluoride. Alternatively an alkyl group may be removed, for example, by treatment with an alkali metal (1-4C)alkylsulphide such as sodium thioethoxide or, for example, by treatment with an alkali metal diarylphosphide such as lithium diphenylphosphide or, for example, by treatment with a boron or aluminium trihalide such as boron tribromide. Alternatively a (1-4C)alkoxymethyl group or tetrahydropyranyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric or trifluoroacetic acid.
  • Alternatively a suitable protecting group for a hydroxy group is, for example, an acyl group, for example a (2-4C)alkanoyl group (especially acetyl) or an aroyl group (especially benzoyl). The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • A suitable protecting group for an amino, imino or alkylamino group is, for example, an acyl group, for example a (2-4C)alkanoyl group (especially acetyl), a (1-4C)alkoxycarbonyl group (especially methoxycarbonyl, ethoxycarbonyl or tert-butoxycarbonyl), an arylmethoxycarbonyl group (especially benzyloxycarbonyl) or an aroyl group (especially benzoyl). The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl, alkoxycarbonyl or aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a tert-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid, and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-charcoal.
  • A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a (1-4C)alkyl group (especially methyl or ethyl) which may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide; or, for example, a tert-butyl group which may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid.
  • In another aspect the compounds of the formula (I) or (VI) may be prepared:
  • a) from a compound of the formula (VII):
    Figure 00170001
    wherein A, B, D, R3 and X are as hereinabove defined and R10 is a precursor of R7;
  • b) when X is -(CHR4)n- and n is 2 or 3, by reducing a compound of the formula (VIII):
    Figure 00170002
    wherein A, B, D, R3, R4, R7, p and q are as hereinabove defined;
  • c) by reacting a compound of the formula (IX) with a compound of the formula (X):
    Figure 00180001
    L-CH(R3)-B-R7 wherein A, B, D, R3, X and R7 are as hereinabove defined and L is a leaving group;
  • d) when A is a activated heteroaryl ring, by reacting a compound of the formula (XI) with a compound of the formula (XII):
    Figure 00180002
    wherein A, B, D, X and R7 are as hereinabove defined;
    • and thereafter if necessary:
    • i) removing any protecting groups;
    • ii) forming a pharmaceutically acceptable salt; and/or
    • iii) forming an in vivo hydrolysable ester or amide;
    Particular values for R10 include cyano, carbamoyl, alkoxycarbonyl, carboxy and activated carboxy groups such as acid chlorides and activated esters.
  • The cyano group may be converted into a tetrazole ring by reacting, for example, with ammonium or tin azide in an aprotic solvent such as DMF, in a temperature range of 100°C to 130°C. For further information on tetrazole synthesis see S.J. Wittenberger and B.J Donner JOC, 1993, 58, 4139-4141; BE Huff et al, Tet. Lett, 1993, 50, 8011-8014; and J.V. Duncia et al, JOC 1991, 56, 2395-2400.
  • Alkoxycarbonyl may be converted into a carboxy group by acid or base hydrolysis. For example, base hydrolysis may be carried out in an organic solvent such as methanol or THF in a temperature range of ambient to 100°C, in the presence of sodium hydroxide or potassium hydroxide.
  • Acid hydrolysis may, for example, be carried out or in neat formic acid or neat trifluoroacetic acid optionally in an organic solvent such as dichloromethane.
  • An alkoxycarbonyl or an activated carboxy group, such as an acid chloride or activated ester, or an acyl group such as an alkanoyl group may be converted to an amide group by reacting with the appropriate amine in an inert solvent such as DMF or dichloromethane, in a temperature range of 0°C to 150°C, preferably around ambient temperature, in the presence of a base such as triethylamine.
  • The compounds of the formula (VII) may be prepared using processes b), c), d) or e) from the appropriate starting materials wherein R7 is replaced with R10.
  • The compounds of the formula (VIII) may be reduced under standard conditions known in the art for the reduction of olefins, for example, catalytic hydrogenation using Raney nickel, platinum metal or its oxide, rhodium, zinc oxide, palladium-on-charcoal or Wilkinson's catalyst [RhCl(Ph3P)3 as the catalyst.
  • Catalyst hydrogenation is conveniently carried out in the temperature range 0°C to 150°C, but preferably at ambient temperature at slightly above atmospheric pressure, unless the double bond is highly substituted in which case higher temperatures and pressure may be required, or Wilkinson's catalyst in which case a temperature of approximately 50°C and pressure of approximately 50 atmospheres are preferable.
    Figure 00200001
    wherein A, D, R4, p and q are as hereinabove defined, R11-R13 are independently alkyl or aryl (such as phenyl or substituted phenyl) L1 is a leaving group and P is a hydroxy protecting group.
    Figure 00210001
    wherein P, A, D, R4 and q are as hereinabove defined, and n is 2 or 3 and R15 is bromo or iodo.
    Figure 00220001
    wherein A, D, and R4 are as hereinabove defined and L11 is a leaving group.
  • The compounds of the formula (XX) may be converted to compounds of the formula (VIII) by removing the hydroxy protecting group thus forming a compound of the formula (XXa), and reacting the compound of the formula (XXa) with a compound of the formula (X) in an ether forming reaction. Suitable conditions in the ether forming step are similar to those described for the reaction between compounds of the formulae (IX) and (X) below.
  • The compounds of the formula (XX) are conveniently prepared by reacting a compound of the formula (XXI) with a compound of the formula (XXII) (Scheme I) under conditions known for the Wittig reaction. For example in an inert solvent such as hexane, tetrahydrofuran, or diethyl ether in a temperature range of -78°C to ambient. Preferably R11, R12 and R13 are all the same. In particular R11-R13 are all phenyl.
  • The compounds of the formula (XXII) are rarely isolatable and usually prepared in situ by deprotonating a compound of the formula (XXIII). Deprotonation is usually carried out in an inert solvent such as tetrahydrofruan or diethyl ether, in a temperature range of -78°C to ambient, in the presence of a strong base. Examples of strong bases are lithium hexamethyldisilylamide (LiHMS), CH3SOCH2 -Na+ and butyl lithium.
  • A compound of the formula (XXIII) may be prepared by reacting a compound of the formula (XXIV) with a compound of the formula (XXV) (scheme I). Suitable values for L1 include halogen, such as chloro, bromo or iodo. Typically an inert solvent such as acetonitrile, diethyl ether, tetrahydrofuran or toluene is used and a temperature range of 50°C or 120°C.
  • Alternatively, the Horner-Emmons reaction may be used in which case the compound of the formula (XXIII) is replaced with the appropriate Horner-Emmons reagent. This can be prepared in an analogous manner to the Wittig reagent from a compound of the formula (XXIV) and a phosphite, for example PhCH2P(=O) (OEt)2.
  • The Horner-Emmons reaction is conveniently carried out in an inert solvent such as diethyl ether, THF or toluene, in a temperature range of ambient to 65°C. Examples of bases which may be used in the deprotonation include sodium hydride, butyl lithium and LiHMS.
  • The compounds of the formula (XXIV) may be known or prepared from another compound of the formula (XXIV) or a compound of the formula (XXVI):
    Figure 00240001
    wherein R4, D, q and optional substituents on D are as hereinabove defined. For example the compound of the formula (XXVI) may be reduced to a compound of the formula (XXIV), wherein L1 is hydroxy. A compound of the formula (XXIV) wherein L1 is hydroxy, may then be converted to a compound of the formula (XXIV) wherein L1 is bromo by, for example, by bromonating with phosphorous tribromide.
  • Alternatively, when p is 0, and in particular when A is a heteroaryl group, compounds of the formula (XX) may be formed by reacting a compound of the formula (XXVII) with a compound of the formula (XXVIII) in the presence of acetic anhydride or a Lewis acid such as titanium tetrachloride or zinc chloride. The reaction is conveniently perfomed in an inert solvent such as dichloromethane in a temperature range of ambient to 100°C.
  • Compounds of the formula (XX) may also be prepared by dehydrating a compound of the formula (XXIX) using standard methods known in the art for dehydration. For example with sulphuric or phosphoric acid at an elevated temperature or aluminium oxide at an elevated temperature.
  • Compounds of the formula (XXIX) may be prepared by reacting a compound of the formula (XXX) and a compound of the formula (XXVIII) in a Grignard reaction. The compound of the formula (XXX) may be formed by reacting a compound of the formula (XXXI) with magnesium, in an etherial solvent such as diethyl ether optionally with warming to initiate the reaction. The compound of the formula (XXX) may be reacted, in situ, with the compound of the formula (XXVIII) in a temperature range of -78°C to reflux.
  • Alternatively compounds of the formula (XXIX) may be prepared by deprotonating a compound of the formula (XXVII) with a base and reacting with a compound of the formula (XXVIII). When A is not electron-withdrawing, for example when A is phenyl, a strong base may be necessary, for example tert-butyl lithium. The reaction is conveniently carried out in an etherial solvent such as tetrahydrofuran or diethyl ether or, depending on the nature of the base, hexane, in a temperature range of -78°C to ambient.
  • The ether forming reaction between compounds of the formulae (IX) and (X) is typically performed in an inert solvent such as acetone or DMF, in a temperature range of ambient to 60°C, in the presence of a mild base. Suitable values for L include tosylate, mesylate, triflate and halo, for example chloro or bromo. When L is bromo, compounds of the formulae (IX) and (X) may, for example, be reacted together in DMF, at ambient temperature in the presence of a base such as potassium carbonate. When L is hydroxy, the Mitsunobu reaction may be used (O. Synthesis, 1981, 1). For example reacting in tetrahydrofuran or toluene in the presence of diethyl azodicarboxylate and triphenylphosphine.
  • The compounds of the formula (IX) and (X) may alternatively be reacted together using a phase transfer system.
  • Compounds of the formula (IX) may be prepared as indicated in Schemes II and III. For example, by removing P from a compound of the formula (IXa). Compounds of the formula (IXa), when n is 2 or 3, may be prepared by reducing a compound of the formula (XX) using standard methods such as those described for the reduction of compounds of the formula (VIII).
  • As an alternative example compounds of the formula (IXa) may be prepared by reducing a compound of the formula (XXXII) using standard methods known for the reduction of alkynes to alkanes, such as catalytic hydrogenation using palladium-on-carbon or Wilkinson's catalyst as the catalyst.
  • Compounds of the formula (XXXII) may be prepared by reacting a compound of the formula (XXXIII) with a compound of the formula (XXXIV), for example in a trialkylamine solvent such as triethylamine or in dimethylformamide (DMF) or in a DMF/trialkylamine mixture, in the presence of a catalyst such as palladium and preferably also in the presence of copper (I) idodide, in a temperature range of ambient to 100°C.
  • Compounds of the formula (IX), wherein n is 3, may be prepared by deprotecting a compound of the formula (IXa) wherein n is 3.
  • Compounds of the formula (IXa), wherein n is 3, may be prepared by reducing a compound of the formula (XXXV) as shown in scheme III. Suitable conditions are as described for the reduction of compounds of the formula (XXXII).
  • Compounds of the formula (XXXV) are conveniently prepared by deprotonating a compound of the formula (XXXVII) with a base, such as butyl lithium, and reacting with a compound of the formula (XXXVI). In particular L11 is bromo, chloro, tosylate or mesylate. Most commonly L11 is bromo. The reaction is usually carried out in an etherial solvent such as ether or THF in a temperature range of -78°C to ambient temperature.
  • Compounds of the formula (IX), wherein n is 1, may be prepared by reacting together compounds of the formulae (XXXVIII) and (XXXIX). The compounds of the formulae (XXXVIII) and (XXXIX) are reacted together in the presence of PhB(OH)2 and trichloroacetic acid (CCl3CO2H) (or propanoic acid), in an inert hydrocarbon solvent such as toluene, in a temperature range of 60°C to reflux. The boronic acid complex intermediate thus formed may be isolated and used in the subsequent step without further purification. This intermediate is converted to a compound of the formula (IX) by reacting with aluminium trichloride (AlCl3) and borane-tert-butylamine complex (tert-butyl NH2.BH3) in an inert solvent, for example a chlorinated hydrocarbon such as dichloromethane, in a temperature range of 0°C to reflux. C.K. Lau, H.W.R. Williams, S. Tardiff, C. Dufresne, J. Scheigtz, P.C. Belanger, Can. J. Chem., 67, 1384 (1989)).
  • Alternatively, compounds of the formula (IX), wherein n is 1, may be prepared by reducing a compound of the formula (XXXX). Reaction conditions for the reduction of a carbonyl group to methylene are known in the art, for example the Clemmensen and Wolff-Kischner reactions.
  • Compounds of the formula (XXXX) are conveniently prepared by the rearrangement of a compound of the formula (XXXXI). The rearrangement is carried out in the presence of aluminium trichloride at elevated temperature, for example 50-150°C, preferably in the absence of solvent.
  • The compounds of the formula (XXXXI) may be prepared by reacting a compound of the formula (XXXVIII) with a compound of the formula (XXXXII) in the presence of a base such as triethylamine and optionally also in the presence of dimethylaminopyridine (DMAP). Conveniently the reaction is carried out in an etherial solvent such as diethyl ether, in a temperature range of 0°C to 100°C, preferably at ambient temperature.
  • The reaction between compounds of the formulae (XI) and (XII) is most suitable when A is an 'activated' heterocycle for example when A is pyridine, pyrimidine, pyrazine or pyridazine and in compounds of the formula (XI) the chloro group is in the 2- or 4-position of the pyridine, 2- or 4- position of the pyrimidine, 2-position of the pyrazine and 3-position of the pyridazine ring. Such ring systems being optionally further substituted.
  • Typically compounds of the formulae (XI) and (XII) are reacted together in the presence of a base, such as sodium hydride, potassium tert-butoxide and lithium hexamethyldisilylamide. The reaction may, for example be carried out in an etherial solvent such as diethyl ether or tetrahydrofuran in a temperature range of 0° to 60°C.
  • Compounds of the formula (XI) may be prepared from compounds of the formula (IX), which in one tautomeric form may contain an oxo group. This oxo group may be converted to a chloro group by reacting the compound of the formula (IX) with a chlorinating agent such as sulphonyl chloride, phosphorous trichloride, phosphorous pentachloride or P(O)Cl3. The reaction is often carried out in the absence of a solvent, although N,N-dimethylaniline may be used if acid-sensitive groups are present. Alternatively an inert organic solvent may be used.
  • The compounds of the formula (X), (XII), (XXI), (XXIV), (XXVII), (XXVIII), (XXXI), (XXXIII), (XXXIV), (XXXVI) and (XXXVIII) are generally known in the art or can be made by methods analogous to or similar to those used in the examples or those known in the art for related compounds.
  • It is also possible to synthesise certain intermediates and even protected compounds using primarly ring synthesis. Here, reference is made to the compendiums 'The Chemistry of Heterocyclic Compounds' E.C. Taylor and A. Weissberger (published by John Wiley and Sons) and 'Comprehensive Heterocyclic Chemistry', A.R Katritzky and C. W Rees (published by Pergamon Press (Elsevier)).
  • Optional substituents may be converted into other optional substituents. For example an alkylthio group may be oxidised to an alkylsulphinyl or alkysulphonyl group, a nitro group reduced to an amino group, a hydroxy group alkylated to a methoxy group, or a bromo group converted to an alkylthio group.
  • Various substituents may be introduced into compounds of the formulae (I) and (III) and intermediates in the preparation of compounds of the formulae (I) and (III), when appropriate, using standard methods known in the art. For example, an acyl group or alkyl group may be introduced into an activated benzene ring using Friedel-Crafts reactions, a formyl group by formylation with titanium tetrachloride and dichloromethyl ethyl ether, a nitro group by nitration with concentrated nitric acid concentrated sulphuirc acid and bromination with bromine or tetra(n-butyl)ammonium tribromide.
  • It will be appreciated that, in certain steps in the reaction sequence to compounds of the formula (I), it will be necessary to protect certain functional groups in intermediates in order to prevent side reactions. Deprotection may be carried out at a convenient stage in the reaction sequence once protection is no longer required.
  • As stated hereinbefore compounds of the formula (I) are antagonists of the pain enhancing effects of E-type prostaglandins and of value in the relief of mild to moderate pain which, for example, accompanies inflammatory conditions such as rheumatoid arthritis and osteoarthritis. Certain properties of the compounds may be demonstrated using the test procedures set out below:-
  • (a) an in-vitro guinea pig ileum assay which assesses the inhibitory properties of a test compound against PGE2-induced contractions of the ileum; ileum was immersed in oxygenated Krebs solution containing indomethacin (4 µg/ml) and atropine (1 µM) and which was maintained at 37°C; the ileum was subject to a tension of 1 g; a control dose response curve for PGE 2 -induced contraction of the ileum was obtained; test compound (dissolved in dimethylsulphoxide) was added to the Krebs solution and a dose response curve for the PGE2-induced contraction of the ileum in the presence of the test compound was obtained; the pA2 value for the test compound was calculated;
  • (b) an in-vivo assay in mice which assesses the inhibitory properties of a test compound against abdominal constriction response induced by the intraperitoneal administration of a noxious agent such as dilute acetic acid or phenylbenzoquinone (hereinafter PBQ) using the procedure disclosed in European Patent Application No. 0218077.
  • Although the pharmacological properties of the compounds of the formula I vary with structural change as expected, in general activity possessed by compounds of the formula I may be demonstrated at the following concentrations or doses in one or more of the above-mentioned Tests (a) and (b):-
  • Test (a):- pA2 > 5.3;
  • Test (b):- ED30 in the range, for example, 0.01-100 mg/kg orally.
  • No overt toxicity or other untoward effects were noted in Test (b) when compounds of the formula I are administered at several multiples of their minimum inhibitory dose.
  • Prostaglandin receptors and in particular receptors for PGE2 have been tentatively characterised by Kennedy et al. (Advances in Prostaglandin, Thromboxane and Leukotriene Research, 1983, 11, 327). The known PGE2 antagonist SC-19220 blocks the effect of PGE2 on some tissues such as guinea pig ileum or dog fundus but not on other tissues such as the cat trachea or chick ileum. Those tissues which did possess SC-19220 sensitive mediated effects were said to possess EP1 receptors. Based on this compounds of the present invention, possessing activity in Test (a), are EP1 antagonists.
  • According to a further feature of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I) or an in-vivo hydrolysable ester thereof or an amide thereof, or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier.
  • The composition may be in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use, for example a cream, ointment, gel, spray or aqueous or oily solution or suspension; for nasal use, for example a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example a suppository or rectal spray; for administration by inhalation, for example as a finely divided powder or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oily solution or suspension. In general the above compositions may be prepared in a conventional manner using conventional excipients.
  • The amount of active ingredient (that is a compound of the formula (I) or a pharmaceutically-acceptable salt thereof) that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.
  • According to a further feature of the invention there is provided a compound of the formula (1) or an in-vivo hydrolysable ester or amide or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of the animal (including human) body by therapy.
  • According to a further feature of the invention there is provided the use of a compound of the formula I, or an in-vivo hydrolysable ester or amide or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for use in the relief of pain in the animal (including human) body.
  • As mentioned above, a compound of the formula (I) is useful in treating the pain which, for example, accompanies inflammatory conditions such as rheumatoid arthritis and osteoarthritis. In using a compound of the formula I for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.1 mg to 75 mg per kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.05 mg to 30 mg per kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.05 mg to 25 mg per kg body weight will be used.
  • Although the compounds of the formula (I) are primarily of value as therapeutic agents for use in warm-blooded animals (including man), they are also useful whenever it is required to antagonise the effects of PGE2 at the EP1 receptor, based on test a). Thus, they are useful as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents.
  • By virtue of their ability to relieve pain, the compounds of the formula I are of value in the treatment of certain inflammatory and non-inflammatory conditions which are currently treated with a cyclooxygenase-inhibitory non-steroidal anti-inflammatory drug (NSAID) such as indomethacin, ketorolac, acetylsalicyclic acid, ibuprofen, sulindac, tolmetin and piroxicam or other analgesics such as paracetamol, tramadol, Codein or in some circumstances morphine. Co-administration of a compound of the formula I with a NSAID can result in a reduction of the quantity of the latter agent needed to produce a therapeutic effect. Thereby the likelihood of adverse side-effects from the NSAID such as gastrointestinal effects are reduced. Thus according to a further feature of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or an in-vivo hydrolysable ester or amide or pharmaceutically-acceptable salt thereof, in conjunction or admixture with a cyclooxygenase inhibitory non-steroidal anti-inflammatory agent, and a pharmaceutically-acceptable diluent or carrier.
  • The compounds of the invention may also be used with other anti-inflammatory agents such as an inhibitor of the enzyme 5-lipoxygenase (such as those disclosed in European Patent Applications Nos. 0351194, 0375368, 0375404, 0375452, 037547, 0381375, 0385662, 0385663, 0385679, 0385680).
  • The compounds of the formula (I) may also be used in the treatment of conditions such as rheumatoid arthritis in combination with antiarthritic agents such as gold, methotrexate, steroids and penicillinamine, and in conditions such as osteoarthritis in combination with steroids.
  • The compounds of the present invention may also be administered in degradative diseases, for example osteoarthritis, with chondroprotective, anti-degradative and/or reparative agents such as Diacerhein, hyaluronic acid formulations such as Hyalan, Rumalon, Arteparon and glucosamine salts such as Antril.
  • The compositions of the invention may in addition contain one or more other therapeutic or prophylactic agents known to be of value for the treatment of pain. Thus for example, a known opiate pain-killer (such as dextropropoxyphene, dehydrocodeine or codeine) or an antagonist of other pain or inflammation mediators, such as bradykinin, neurokinin and calcitonin gene related peptides (CGRP), or an alpha2-adrenoceptor agonist, a GABAB receptor agonist, a calcium channel blocker, a sodium channel blocker, a CCKB receptor antagonist, or an antagonist or modulator of the action of glutamate at the NMDA receptor may usefully also be present in a pharmaceutical composition of the invention.
  • The compounds of the present invention may also be administered in bone diseases such as osteoporosis alone or in combination with calcitonin and bisphosphonates and estrogens.
  • The invention will now be illustrated in the following non-limiting Examples in which, unless otherwise stated:-
  • (i) evaporations were carried out by rotary evaporations in vacuo and work-up procedures were carried out after removal of residual solids by filtration;
  • (ii) yields are given for illustration only and are not necessarily the maximum attainable;
  • (iii) the end-products of the formula I have satisfactory microanalysis and their structures were generally confirmed by NMR and mass spectral techniques;
  • (iv) intermediates were not generally fully characterised and purity was assessed by thin layer chromatographic, infra-red (IR) or NMR analysis;
  • (v) melting points are uncorrected and were determined using a Mettler SP62 automatic melting point apparatus or an oil-bath apparatus; melting points for the end-products of the formula I were determined after recrystallisation from a conventional organic solvent such as ethanol, methanol, acetone, ether or hexane, alone or in admixture;
  • (vi) the following abbreviations have been used:-
    DMF
    N,N-dimethylformamide;
    THF
    tetrahydrofuran;
    DMSO
    dimethylsulphoxide;
    AIBN
    2,2'-azobisisobutyronitrile
    • Example 1 4-[2-(2-Phenethyl)phenoxymethyl]benzoic acid
  • A suspension of methyl 4-[2-(2-phenethyl)phenoxymethyl]benzoate (2.89 g) in ethanol (16 ml) containing aqueous 1N sodium hydroxide solution (16 ml) was stirred at ambient temperature for 16 hours. An additional portion of ethanol was added (10 ml) and stirring was continued for 16 hours. The reaction mixture was concentrated and the solid obtained on addition of ice-water was removed and discarded. The pH of the aqueous filtrate was adjusted to 3 by the addition of aqueous 1N hydrochloric acid. The solid which precipitated was filtered, washed with water (10 ml) and air dried. Crystallisation of this solid from aqueous ethanol gave 4-[2-(2-phenethyl)phenoxymethyl]benzoic acid, m.p. 122-123°C, (2.45 g; 88%).
    • Example 2
  • The compounds in Table I were prepared from the appropriate methyl esters using a similar method to that of example 1.
    Figure 00340001
    Figure 00350001
    Figure 00360001
    Figure 00370001
    • Example 3 4-[2-(2-Phenethyl)-6-(methylsulphinylmethyl)phenoxymethyl]benzoic acid
  • t-Butyl 4-[2-(2-phenethyl)-6-(methylsulphonyl)phenoxymethyl]benzoate (0.441 g, 0.95 mMole) was treated with formic acid (3 ml) and the reaction mixture stirred at ambient temperature for 3 hours. The mixture was then diluted with water and the product which precipitated was filtered, washed with water and dried to give 4-[2-(2-phenethyl)-6-(methylsulphinylmethyl)phenoxymethyl]benzoic acid.
    MS FAB-: 407 [M-H]-
    m.p. 122.5-124.6°C.
    • Example 4
  • The compounds in Table II were prepared from the appropriate t-butyl ester using a similar method to that of example 3, with variation in conditions noted.
    Figure 00380001
    Figure 00390001
    Figure 00400001
    Figure 00410001
    Figure 00420001
    Figure 00430001
    • Example 5 5-[4-(4-bromo-2-(2-phenethyl)phenoxymethyl)phenyl]-1H-tetrazole
  • Sodium azide (1.33 g) was added to a mixture of 4-[4-bromo-2-(2-phenethyl)phenoxymethyl]benzonitrile (2.05 g) and ammonium chloride (1.09 g) in DMF (25 ml) and the mixture was stirred and heated at 125°C for 40 hours. The cooled reaction mixture was poured into ice-water (100 ml) and the pH of the mixture adjusted to 4-5 with aqueous 2N hydrochloric acid. The solid obtained on filtration was washed with water (50 ml) and air dried. The solid was purified by subjecting to chromatography on silica, eluting with a mixture of methanol and dichloromethane (1:9 v/v) to give 5-[4-(4-bromo-2-(2-phenethyl)phenoxymethyl)phenyl]-1H-tetrazole 1.8 g (78%) m.p. 183-5°C.
    • Example 6
  • The compounds of Table III were prepared using a similar method to that of example 5.
    Figure 00430002
    Figure 00440001
    Figure 00450001
    Figure 00460001
    • Example 7 N-(2-Hydroxyethyl)-4-[2-(2-phenethyl)phenoxymethyl]benzenecarboxamide
  • A mixture of methyl 4-[2-(2-phenethyl)phenoxymethyl]benzoate (0.5 g) in 2-aminoethanol (6 ml) was heated at 160°C under argon for 3 hours. Water (10 ml) was added to the cooled reaction mixture which was extracted three times with ethyl acetate (25 ml each time). The combined ethyl acetate extracts were dried (MgSO4). The residue obtained on removal of the solvent was purified by chromatography on silica, eluting with a mixture of ethyl acetate and dichloromethane (1:1 v/v), and crystallised from a mixture of ethyl acetate and hexane to give N-(2-hydroxyethyl)-4-[2-(2-phenethyl)phenoxymethyl]benzenecarboxamide, (0.23 g; 44%) m.p. 95-7°C.
    • Example 8
  • The compounds of Table IV were prepared using a similar method to that described in Example 7, except using the appropriate ester in place of methyl 4-[2-(2-phenethyl)phenoxymethyl]benzoate.
    Figure 00470001
    • Example 9 N-(3-Pyridylmethyl)-4-[2-(2-phenethyl)phenoxymethyl]benzenecarboxamide
  • a) A solution of 4-[2-(2-phenethyl)phenoxymethyl]benzenecarbonyl chloride (0.4 g) in dichloromethane (2.5 ml) was added to a mixture of triethylamine (0.48 ml) and 3-aminomethylpyridine (0.13 ml) in dichloromethane (5 ml) at 0°C. The reaction mixture was allowed to warm to ambient temperature and was stirred for 16 hours. The reaction mixture was diluted with ethyl acetate (20 ml) and the solution washed consecutively with water (15 ml), saturated aqueous sodium bicarbonate solution (15 ml) and brine (15 ml). The ethyl acetate solution was dried (MgSO4) and the solid obtained on removal of the solvent was purified by subjecting to chromatography on silica, eluting with ethyl acetate, to give N-(3-pyridylmethyl)-4-[2-(2-phenethyl)phenoxymethyl]- benzenecarboxamide (0.23 g; 48%) m.p. 142-4°C.
  • b) The 4-[2-(2-phenethyl)phenoxymethyl]benzenecarbonyl chloride used as starting material was prepared as follows: Oxalyl chloride (0.24 ml) was added to a solution of 4-[2-(2-phenethyl)phenoxymethyl]benzoic acid (0.76 g) in dichloromethane (15 ml) containing one drop of DMF maintained at 0°C. The reaction mixture was allowed to warm to ambient temperature and was stirred at this temperature for 3 hours. The reaction mixture was evaporated to dryness to give 4-[2-(2-phenethyl)phenoxymethyl]- benzenecarbonyl chloride as a gum which was used without further purification.
    • Example 10
  • The compounds of Table V were prepared using a similar method to that described in Example 9, except using the appropriate amine in place of 3-aminomethylpyridine.
    Figure 00480001
    Figure 00490001
    Figure 00500001
    Figure 00510001
    Figure 00520001
    Figure 00530001
    Figure 00540001
    Figure 00550001
    Figure 00560001
    Figure 00570001
    Figure 00580001
    • Example 11 N-(2-Pyridylmethyl)-4-[6-methoxy-2-(phenethyl)phenoxymethyl]benzenecarboxamide
  • Triethylamine (0.24 ml) was added to a solution of 4-(6-methoxy-2-(2-phenethyl)phenoxymethyl)benzoic acid (0.6 g) and 2-aminomethylpyridine (0.20 ml) in DMF (20 ml) maintained at 5°C. Diphenylphosphoryl azide (0.37 ml) was added to this mixture and the solution was allowed to warm to ambient temperature and was stirred at this temperature for 16 hours. Water (50 ml) was added to the reaction mixture. This mixture was extracted with ethyl acetate (2 x 50 ml) and the ethyl acetate extracts washed with water (50 ml) and dried (MgSO4). The residue obtained on evaporation of the solvent was purified by subjecting to chromatography on silica eluting with a mixture of methanol and dichloromethane (1:49 v/v) to give N-(2-pyridylmethyl)-4-[6-methoxy-2-(2-phenethyl)phenoxymethyl]benzenecarboxamide (0.5 g; 66%) m.p. 126-7°C.
    • Example 12
  • The compounds of Table VI were prepared using a similar method to that outlined in Example 11, except using the appropriate amine in place of 2-aminomethylpyridine.
    Figure 00600001
    Figure 00610001
    Figure 00620001
    Figure 00630001
    Figure 00640001
    • Example 13 2-[2-(2-Phenethyl)-6-bromophenoxymethyl]-4-thiazolecarboxylic acid
  • A solution of ethyl 2-[2-(2-phenethyl)-6-bromophenoxymethyl]-4-thiazolecarboxylate (1.33 g, 2.98 mmol) in ethanol (10 mL) and THF (10 mL) was treated with 1N NaOH (6 mL). The reaction was stirred at ambient temperature overnight and then partially evaporated and diluted with water. Acetic acid was added to precipitate the title product, which was filtered and dried (1.21 g, 97%). NMR: (250 MH2,DMSO-d6): δ 8.14 (s, 1H), 7.53 (dd, 1H), 7.18 (m, 7H), 5.2 (s, 2H), 2.9 (m, 4H).
    • Preparation of the starting material:
  • A solution of ethyl 2-methyl-4-thiazolecarboxylate [JCS 1946, 87, E.R.H. Jones, F.A. Robinson, M.N. Strachan] (5.0 g, 29.2 mmol) in CCl4 (30 ml) was treated with N-bromosuccinimide (5.2 g, 29.2 mmol) and benzoylperoxide (0.03 g). The reaction was heated to reflux while irradiating with a strong lamp for 2½ hours. The reaction mixture was allowed to cool to ambient temperature, filtered and evaporated. The residue was purified by chromatography (eluant: CH2Cl2) to obtain ethyl 2-bromomethyl-4-thiazolecarboxylate (2.27 g, 31%).
    NMR (250 MH, DMSO-d6): δ 8.55 (s, 1H), 5.04 (s, 2H), 4.30 (g, 2H), 1.32 (t, 3H).
  • A solution of 6-bromo-2-(2-phenethyl)phenol (1.2 g, 4.33 mmoles) in DMF (5 mL) was treated with K2CO3 (1.2 g, 8.7 mmoles) and ethyl 2-bromomethyl-4-thiazole carboxylate (1.08 g, 4.32 mmoles). The reaction was stirred at ambient temperature overnight and then partitioned between ethyl acetate/H2O. The organic phase was washed well with water, dried over (MgSO4) and evaporated. The residue was purified by chromatography (eluant: CH2Cl2/hexane) to give ethyl 2-[2-(2-phenethyl)-6-bromophenoxymethyl]-4-thiazolecarboxylate (1.425 g, 74%).
    NMR (250 MH2, DMSO-d6): δ 8.60 (s, 1H), 7.54 (dd, 1H), 7.33 (dd, 1H), 7.18 (m, 6H), 5.27 (s, 2H), 4.34 (f, 2H), 2.9 (m, 4H), 1.33 (t, 3H).
    • Example 14
  • The compounds of Table VII were prepared using a similar method to that of Example 13.
    Figure 00650001
    Figure 00660001
    • Example 15 Preparation of N-(3-pyridylmethyl)-2-[2-(2-phenethyl)-4-methoxyphenoxymethyl]-4-thiazoleamide:
  • To a cooled solution (5°C) of triethylamine (0.24 g, 2.4 mmole) and 3-aminomethylpyridine (0.097 g, 0.89 mmole) in dichloromethane (6 ml) was added a solution of 2-[2-(2-phenethyl)-4-methoxyphenoxymethyl]-4-thiazolylchloride (prepared from compound 1 of Table VII, Example 14, using a similar method to that of the first part of Example 18) (0.8 mmoles) in dichloromethane (5.3 ml). The reaction was allowed to warm to ambient temperature and allowed to stand for 60 hours. The reaction mixture was evaporated. The residue was purified by chromatography (ethyl acetate/hexane) to give the title product (0.205 g, 56%), m.p 113-115°C.
    MS (FAB+): 460 (M+H)+.
    • Example 16
  • The compounds of Table VIII were prepared using a similar method to that of Example 15.
    Figure 00660002
    Figure 00670001
    • Example 17
  • The compounds of Table IX were prepared using a similar method to that of example 13, from the appropriate 2-(2-phenethyl)phenol and ethyl 2-bromomethyl-5-thiazolecarboxylate (Reference Example 18).
    Figure 00680001
    • Example 18 N-(2-Hydroxyethyl)-2-[2-(2-phenethyl)-6-bromophenoxymethyl]-5-thiazoleamide
  • A solution of 2-[6-bromo-2-(2-phenethyl)phenoxymethyl]-5-thiazole carboxylic acid (Table IX, Compound 2) (1.029 g, 2.4 mmol) in dichloromethane (10 ml) was treated with oxalyl chloride (0.459 g, 3.6 mmol) and two drops of DMF. The reaction was stirred at ambient temperature for 1 hour. The reaction mixture was evaporated to dryness to give the acid chloride which was then taken up in a measured amount of dry dichloromethane (9 ml).
  • To a cooled (5°C) stirred solution of ethanolamine (0.061 g, 1 mmol) and triethylamine (0.101 g, 1 mmol) in dichloromethane (4 ml) was added an aliquot of the acid chloride solution prepared above (0.8 mmol, 3 ml). The reaction was allowed to warm to ambient temperature and stirred overnight. The reaction mixture was evaporated to dryness and the residue purified by chromatography (methanol/CH2Cl2) to give the title amide (0.26 g, 71%) as an off-white solid. m.p.
    102.6-104.8°C. MS(CI+): 461/463 (M+H)+.
    • Example 19
  • The compounds of Table X were prepared using a similar method to that of example 18.
    Figure 00690001
    Figure 00700001
    • Example 20 2-(2-(2-Phenethyl)-4-bromophenoxymethyl)-5-pyridinecarboxylic acid
  • A solution of methyl 2-(2-(2-phenethyl)-4-bromophenoxymethyl)-5-pyridinecarboxylate (1.82 g, 4.27 mmol) in ethanol (16 ml) and THF (8 ml) was treated with 2N NaOH (5 ml). The reaction mixture was stirred at ambient temperature for 24 hours. The reaction mixture was partially evaporated and diluted with H2O. The pH of the reaction mixture was adjusted to approximately 4-5 with glacial acetic acid. The precipitate was filtered, washed with water and dried. Recrystallization from ethanol/water gave the title compound as a white solid (1.78 g, quantitative) m.p. 197-199°C.
    NMR: (200 MH2; DMSO-d6): δ 13.4 (bs, 1H), 9.08 (m, 1H), 8.32 (dd, 1H), 7.62 (d, 1H), 7.25 (m, 7H), 6.98 (d, 1H), 5.28 (s, 2H), 2.90 (m, 4H).
  • The starting material was prepared as follows:
  • A solution of methyl 2-methyl-5-pyridinecarboxylate (10 g, 66.2 mmoles) in CCl4 (120 ml) was treated with acetic acid (5 ml) followed by N-bromosuccinimide (66 mmol, 11.8 g). The reaction was heated to reflux over a bright lamp and held at reflux for 2 hours. The mixture was filtered and the filtrate washed with H2O (x1), NaHCO3 (x1) and brine (x1). The organic phase was dried (MgSO4) and evaporated to give a residual red oil which was purified by chromatography (eluant: CH2Cl2/hexane) to give 2-bromomethyl-5-pyridinecarboxylate (2.2 g, 14%).
    NMR (250 MH2, DMSO-d6): δ 9.04 (m, 1H), 8.30 (dd, 1H), 7.70 (dd, 1H), 4.74 (s, 2H), 3.89 (s, 3H).
  • A solution of the 4-bromo-2-(2-phenethyl)phenol (1.25 g, 14.5 mmol in DMF (10 ml) was treated with K2CO3 (0.82 g, 5.96 mmol) and methyl 2-bromomethyl-5-pyridine carboxylate (1.14 g, 4.96 mmol). The reaction was stirred at ambient temperature and then evaporated in vacuo. The residue was partitioned between ethyl acetate/H2O and the combined organic extracts were washed with at NaCl solution, dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl acetate/hexane) to give methyl 2-(2-phenethyl)-4-bromophenoxy methyl)-5-pyridinecarboxylic acid (1.82 g, 95%). NMR: (200 MH2, DMSO-d6): δ 9.1 (d, 1H), 8.36 (dd, 1H), 7.65 (d, 1H), 7.25 (m, 7H), 6.99 (d, 1H), 5.28 (s, 2H), 3.90 (s, 3H), 2.9 (m, 4H).
    • Example 21
  • The compounds of Table XI were prepared from the appropriate ester and phenol using a similar method to that of example 20.
    Figure 00710001
    • Example 22 Preparation of 3-[6-isopropyl-2-(2-phenethyl)phenoxymethyl]benzoic acid:
  • A solution of methyl 3-[6-isopropyl-2-(2-phenethyl)phenoxymethyl]benzoate (2.368 g, 608 mmol) in ethanol (10 ml) was treated with 1N NaOH (13 ml). The reaction stirred at ambient temperature overnight and then partially evaporated and diluted with water. Acetic acid was added to precipitate the product which was filtered, washed with water, and dried to give the title product as a sticky solid (2.01 g, 88%). NMR (250 MH2; DMSO-d6): δ 8.07 (bs, 1H), 7.91 (m, 1H), 7.58 (m, 1H), 7.42 (t, 1H), 7.16 (m, 8H), 4.73 (s, 2H), 3.39 (m, 1H), 2.88 (bs, 4H), 1.19 (d, 6H).
    • Example 23
  • The compounds of table XII were prepared from the appropriate methyl ester using a similar method to that of example 22.
    Figure 00720001
    Figure 00730001
    • Example 24 Preparation of N-(2-hydroxyethyl)-3-[2-(2-phenethyl)-6-bromophenoxymethyl]benzamide:
  • To a cooled solution (5°C) of ethanolamine (0.06 g, 1 mmole) and triethylamine (0.101 g, 1 mmole) in dichloromethane (10 ml) was added a solution of 3-[2-(2-phenethyl)-6-bromophenoxymethyl]benzoyl chloride [0.79 mmole] in dichloromethane [33 ml)]. The reaction was allowed to warm to ambient temperature over 1 hour. The reaction mixture was evaporated and the residue purified by chromatography (methanol/CH2Cl2) to give the title product as a white solid (0.18 g, 50%), m.p. 82.2-84.2°C.
    MS (FAB+): 454/456 (M+H)+.
    3-[2-(2-phenethyl)-6-bromophenoxymethyl]benzoyl chloride was prepared according to the method described in example 9b).
    • Example 25
  • The compounds of Table XIII were prepared using a similar method to that of example 24.
    Figure 00730002
    Figure 00740001
    Figure 00750001
    Figure 00760001
    Figure 00770001
    • Example 26
  • Not used
    • Example 27 Preparation of 4-(4-carboxy-2-(2-phenethyl)phenoxymethyl)benzoic acid:
  • To a solution of ethyl 4-hydroxy-3-(2-phenethyl)benzoate (1.04 g, 3.85 mmol) in DMF (16 ml) was added K2CO3 (0.94 g, 6.8 mmol) and methyl 4-bromomethylbenzoate (1.25 g, 5.5 mmol). The reaction was stirred at ambient temperature 18 hours, then evaporated at reduced pressure. The residue was partitioned between ethyl acetate and water and the organic phase dried (MgSO4) and evaporated to give methyl 4-(4-ethoxycarbonyl-2-(2-phenethyl)phenoxymethyl)benzoate as a white solid after chromatography (eluant: ethyl ether/hexane) (1.2 g, 75%). NMR (200 MHz, DMSO-d6): δ8.0 (d, 2H), 7.79 (m, 2H), 7.62 (d, 2H), 7.18 (m, 6H), 5.32 (s, 2H), 4.26 (q, 2H), 3.87 (s, 3H), 2.89 (m 4H), 1.30 (t, 3H).
  • The above diester (1.2 g, 2.87 mmol) was dissolved in ethanol (10 ml) and THF (10 ml) and 3N NaOH (10 mL) added. The reaction was allowed to stir at ambient temperature for 2 days. The reaction was partially evaporated, diluted with water and acidified to pH4 with dilute HCl. The precipitate was filtered, washed with water, and dried to give the title product (0.66 g, 61%).
    NMR (250 MHz, DMSO-d6): δ12.7 (bs, 1H), 8.0 (d, 2H), 7.79 (m, 2H), 7.6 (d, 2H), 7.18 (m, 6H), 5.3 (s, 2H), 2.9 (m, 4H).
    • Example 28 Preparation of 4-(2-(2-phenethyl)phenoxymethyl)-2-hydroxybenzoic acid:
  • A solution of 2-hydroxy-4-methylbenzoic acid (20.0 g, 0.132 mol) in methanol (200 ml) was cooled in an ice bath. Concentrated, H2SO4 (20 ml) was added cautiously and the reaction heated to reflux and held at reflux for 48 hours. The reaction was allowed to cool to ambient temperature, the solvent evaporated and the residue purified by chromatography (eluant: CH2Cl2) to give methyl 2-hydroxy-4-methylbenzoate (19.76 g, 90%).
    NMR (200 MHz DMSO-d6): δ10.47 (s, 1H), 7.64 (d, 1H), 6.78 (m, 2H), 3.86 (s, 3H), 2.3 (s, 3H).
  • A solution of methyl 2-hydroxy-4-methylbenzoate (19.7 g, 0.119 mole) in pyridine (15 ml) was treated with acetic anhydride (15 ml, 16.23 g, 0.158 mol). The reaction was stirred at ambient temperature overnight and then the solvent evaporated. The residue was dissolved in CH2Cl2 and the solution washed with 2N aqueous HCl, water, saturated aqueous NaHCO3 solution, dried (MgSO4) and evaporated to give methyl 2-acetoxy-4-methylbenzoate which was used without further purification (24.58 g, 99%).
    NMR: (250 MHz, DMSO-d6): δ7.84 (d, 1H), 7.21 (m, 1H), 7.04 (bs, 1H), 3.28 (s, 3H), 2.38 (s, 3H), 2.26 (s, 3H).
  • A solution of methyl 2-acetoxy-4-methylbenzoate (24.5 g, 0.118 mole) in carbon tetrachloride (700 ml) was treated with N-bromosuccinimide (20.96 g, 0.118 mole), benzoyl peroxide (0.5 g, catalytic) and AIBN (0.03 g). The reaction mixture was heated to reflux, held at reflux for 1 hour and then allowed to cool to ambient temperature, filtered and evaporated to give methyl 2-acetoxy-4-bromomethylbenzoate which was used without further purification (34 g, 63% of mixture is desired product).
  • A solution of 2-(2-phenethyl)phenol (2.0 g, 10 mmol) in DMF (20 ml) was heated with K2CO3 (2.8 g, 20 mmol) and methyl 2-acetoxy-4-bromomethylbenzoate (5.1 g, 12.3 mmol). The reaction was stirred at ambient temperature for 48 hours, then partitioned between ethyl acetate and water. The organic phase was washed with water (3 x), dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl/hexane) to give 4-(2-(phenethyl)phenoxymethyl)-2-acetoxybenzoate (1.78 g, 44%).
    NMR (200 MHz, DMSO-d6): δ7.98 (d, 1H), 7.46 (m, 1H), 7.22 (m, 8H), 6.95 (m, 2H), 5.21 (s, 1H), 3.82 (s, 3H), 2.86 (m, 4H), 2.28 (s, 3H).
  • The product from previous step (1.54 g, 3.81 mmol) was dissolved in ethanol (20 ml) and THF (15 ml) and 1N aqueous NaOH, (7.6 ml) was added. The reaction was stirred at ambient temperature for 30 hours then the solvent partially evaporated and diluted with water. Acetic acid was added dropwise until no further precipitation was observed. The solution was extracted with ethyl acetate (2 x) and the organic phase dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: methanol/CH2Cl2) to give the title product (0.59 g, 44%), m.p. 124.2-126°C
    NMR (200 MHz, DMSO-d6): δ7.78 (d, 1H), 7.2 (m, 7H), 6.95 (m, 4H), 5.12 (s, 2H), 2.88 (m, 4H).
    • Example 29
  • 4-(2-(2-Phenethyl)-6-bromophenoxymethyl)-2-hydroxybenzoic acid was prepared from 6-bromo-2-(2-phenethyl)phenol and 2-acetoxy-4-bromomethylbenzoate using a similar method to that of Example 28, m.p. 124.8-133°C; MS -ve FAB: 425/427 [M-H]-
    • Example 30 Preparation of 4-(2-benzyl-6-bromophenoxymethyl)benzoic acid:
  • Methyl 4-(2-benzyl-6-bromophenoxymethyl)benzoate (prepared below) was dissolved in ethanol (50 ml) and THF (15 ml) and treated with a solution of sodium hydroxide (1N, 32 ml). The reaction was stirred for 72 hours, partially evaporated and the residue diluted with water and acidified with ethyl acetate to give a precipitate. The precipitate was recrystallised from ethanol/water to give the title product. MS(CI+):397(M+H)+
    Elemental analysis:
    Calc 63.5%C. 4.31%H
    Found 63.3%C, 4.3%H
  • The methyl 4-(2-benzyl-6-bromophenoxymethyl)benzoate used above was prepared as follows:
  • A solution of 2-bromophenol (4.7 g, 27.2 mmol) in toluene (50 ml) was treated with benzaldehyde (3.75 g, 35.3 mmol), phenylboronic acid (3.98 g, 32.6 mmol) and trichloroacetic acid (1.33 g, 8.1 mmol). The mixture was heated to reflux and held at reflux for 18 hours. The reaction mixture was then evaporated and the residue subjected to chromatography to give the boronic acid complex of the adduct which was used in the subsequent step without further purification.
  • Borane-tert-butylamine complex (8.51 g, 97.8 mmol) was added to a suspension of AlCl3 (6.5 g, 48.8 mmol) in dichloromethane (20 ml), at 0°C. The mixture was stirred for 0.75 hours, at 0°C, to give a fine white suspension. The boronic acid complex (prepared above) in dichloromethane (10 ml) was then added and the mixture allowed to warm to ambient temperature and to stir overnight. Hydrochloric acid (1N) was added dropwise until pH1 was achieved. A white precipitate appeared transiently. The mixture was extracted with dichloromethane (x2), the organic phase dried (MgSO4) and evaporated and the residue purified by chromatography eluting with ethyl ether/hexane to give 2-benzyl-6-bromophenol (3.58 g, 50%) as an oil.
    MS(CI+):262(M+).
  • A solution of 2-benzyl-6-bromophenol (3.2 g, 12.2 mmol) in DMF (50 ml) was treated with K2CO3 (2.19 g, 15.9 mmol) and methyl 4-bromomethylbenzoate (3.21 g, 14.02 mmol). The reaction was stirred at ambient temperature overnight, filtered and partitioned between ethyl acetate and water. The organic phase was washed with water (4x), dried (MgSO4) and evaporated to give methyl 4-(2-benzyl-6-bromophenoxymethyl)benzoate (5.96 g), which was used without further purification.
    MS(CI+):411(M+H)+
    • Example 31 4-[2-(2-Phenethyl)phenoxyethyl]benzoic acid
  • A solution of methyl 4-[2-(2-phenethyl)phenoxyethyl]benzoate (0.44 g, 1.2 mmol) in methanol (20 ml) and THF (5 ml) was treated with NaOH (1N 5 ml). The reaction was heated to reflux for 4 hours. The reaction was evaporated at reduced pressure. The residual solution was acidified to pH1 with 1N HCl. The acidic solution was extracted with ethyl acetate, dried over MgSO4 and evaporated to give the title compound as a viscous oil (0.29 g, 67%).
    Elemental analysis:
    Calc for C23H22O3 79.7% C 6.40%H
          Found 77.7% C 6.50%H
    Calc for C23H22O3.05H2O 77.8% C 6.5%H
    NMR (200MH2, DMSO-d6), δ1.6 (d, 3H), 2.9 (m, 4H), 5.57 (q, 1H), 6.78 (m, 2H), 7.15 (m, 7H), 7.53 (d, 2H), 7.9 (d, 2H).
  • The starting material was prepared as follows:
  • 4-ethyl benzoic acid (5.0g, 26.7 mmol) was dissolved in methanol (40ml) and treated with concentrated H2SO4 (0.5ml). The reaction was heated at reflux for 24 hours. The reaction was evaporated at reduced pressure, partitioned between ethyl acetate/H2O. The aqueous layer was washed with ethyl acetate (1x). The organic phases were combined, washed with H2O, dried over MgSO4 and evaporated. The material was used without further purification in the subsequent transformation.
  • A solution of methyl 4-ethyl benzoate (5.4 g, 33.3 mmol) in CCl4 (200 ml) was treated with N-bromosuccinimide (5.93 g, 33.3 mmol). The mixture was treated with benzoylperoxide (0.1 g). The reaction was heated to reflux for 2 hours. After cooling the reaction mixture was filtered and evaporated to obtain 8.1 g of pale yellow oil (quantitative).
  • This material was used without purification in the subsequent step.
    NMR (200 MHz DMSO-d6) : δ2.0 (d, 3H), 3.90 (s, 3H), 5.54 (q, 1H), 7.65 (d, 2H), 7.77 (d, 2H).
  • 2-(2-Phenethyl)phenol (1.5g 7.6 mmol) was dissolved in DMF (5 ml). The solution was treated with K2CO3 (2.2 g, 16 mmol) and methyl 4-(1-bromoethyl)benzoate (2.0g, 8.3 mmol). The reaction was allowed to stir for 60 hours at room temperature then heated to 90°C for 4 hours. The reaction was partitioned between ethyl acetate/H2O. The aqueous layer was washed with ethyl acetate (1x). The combined organic layers were washed with H2O (4x), dried over MgSO4 and evaporated. Purification by chromatography (ethyl acetate/hexane) gave 1.99 g of methyl 4-[2-(2-phenethyl)phenoxymethyl]benzoate as a colourless oil (73%).
    NMR (DMSO d6/200MHz) : δ 1.58 (d, 3H), 2.9 (m, 4H), 3.83 (s, 3H), 5.59 (q, 1H), 6.77 (t, 2H), 6.96-7.33 (m, 7H), 7.57 (d, 2H), 7.95 (d, 2H).
    MS CI+ : 360 (M+]
    • Reference Example 1 Methyl 4-[6-methyl-2-(2-phenethyl)phenoxymethyl]benzoate
  • A mixture of 2-(2-phenethyl)-6-methylphenol (0.59 g 2.78 mmol), methyl 4-bromomethylbenzoate (0.96 g 4.21 mmol) and potassium carbonate (0.59 g) in DMF (30 ml) was stirred under argon at ambient temperature for 48 hours. The reaction mixture was diluted with water (50 ml) and extracted twice with ethyl acetate (50 ml each time). The ethyl acetate extracts were dried (MgSO4) and the residue obtained on removal of the solvent was subjected to chromatography on silica, eluting with a mixture of ethyl acetate and hexane (1:50 v/v) to give methyl 4-[6-methyl-2-(2-phenethyl)phenoxymethyl]benzoate (0.95 g; 94%). MS (CI+): 378 (M+NH4)+
    • Reference Example 2
  • A similar method to that outlined in Reference Example 1, except using the appropriately substituted phenol in place of 2-(2-phenethyl)-6-methylphenol, was used to prepare the compounds of Table XV.
    Figure 00820001
    Figure 00830001
    Figure 00840001
    Figure 00850001
    Figure 00860001
    • Reference Example 3
  • Not used.
    • Reference Example 4 Methyl 4-[5-t-butylcarbonyloxy-(2-phenetyl)phenoxymethyl]benzoate
  • Triethylamine (5 ml) was added to a stirred suspension of 2,4-dihydroxybenzaldehyde (12 g) in dichloromethane (50 ml) at -8°C. To this mixture was added t-butylcarbonyl chloride (4.4 ml) and the mixture was allowed to warm to ambient temperature and was stirred at this temperature for 16 hours. The reaction mixture was washed consecutively with aqueous 1N hydrochloric acid (20 ml), water (20 ml) and saturated aqueous sodium bicarbonate solution (20 ml) and then dried (MgSO4). The residue obtained on removal of the solvent was subjected to chromatography on silica eluting with a mixture of ethyl acetate and hexane (1:9 v/v) to give 4-(t-butylcarbonyloxy)-2-hydroxybenzaldehyde (5.82 g; 35%).
  • The 5-(t-butylcarbonyloxy)-2-(2-phenethenyl)phenol was prepared by reaction of 4-(t-butylcarbonyloxy)-2-hydroxybenzaldehyde with benzyltriphenylphosphonium bromide using a similar method to that described in Reference Example 12.
  • The 5-(t-butylcarbonyloxy)-2-(2-phenethyl)phenol was prepared by hydrogenation of 5-(t-butylcarbonyloxy)-2-(2-phenethenyl)phenol as described in Reference Example 8.
  • The methyl 4-[5-t-butylcarbonyloxy-2-(2-phenethyl)phenoxymethyl]benzoate was prepared from 5-(t-butylcarbonyloxy)-2-(2-phenethyl)phenol and methyl 4-bromomethylbenzoate as described in Reference Example 1.
    • Reference Example 5 4-[4-Bromo-2- (2-phenethyl)phenoxymethyl]benzonitrile
  • The 4-[4-bromo-2-(2-phenethyl)benzonitrile used as starting material in Example 5 was prepared by reacting 4-bromo-2-(2-phenethyl)phenol and 4-bromomethylbenzonitrile under similar conditions to those described in Reference Example 1.
    • Reference Example 6
  • The compounds of Table XVI were prepared by reacting 4-bromomethylbenzonitrile with the appropriate phenol using a similar method to that described in Reference Example 5.
    Figure 00870001
    Figure 00880001
    • Reference Example 7
  • The t-butyl esters used as starting material in Examples 3 and 4 were prepared from the appropriately substituted 2-(2-phenethyl)phenols and t-butyl 4-bromomethylbenzoate (Tilley et al J Med Chem 34 1125-36 (1991)) using a similar method to that described in Reference Example 1.
    Figure 00890001
    • Reference Example 8 5-Methyl-2-(2-phenethyl)phenol
  • A solution of (E)-5-methyl-2-(2-phenethenyl)phenol (1.1 g) in ethanol (80 ml) containing 10% palladium/carbon as catalyst (200 mg) was hydrogenated at atmospheric pressure. The catalyst was removed by filtration through acid washed silica and the filtrate concentrated to give 5-methyl-2-(2-phenethyl)phenol as a gum (yield 1.1 g).
    • Reference Example 9
  • The compounds of Table XVIII were prepared from the appropriate olefin using a similar method to that described in Reference example 8.
    Figure 00900001
    Figure 00910001
    • Reference Example 10 2-(2-Phenethyl)-6-nitrophenol
  • A solution of 2-(2-phenethenyl)-6-nitrophenol (6.82 g) in a mixture of ethanol (200 ml) and toluene (200 ml) containing Wilkinson's catalyst (tris (triphenylphosphine)rhodium(I)chloride) (638 mg) was hydrogenated at 50°C at a pressure of 50 atmospheres for 13 hours. The catalyst was removed by filtration and the filtrate was evaporated to dryness to give 2-(2-phenethyl)-6-nitrophenol (5.38 g; 78%) which was used in subsequent reactions without further purification.
    • Reference Example 11
  • The compounds of Table XIX were prepared from the appropriate olefin using a similar method to that of Reference example 10.
    Figure 00910002
    Figure 00920001
    • Reference Example 12 E 5-Methyl-2-(2-phenethenyl)phenol was prepared as follows:
  • A solution of lithium bis(trimethylsilyl)amide in THF (37 ml of a 1N solution) was added to a stirred suspension of benzyltriphenylphosphonium bromide (8.76 g) in THF (60 ml) at ambient temperature under argon and the mixture was stirred for 45 minutes. A solution of 4-methyl-2-hydroxybenzaldehyde (made from 4-methylsalicylic acid by the procedure described in reference example 53a)-b)) (2.4 g) in THF (15 ml) was added and the reaction mixture stirred for 16 hours. The reaction mixture was partitioned between water (100 ml) and diethyl ether (100 ml). The aqueous phase was extracted once with diethyl ether and the combined extracts were dried (MgSO4). The oil obtained on removal of the solvent was subjected to chromatography on silica, eluting with a mixture of ethyl acetate and hexane (1:4 v/v) to give (E)5-methyl-2-(2- phenethenyl)phenol (1.1 g; 26%).
    • Reference Example 13
  • The compounds of Table XX were prepared from the appropriate aldehyde using a similar method to that of Reference example 12.
    Figure 00930001
    Figure 00940001
    Figure 00950001
    • Reference Example 14 3,5-Dibromo-2-hydroxybenzaldehyde
  • Hexamine (3.35 g, 23.92 mmol) was added portionwise to trifluoroacetic acid (25 ml) keeping the temperature below 40°C with a water bath. 2,4-Dibromophenol was then added slowly and the reaction mixture heated at 80°C for 3½ hours. The reaction mixture was cooled, partially evaporated and then poured into ice/water. This mixture was stirred at ambient temperature overnight and the precipitate that formed filtered, dried and purified by chromatography (CH2Cl2/hexane) to give the title compound (2.1 g).
    MS (CI)+ :279 [M+H]+
    NMR: (250 MHz, DMSO-d6):
    • Reference Example 15
  • The compounds of Table XXI were prepared from the appropriate phenol using a similar method to that of Reference example 14.
    Figure 00960001
    Figure 00970001
    • Reference Example 16 3-Bromo-2-hydroxybenzaldehyde
  • Over 0.25 hours 2-bromophenol (22.38 g, 129 mmol) was added to a solution of Mg(OMe)2 in methanol (111.9 ml, 8% w/w) and toluene (35 ml). The reaction was heated to reflux and maintained at reflux for 1 hour, then toluene (118 ml) was added. The solvent was distilled off until the temperature reached 92-94°C. A solution of paraformaldehyde in toluene was added portionwise over 1 hour at 80-90°C and the reaction mixture heated to reflux and maintained at reflux for 3 hours. The reaction mixture was then allowed to cool to ambient temperature and left to stand overnight. Toluene (140 ml) was added to the reaction mixture, which was then washed with 2M H2SO4 (140 ml). The organic phase was dried and evaporated and the crude material used in the next step without further purification.
    MS (CI+): 201 [M+H]+
    • Reference Example 17
  • The compounds of table XXII were prepared from the appropriate phenol using a similar method to that of Reference example 16.
    Figure 00970002
    Figure 00980001
    • Reference Example 18 Ethyl 2-bromomethyl-5-thiazolecarboxylate
  • A solution of ethyl 2-methyl-5-thiazole carboxylate [S.H Mashragui, P.M. Keehn, JACS 104 4461-4465 (1982)] (4.73 g, 27.68 mmol) in carbon tetrachloride (30 ml) was treated with N-bromosuccinimide (4.92 g, 27.64 mmol) and benzoyl peroxide (0.03 g). The reaction mixture was heated to reflux under a strong light for 1¼ hours. The reaction was allowed to cool to ambient temperature and filtered. The filtrate was evaporated and subjected to chromatography (CH2Cl2) to give the title product (1.16 g, 17%).
    NMR (200 MH2, DMSO-d6): δ 8.4 (s, 1H), 5.06 (s, 2H), 4.33 (g, 2H), 1.3 (t, 3H).
    • Reference Example 19 Methyl 4-[4-Cyano-2-(2-phenethyl)phenoxymethyl]benzoate
  • a) A solution of methyl-4-[4-bromo-2-(2-phenethyl)phenoxymethyl]benzoate (4.0 g) in DMF (120 ml) containing cuprous cyanide (2.08 g) was stirred and heated under reflux for 24 hours in an atmosphere of argon. The reaction mixture was allowed to cool and was added to a solution of 1,2-diaminoethane (120 ml) in water (600 ml). The mixture was extracted four times with diethyl ether (150 ml each time), washed with brine (100 ml) and evaporated to dryness. Toluene (100 ml) was added to the residue and the mixture evaporated to dryness. The residue was subjected to chromatography on silica, eluting with a mixture of diethyl ether and hexane (1:3 v/v) to give methyl-4-[4-cyano-2-(2-phenethyl)phenoxymethyl]benzoate (3.3 g; 94%).
  • b) The starting material was prepared as follows: Tetrabutylammonium tribromide (10.00 g) was added to a solution of 2-(2-phenethyl)phenol (3.77 g) in dichloromethane (140 ml) at ambient temperature and the mixture stirred for 2 hours. The reaction mixture was washed consecutively with aqueous sodium thiosulphate solution (2 x 100 ml), water (3 x 100 ml) and brine (100 ml) and then dried (MgSO4). Removal of the solvent gave an oil which was subjected to chromatography on silica, eluting with a mixture of ethyl acetate and hexane (1.9 v/v), to give as an oil 4-bromo-2-(2-phenethyl)phenol (4.5 g; 85%).
  • The methyl 4-[4-bromo-2-(2-phenethyl)phenoxymethyl]benzoate was prepared by reaction of 4-bromo-2-(2-phenethyl)phenol with methyl 4-bromomethylbenzoate using a similar method to that described in Reference Example 1.
    • Reference Example 20
  • The compounds of Table XXIII were prepared from the bromo compound using a similar method to that of Reference example 19a).
    Figure 00990001
    Figure 01000001
    • Reference Example 21 Preparation of methyl 4-[4-bromo-6-cyano-2-(2-phenethylphenoxymethyl]benzoate and methyl 4-[6-bromo-4-cyano-2-(2-phenethylphenoxymethyl]benzoate;
  • To a solution of methyl 4-[4,6-dibromo-2-(2-phenethylphenoxymethyl]benzoate (0.92 g, 1.82 mmole) in DMF (30 ml) was added CuCN (0.188 g, 21. mmol). The reaction was heated at reflux (under argon) for 20 hours.
  • The reaction was cooled, poured into a solution of ethylene diamine (30 ml) in ice water (120 ml). The aqueous solution was extracted with ethyl acetate (3 x 60 ml). The combined organic extracts were washed with brine (2x), dried (MgSO4) and evaporated. The residue was purified by chromatography (diethyl ether/hexane) to give the title compounds; 4-bromo-6-cyano compound (0.127 g) and 4-cyano-6-bromo compound (0.104 g).
  • 4-bromo-6-cyano compound:
    NMR (200 MHz, DMSO-d6) δ: 8.02 (d, 2H), 7.98 (s, 1H), 7.85 (d, 1H), 7.6 (d, 2H), 7.16 (m, 5H), 5.19 (s, 2H), 3.88 (s, 3H), 2.84 (m, 4H).
  • 4-cyano-6-bromo compound:
    NMR (200 MHz, DMSO-d6) δ: 8.14 (d, 1H), 8.02 (d, 2H), 7.85 (d, 1H), 7.65 (d, 2H), 7.18 (m, 5H), 5.07 (s, 2H), 3.89 (s, 3H), 2.87 (m, 4H).
    • Reference Example 22 Preparation of 6-cyano-2-(2-phenethyl)phenol:
  • A solution of 6-bromo-2-(2-phenethyl)phenol (8.0 g, 28.88 mmol) in DMF (60 ml) was treated with K2CO3 (10.0 g, 72.46 mmol) and benzyl bromide (3.78 ml, 5.44 g, 31.79 mmol). The reaction was stirred for 3 hours at ambient temperature then filtered and evaporated. The residue was partitioned between ethyl acetate/water and the organic phase washed with H2O (4x), dried (MgSO4) and evaporated to give benzyl 6-bromo-2-(2-phenethyl)phenyl ether as an oil. (11.86 g [crude]). MS (EI):366 (M)+.
  • Benzyl 6-bromo-2-(2-phenethyl)phenyl ether (10.57 g, 28.8 mmol) was dissolved in DMF (100 ml). Cuprous cyanide (6.72 g, 75 mmol) was added and the reaction heated to 150°C for 18 hours. The reaction was poured in ethylene diamine (440 ml) and water (1.5 l) and the product was extracted with ethyl acetate (3x). The organic extracts were combined, dried (MgSO4) and evaporated. The residue was purified by chromatography (diethyl ether/hexane) to give benzyl 6-cyano-2-(2-phenethyl)phenyl ether as a solid (7.23 g, 80%).
    MS (CI+): 314 (M+H)+.
  • Benzyl 6-cyano-2-(2-phenethyl)phenyl ether (4.86 g, 15.5 mmol) was dissolved in ethanol (100 ml). The solution was treated with 10% Pd on Carbon (500 mg). The reaction was placed under an atmosphere of hydrogen and allowed to react with vigorous stirring for 2.5 hours. The reaction mixture was filtered through Celite and evaporated. The residue was purified by chromatography (diethyl ether/hexane) to give the title product (2.86 g, 83%).
    MS (CI+): 224 [M+H]+.
    • Reference Example 23 6-Methyl-2-(2-phenethyl)phenol
  • A solution of 1-(2-benzyloxy-3-methylphenyl)-2-phenylethene (2.19 g) in ethanol (50 ml) containing 10% palladium on charcoal as catalyst was hydrogenated at atmospheric pressure. The reaction mixture was filtered through acid washed silica and the residue obtained on concentration of the filtrate was subjected to chromatography on silica, eluting with a mixture of ethyl acetate and hexane (1:50 v/v) to give 6-methyl-2-(2-phenethyl)phenol (0.66 g; 42%; m.p. 45.5-46°C).
  • Using this same procedure there was obtained
    Figure 01020001
  • The 1-[(2-benzyloxy-3-methyl)phenyl]-2-phenylethene used as starting material was prepared as follows:
  • A solution of lithium bis(trimethylsilyl)amide in THF (15.8 ml of a 1N solution) was added to a stirred suspension of benzyl triphenylphosphonium bromide (6.84 g) in THF (40 ml) and the mixture stirred under argon for 30 minutes. A solution of 2-benzyloxy-3-methylbenzaldehyde (2.38 g) (prepared from 2-hydroxy-3-methylbenzoic acid according to Reference example 29a)-c)); in THF (15 ml) was added to the reaction mixture and stirring continued for 48 hours. The reaction mixture was quenched with water (50 ml) and extracted three times with ethyl acetate (50 ml each time). The ethyl acetate extracts were dried (MgSO4) and the residue obtained on removal of the solvent was subjected to chromatography on silica, eluting with an ethyl acetate/hexane mixture (1:100 v/v) to give 1-[(2-benzyloxy-3-methyl)phenyl]-2-phenylethene (2.47 g; 78%) as a mixture of E and Z isomers.
    MS (CI+) (M+NH4)+ 318; (M+H)+ 301.
  • This method was used to prepare 1-(2-benzyloxy-4-chlorophenyl)-2-phenylethene as a gum; 2-benzyloxy-4-chlorobenzaldehyde was prepared according to Reference example 29a)-c).
    • Reference Example 24 Preparation of 4-bromo-2-(2-phenethyl)phenol:
  • Tetrabutylammonium tribromide (10.00 g) was added to a solution of 2-(2-phenethyl)phenol (3.77 g) in dichloromethane (140 ml at ambient temperature and the mixture stirred for 2 hours. The reaction mixture was washed consecutively with aqueous sodium thiosulphate solution (2 x 100 ml), water (3 x 100 ml) and brine (100 ml) and then dried (MgSO4). Removal of the solvent gave an oil which was subjected to chromatography on silica, eluting with a mixture of ethyl acetate and hexane (1.9 v/v), to give as an oil 4-bromo-2-(2-phenethyl)phenol (4.5 g; 85%).
  • The 2-(2-phenethyl)phenol was prepared according to the route described in the literature JACS, 81, 2795, (1959).
    • Reference Example 25 Preparation of methyl 4-(2-(2-phenethyl)-6-hydroxyphenoxymethyl)benzoate:
  • A suspension of 2,3-dihydroxybenzaldehyde (15 g, 109 mmole) in CH2Cl2 (70 ml) was cooled to -10°C. Triethyl amine (5.49g, 54.3 mmol) was added followed by pivaloyl chloride (6.49 g, 53.9 mmol). The reaction was allowed to stir for 1 hour at -10°C and then warmed to ambient temperature. The reaction mixture was stirred at ambient temperature overnight, then washed with water, 1N aqueous HCl, saturated aqueous NaHCO3 and water. The organic phase was dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl acetate/hexane) to give 2-hydroxy-3-pivaloyloxybenzaldehyde: (10.15 g, 84%).
    NMR (200 MHz, DMSO-d6): δ10.78 (s, 1H), 10.15 (s, 1H), 7.64 (dd, 1H), 7.38(dd, 1H), 7.05 (t, 1H), 1.32 (s, 9H).
  • To a solution of 2-hydroxy-3-pivaloyloxybenzaldehyde (1.0g, 4.5 mmole) in DMF (5 ml) was added Na2CO3 (0.859 g, 8.10 mmol) and methyl 4-bromomethylbenzoate (1.13 g, 4.93 mmol). The reaction was stirred at ambient temperature for 60 hours then partitioned between ethyl acetate/H2O. The organic phase was washed with water (x1) dried (MgSO4) and evaporated to give methyl 4-(2-formyl-6-pivaloyloxyphenoxymethyl)benzoate as a product which was used in subsequent steps without further purification.
    NMR (200 MHz, DMSO-d6): δ10.12 (s, 1H), 7.97 (d, 2H), 7.67 (dd, 1H), 7.54 (m, 3H), 7.36 (t, 1H), 5.18 (s, 2H), 3.86 (s, 3H), 1.26 (s, 9H).
  • LiN(SiMe3)2 [1N in THF, 17.2 ml] was added to a suspension of benzyl triphenylphosphonium bromide (7.45 g, 17.2 mmol) in THF (80 ml). The reaction was stirred for 30 minutes at ambient temperature. A solution of methyl 4-(2-formyl-6-pivaloyloxyphenoxymethyl)benzoate (3.183 g, 8.59 mmole) in THF (20 ml) was added keeping the temperature below 40°C. The reaction was stirred at ambient temperature for 18 hours then treated with water, neutralised with dilute aqueous HCl and extracted with ethyl acetate. The organic phase was dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl acetate/hexane) to give methyl 4-(2-(2-phenethenyl)-6-hydroxyphenoxymethyl)benzoate (1.68 g, 55%).
    NMR (200 MH2, DMSO-d6) (mixture of cis and trans isomers):
    69.52 (bs, 1H), 7.96 (m, 2H), 7.62 (m, 2H), 7.45 to 6.4 (complex multiplets, 10H) (two singlets together, 2H), 5.08 and 5.07 (two singlets together, 3H), 3.86 and 3.85 (two singlets together, 3H).
  • A solution of methyl 4-(2-(2-phenethenyl)-6-hydroxyphenoxymethyl)benzenecarboxylate (1.39 g, 3.87 mmol) in ethanol (50 ml) and toluene (50 ml) was treated with Wilkinson's catalyst (0.15 g). The reaction was hydrogenated at 50°C and 50 bar for 18 hours, then evaporated. The residue was purified by chromatography (eluant: ethyl acetate/hexane) to give methyl 4-(2-(phenethyl)-6-hydroxyphenoxymethyl)benzoate: (1.12 g, 80%).
    NMR (200 MHz, DMSO-d6): δ9.40 (bs, 1H), 7.98 (d, 2H), 7.6' (d, 2H), 7.14 (m, 5H), 6.85 (t, 1H), 6.76 (dd, 1H), 6.66 (dd, 1H), 5.01 (s, 2H), 3.87 (s, 3H), 2.56 (bs, 4H).
    • Reference Example 26 Preparation of 6-(N-diethylcarbamoyl)-2-(2-phenethyl)phenol:
  • To a suspension of hexane washed NaH (60% in mineral oil, 0.16 g, 4 mmol) in THF (5 ml) was added to a solution of 6-bromo-2-(2-phenethyl)phenol (1.0 g, 3.6 mmol) in THF (5 ml). The reaction was stirred at ambient temperature for 45 minutes then cooled to -70°C. A solution of n-butyl lithium (1.6M in hexane, 4.62 ml, 7.4 mmol) was added keeping the temperature below -55°C. The reaction mixture was stirred at -70°C for 1.25 hours then poured onto crushed solid CO2 in THF. The reaction was allowed to warm to ambient temperature, acidified with dilute HCl and extracted with ethyl acetate. The organic phase was dried (MgSO4) and evaporated to give 2-hydroxy-3-(2-phenethyl)benzoic acid. The crude material was used without further purification in the subsequent step (0.805 g).
  • The crude 2-hydroxy-3-(2-phenethyl)benzoic acid (0.805 g 3.33 mmol) was dissolved in CH2Cl2 (15 ml) and treated with oxalyl chloride (0.55 ml, 0.8 g, 6.3 mmol) and 2 drops of DMF. The reaction was stirred at ambient temperature for 1 hour, then evaporated. The residue was dissolved in CH2Cl2 (15 ml), evaporated and dissolved in dichloromethane (4 ml).
  • The acid chloride solution was added to a stirred solution of diethyl amine (1.19 g, 16.3 mmol) in dichloromethane (10 ml). The reaction mixture turned a deep green/brown colour. After 30 minutes the reaction was evaporated and the residue purified by chromatography (eluant: methanol/CH2Cl2) to give 6-(N-diethylcarbamoyl)-2-(2-phenethyl)phenol (0.314 g, 32%).
    NMR (200 MHz; DMSO-d6): δ9.0 (bs, 1H), 7.23 (m, 5H), 7.09 (dd, 1H), 6.95 (dd, 1H), 6.78 (t, 1H), 3.31 (m, 4H), 2.85 (bs, 4H), 1.07 (t, 6H).
    • Reference Example 27 Preparation of 6-methylthio-2-(2-phenethyl)phenol:
  • To a suspension of hexane washed NaH (60% in mineral oil, 0.238 mg, 5.95 mmol) in THF (4 ml) was added to a solution of 6-bromo-2-(2-phenethyl)phenol (1.5 g, 5.4 mmol) in THF (4 ml). The reaction was stirred for 30 minutes at ambient temperatature, then cooled to -70°C. A solution of n-butyl lithium (1.6 M in hexane, 3.72 ml, 5.95 mmol) was added keeping the temperature below -65°C. The reaction was stirred at -70°C for 30 minutes and Me2S2 (0.25 g, 2.6 mmoles) added. The reaction temperature rose to -50°C and was allowed to warm to ambient temperature. The reaction mixture was partitioned between ethyl acetate/dilute aqueous HCl, the organic phase was dried (MgSO4) and evaporated and the residue purified by chromatography (eluant ethyl ether/hexane) to give a 1:1 mixture of 6-bromo and 6-methylthio-2-(2-phenylethyl)phenol. (1.29 g, 98%).
    Ms(CI+): 2.5 [M+H]+ [6-SMe].
  • The mixture was alkylated using a similar method to that of Reference Example 1 and purified by chromatography (eluant: ethyl ether/hexane to give methyl 4-(2-(2-phenethyl)-6-methylthiophenoxymethyl)benzoate cleanly.
    NMR (200 MH2, DMSO-d6): δ8.01 (d, 2H), 7.64 (d, 2H), 7.18 (m, 8H), 4.93 (s, 2H), 3.87 (s, 3H), 2.85 (bs, 4H), 2.42 (s, 3H).
    • Reference Example 28 Preparation of methyl 4-(6-amino-2-(2-phenethyl)phenoxymethyl)benzoate:
  • A solution of methyl 4-(6-nitro-2-(2-phenethyl)phenoxymethyl)benzoate (1.5 g, 3.84 mmol) in ethyl acetate (20 ml) was treated with stannous chloride (4.34 g, 19.2 mmole). The reaction was heated to 70°C for 5 hours, then allowed to cool to ambient temperature. The reaction mixture was partitioned between ethyl acetate/water and the organic phase dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl acetate/hexane) to give the title product (0.946 g, 68%).
    NMR (200 MH2, DMSO-d6): δ9.99 (dd, 2H), 7.64 (dd, 2H), 7.16 (m, 5H), 6.80 (t, 1H), 6.63 (dd, 1H), 6.50 (dd, 1H), 4.86 (s, 2H), 3.87 (s, 3H), 2.77 (bs, 4H).
    • Reference Example 29 Preparation of 6-isopropyl-2-(phenethyl)phenol:
  • A solution of 2-hydroxy-3-isopropylbenzoic acid (5 g, 27.8 mmol) in acetone (40 ml) was treated with K2CO3 (7.67 g, 55.6 mmol) and benzyl bromide (9.98 g; 58.4 mmol). The reaction was stirred at ambient temperature for 60 hours, then evaporated. The residue was partitioned between ethyl acetate/H2O and the organic phase dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl acetate/hexane) to give benzyl 2-benzyloxy-3-isopropylbenzoate (6.52 g, 18.11 mmol, 65%)
    NMR (200 MHz, DMSO-d6): δ7.58 (m, 2H), 7.39 (m, 10H), 7.23 (t, 1H), 5.32 (s, 2H), 4.86 (s, 2H), 3.30 (m, 1H), 1.14 (d, 6H).
  • A solution of LiAlH4 (1M in THF, 8.13 ml) was added to freshly distilled THF (10 ml) 10 ml. A solution of benzyl 2-benzyloxy-3-isopropylbenzoate (2.27 g, 6.31 mmole) in THF (10 ml) was added via a syringe to the LiAlH4 solution. The temperatue was maintain below 40°C using a water bath and the reaction mixture stirred at ambient temperature overnight. The reaction was quenched with water and the pH adjusted to -7 with dilute HCl. The resultant precipitate was filtered off and the filtrate partitioned between ethyl acetate/H2O. The organic phase was dried (MgSO4), evaporated and the residue purified by chromatography (eluant: ethyl acetate/hexane) to give 2-benzyloxy-3-isopropylbenzylalcohol (1.38 g, 83%).
    NMR (200 MHz, DMSO-d6): δ7.29 (m, 8H), 4.82 (s, 2H), 4.58 (s, 2H), 3.30 (m, 1H), 1.17 (d, 6H).
  • A solution of 2-benzyloxy-3-isopropylbenzyl alcohol (1.26 g, 4.9 mmoles) in chloroform (50 ml) was heated with manganese dioxide (1.92 g, 22 mmole). The reaction was stirred at ambient temperature overnight, filtered and evaporated. The residue was purified by chromatography (eluant: ethyl acetate/hexane) to give 2-benzyloxy-2-isoproplybenzaldehyde, (0.71 g, 57%).
  • A suspension of benzyl triphenylphosphonium bromide (1.43 g, 3.3 mmol) in THF (20 ml) was treated with LiN(SiMe3)2 [1M in THF, 3.3 ml). The reaction was stirred at ambient temperature for 30 minutes. A solution of 2-benzyl-3-isopropyl benzaldehyde (0.56 g, 2.2 mmole) in THF (10 ml) was added and the reaction was stirred at ambient temperature for 48 hours. The reaction was partitioned between ethyl acetate/H2O and the organic phase washed well with H2O, dried (MgSO4) and evaporated. The residue was purified by chromatography to give 2-benzyloxy-1-isopropyl-3-(2-phenethenyl)benzene (0.52 g, 72%). NMR (200 MHz, DMSO-d6): (mixture of cis trans isomers) δ7.7 to 6.6 (complex multiplets, 15H), 4.90 and 4.85 (two singlets together 2H 3.32 (m, 1H), 1.16 (m, 6H).
  • A solution of 2-benzyloxy-1-isopropyl-3-(2-phenethenyl)benzene, (0.46 g, 1.4 mmol) in ethanol 30 ml was treated with 10% palladium carbon [0.10g]. The reaction was placed under a hydrogen atmosphere and stirred vigorously until the uptake of hydrogen ceased. The reaction was filtered through Celite and evaporated to give 2-(2-phenethyl)-6-isopropylphenol (0.34 g, quantitative).
    NMR (200 MHz, DMSO-d6): δ8.1 (s, 1H), 7.23 (m, 5H), 6.99 (dd, 1H), 6.91 (t, 1H), 3.31 (m, 1H), 2.63 (bs, 1H), 1.16 (d, 6H).
    • Reference Example 30 Preparation of 2-(2-phenethyl)-6-phenylphenol:
  • Methanol (50 ml) was treated with concentrated sulphuric acid (4.9g, 2.66 ml) cautiously. 2-Hydroxy-3-phenylbenzoic acid (10.7 g, 50 mmol) was added and the reaction mixture stirred at ambient temperature for 18 hours. The mixture was then heated at reflux for 4 hours, cooled to ambient temperature and evaporated. The residue was partitioned between ethyl acetate/and water, the organic layer washed twice with water, dried (MgSO4) and evaporated to give methyl 2-hydroxy-3-phenylbenzoate.
  • A solution of methyl 2-hydroxy-3-phenylbenzoate (9.5 g, 41.7 mmol) in DMF (80 ml) was treated with K2CO3 (8.6 g, 62.5 mmole) and benzyl bromide (10.6 g 62.2 mmol). The reaction was stirred at ambient temperature overnight, then partitioned between ethyl acetate/and water. The organic phase was washed well with water, dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl acetate/hexane) to give methyl 2-benzyloxy-3-phenylbenzoate (11.23 g, 8.5%).
    NMR (250 MHz, DMSO-d6): δ7.72 (dd, 1H), 7.65-7.07 (complex multiplets, 10H), 7.06 (m, 2H), 4.53 (s, 2H), 3.82 (s, 3H).
  • This was reduced with LiAlH4 using a similar method to that of Reference example 29 to give 2-benzyloxy-3-phenylbenzyl alcohol.
  • 2-Benzyloxy-3-phenylbenzyl alcohol was oxidised with manganese dioxide using a similar method to that discribed in Reference Example 29 to give 2-benzyloxy-3-phenylbenzaldehyde.
  • 2-Benzyloxy-3-phenylbenzaldehyde was reacted with benzyl triphenylphosphonium bromide using a similar method to that of Example 48 to give 2-benzyloxy-1-phenyl-3-styrylbenzene, which was hydrogenated using a similar method to that of Reference Example 29 to give 2-(2-phenethyl)-6-phenylphenol.
    • Reference Example 31 Preparation of 6-hexyl-2-(2-phenethyl)phenol:
  • To a stirred suspension of pentyl triphenylphosphonium bromide (10.4 g, 25.2 mM) in freshly distilled THF (40 ml) was added LiN(SiMe3)2 (1M in THF, 50 ml). The reaction was stirred at ambient temperature for 1 hour. Salicylaldehyde (2.8 g, 22.9 mM) was added to the reaction mixture which was stirred at ambient temperature for 60 hours. The reaction was then treated with water, the pH adjusted with 1N aqueous HCl to pH7 and extracted twice with ethyl acetate. The organic layers were combined, dried over (MgSO4) and evaporated. The residue was purified by chromatography to give 2-(1-hexenyl)phenol, (3.57 g, 88%).
    NMR (200 MHz, DMSO-d6): δ9.40 (bs, 1H), 67.32 (dd, 1H), 7.0 (m, 1H), 6.72 (m, 3H), 6.19 (m, 1H), 2.18 (m, 2H), 1.38 (m, 4H), 0.90 (m, 3H).
  • To a stirred solution of Mg(OMe)2 (8% by weight in methanol 16.88 ml, 12.76 mM) was added 2-(1-hexenyl)phenol (3.44 g, 19.5 mmol) in toluene (18 ml). The reaction mixture was warmed to reflux and held at reflux for 2 hours. Toluene (18 ml) was added and the solvent distilled off until the reaction temperature rose to 93°C. A slurry of paraformaldehyde (1.8 g, 60 mmol) in toluene (18 ml) was added and the reaction heated at reflux for 3 hours. The reaction was allowed to cool to ambient temperature and stirred overnight. The reaction was diluted with toluene (20 ml) and washed with 2M aqueous H2SO4 (20 ml). The organic phase was washed with water until the aqueous phase was neutral in pH, dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl ether/hexane) to give 3-(1-hexenyl)-2-hydroxybenzaldehyde (2.32 g, 58%).
    NMR (200 MHz, DMSO-d6): δ11.35 (s, 1H), 10.02 (s, 1H), 7.77 (d, 1H), 7.65 (dd, 1H), 7.04 (t, 1H), 6.67-6.3 (m, 2H), 2.21 (m, 2H), 1.4 (m, 4H), 0.90 (t, 3H).
  • To a suspension of benzyltriphenylphosphonium bromide (5.25 g, 12.12 mmol) in THF (30 ml) was added LiN(SiMe3)2 [1N in THF, 24.26 ml]. The reaction was stirred at ambient temperature for 30 minutes and a solution of 3-(1-hexenyl)-2-hydroxybenzaldehyde (2.25 g, 11.03 mmol) in THF (5 ml) added. The reaction was stirred at ambient temperature for 60 hours, then quenched with water. The pH of the aqeuous layer was neutralised with HCl (1N) and the reaction mixture extracted twice with ethyl acetate. The combined organic phases were washed with water, dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl ether/hexane) to give 2-(2-phenethenyl)-6-(1-hexenyl)phenol, (2.28 g, 74%).
    NMR (200 MHz, DMSO-d6): (mixture of cis and trans isomers). δ8.9 (bs, 1H), 7.83-6.05 (complex multiplets , 12H), 2.2 (m, 2H), 1.38 (m, 4H), 0.90 (m, 3H).
  • To a solution of 6-hexenyl-2-(2-phenethenyl)phenol (2.15 g, 7.73 mmol) in ethanol (30 ml) was added 10% palladium on carbon (0.2 g). The reaction was placed under an atmosphere of hydrogen and stirred at ambient temperature for 18 hours. The reaction mixture was then filtered through Celite and evaporated. The residue was purified by chromatography to give 6-hexyl-2-(2-phenethyl)lphenol (1.66 g, 7%). NMR (200 MHz, DMSO-d6): δ8.1 (s, 1H, 7.2(m, 5H), 6.9 (d, 2H), 6.66 (t, 1H), 2.53 (m, 4H), 1.63-0.75 (broad multiplets, 13H).
    • Reference Example 32 Preparation of methyl 4-(6-benzene-2-(2-phenethyl)sulphonamidophenoxymethyl)benzoate:
  • A stirred solution of methyl 4-(6-amino-2-(2-phenethyl)phenoxymethyl)benzoate (0.553 g, 1.53 mmol) in dichloromethane (5ml) was treated with pyridine (0.36 g, 4.58 mmol) and benzenesulphonyl chloride (0.346 g, 1.97 mmol). The reaction was stirred at ambient temperature overnight then partitioned between dichloromethane and water. The organic layer was washed well with water, dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl ether/hexane) to give the title product (0.53 g, 69%).
    NMR (200 MHz, DMSO-d6): δ9.76 (bs, 1H) 7.97 (d, 2H), 7.78 (m, 2H), 7.57 (m, 5H), 7.05 (m, 8H), 4.68 (s, 2H), 3.88 (s, 3H), 2.71 (s, 4H).
    • Reference Example 33 Preparation of 2-hydroxy-3-(2-phenethyl)benzaldehyde:
  • To a stirred solution of Mg(OMe)2 [8% weight in methanol, 21.9 ml 16.47 mM) was added, over 5 minutes, a solution of 2-(2-phenethyl)phenol [5.0 g, 25.25 mM] in toluene (7 ml). The reaction was then heated to reflux and held at reflux for 1 hour (64°C), then toluene (23 ml) was added and the solvent distilled off until the reaction temperature reached 93°C. A suspension of paraformaldehyde (2.35 g, 78.3 mM) in toluene (15 ml) was then added over 10 minutes keeping the reaction temperature at 86°C. The reaction was heated at reflux for 3 hours, then allowed to cool to ambient temperature and to stand for 18 hours. The reaction was diluted with toluene (28 ml) and washed with 2M aqueous H2SO4 (27 ml). The organic phase was washed with water until a neutral pH was achieved. After drying (MgSO4) the solution was evaporated and the residue purified by chromatography (eluant: ethyl ether/hexane) to give the title product (3.11 g, 54%).
    NMR (200 MHz, DMSO-d6): δ11.15 (bs, 1H), 10.03 (s, 1H), 7.63 (dd, 2H), 7.44 (dd, 2H), 7.23 (m, 5H), 6.98 (t,1H), 2.88 (m, 9H).
    • Reference Example 34 Preparation of methyl 4-(6-acetyl-2-(2-phenethyl)phenoxymethyl)benzoate:
  • A solution of 2-hydroxy-3-(2-phenethyl)benzaldehyde (1.0 g, 4.4 mmol) in THF (30 ml) was cooled to -78°C under argon. Methyl lithium (1.4 M in ethyl ether, 6.6 ml, 9.2 mmol) was added dropwise keeping the temperature below -60° and the reaction mixture stirred at -70°C for 1 hour. The reaction was allowed to warm to 0°C and quenched with water, the pH of the mixture was adjusted to neutral with HOAc and it was extracted with ethyl acetate. The organic phase was dried (MgSO4) and evaporated. The resulting 6-(1-hydroxyethyl)2-(2-phenethyl)phenol was used in the subsequent step (1.1 g quantitative) without further purification.
    NMR (250 MHz, DMSO-d6): δ8.9 (s, 1H), 7.25 (m, 6H), 7.0 (m, 2H), 6.7 (t, 1H), 5.94 (bs, 1H), 5.03 (q, 1H), 2.84 (bs, 4H), 1.87 (d, 3H).
  • A solution of the above hydroxy phenol (0.525 g, 2.17 mmol) in DMF (10 ml) was treated with potassium carbonate (0.6 g, 4.35 mmol) and methyl 4-bromomethyl benzoate (0.596 g, 2.6 mmol). The reaction was stirred at ambient temperature overnight, then partitioned between ethyl acetate and water. The organic phase was washed well with water (4 x), brine, dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl ether/hexane) to give methyl 4-(6-(1-hydroxyethyl)-2-(2-phenethyl)-phenoxymethyl)benzoate (0.486 g, 57%).
    NMR (250 MHz, DMSO-d6): δ8.04 (d, 2H), 7.62 (d, 2H), 7.38 (dd, 1H), 7.14 (m, 7H), 5.05 (q, 1H), 4,9 (q, 2H), 3.89 (s, 3H), 2.85 (bs, 4H), 1.33 (d, 3H).
  • A solution of the alcohol from above (0.441 g, 1.13 mmol) in chloroform (10 ml) was treated with manganese dioxide (0.92 g, 10.6 mmol). The reaction was stirred at ambient temperature for 4 hours, then heated to 40°C and held at 40°C for 48 hours. The reaction mixture was filtered through Celite and evaporated. The residue was purified by chromatography (eluant: ethyl ether/hexane) to give methyl 4-(6-acetyl-2-(2-phenethyl)phenoxymethyl)benzoate: (0.268 g, 65%). NMR (250 MHz, DMSO-d6: δ7.99 (d, 2H), 7.57 (d, 2H), 7.5 (d, 2H), 7.15 (m, 6H), 4.4 (s, 2H), 3.87 (s, 3H), 2.85 (m, 4H), 2.54 (s, 3H).
    • Reference Example 35 Preparation of methyl 4-(6-(N-diethylamino)-2-(2-phenethyl)phenoxymethyl)benzoate:
  • A stirred solution of methyl 4-(6-amino-(2-(2-phenethyl)phenoxymethyl)benzoate (0.52 g, 1.44 mmol) in DMF (10 ml) was treated with K2CO3 (0.795 g, 5.76 mmol) and ethyl iodide (1.79 g, 11.5 mmol). The reaction was heated to 40°C and stirred at 40°C for 4 hours, then allowed to cool to ambient temperature and stirred for 18 hours. The reaction was filtered and partitioned between ethyl acetate/H2O. The organic phase washed with water (4X), dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl ether/hexane) to give the title product.
    NMR (200 MHz, DMSO-d6): δ7.98 (d, 2H), 7.57 (d, 2H), 7.05 (m, 8H), 5.04 (s, 2H), 3.87 (s, 3H), 3.14 (q, 4H), 2.78 (s, 4H), 0.96 (t, 6H).
    • Reference Example 36 Preparation of methyl 2-hydroxy-3-(2-phenethyl)benzoate:
  • A stirred suspension of washed sodium hydride (0.875 g, 60%, 21.87 mmol) in THF (30 ml) was treated with a solution of 6-bromo-2-(2-phenethyl)phenol (5.5 g, 19.8 mmol) in THF (20 ml). The reaction was stirred at ambient temperature for 30 minutes then cooled to -70°C. A solution of n-butyl lithium (1.6 M, 26 ml, 41.6 mmol) was added, keeping the temperature below -60°C, and the reaction was stirred at -70°C for 1 hour. The reaction was poured onto excess crushed CO2 in THF and allowed to warm to ambient temperature overnight. The mixture was acidified with aqueous HCl and extracted with ethyl acetate. The organic phase was dried (MgSO4) and evaporated and the residue purified by chromatography (eluant: methanol/CH2Cl2) to give 2-hydroxy-3-(2-phenethyl)benzoic acid (4.29 g, 89%).
    NMR (200 MHz, DMSO-d6): δ7.64 (dd, 1H), 7.2 (m, 6H), 6.63 (t, 1H), 2.64 (s, 4H).
  • A solution of 2-hydroxy-3-(2-phenethyl)benzoic acid (4.43 g, 18.3 mmol) in methanol (50 ml) was treated with concentrated H2SO4 (4 ml). The reaction was heated to reflux on a steam bath and held at reflux for 18 hours, then allowed to cool to ambient temperature and the solvent evaporated. The residue was purified by chromatography (eluant: ethyl ether/hexane) to give the title product (2.94 g, 63%).
    NMR (250 MHz, DMSO-d6): δ10.96 (bs, 1H), 7.66 (dd, 1H), 7.36 (dd, 1H), 7.24 (m, 5H), 6.84 (t, 1H), 3.91 (s, 3H), 2.87 (bs, 4H).
    • Reference Example 37 Preparation of tert-butyl 4-(6-cyanomethyl-2-(2-phenethyl)-phenoxymethyl)benzoate:
  • To a stirred solution of tert-butyl 4-(6-formyl-2-(2-phenethyl)phenoxymethyl)benzoate (6.32 g, 16.9 mmol) in ethanol (100 ml) was added portionwise NaBH4 (0.879 g, 23.25 mmol). The reaction mixture became faintly pink. The temperature of the mixture was kept below 30°C and stirred at ambient temperature for 1.5 hours. The solvent was evaporated and ethyl acetate added to the residue. This solution was added dropwise to a stirred solution of further 1N aqueous HCl (70 ml) and water (50 ml). The organic phase was washed with water, saturated aqueous sodium hydrogen carbonate and brine, dried (MgSO4) and evaporated. The residue containing tert-butyl 4-(6-hydroxymethyl-(2-(2-phenethyl)phenoxymethyl)benzoate was used without further purification in the subsequent step (6.15 g, 87%).
    NMR (250 MHz, DMSO-d6): δ7.95 (d, 2H), 7.59 (d, 2H), 7.18 (m, 8H), 5.05 (t, 1H), 4.9 (s, 2H), 4.57 (d, 2H), 2.83 (s, 4H), 1.58 (s, 9H).
  • A solution of tert-butyl 4-(6-hydroxymethyl-2-(2-phenethyl)phenoxymethyl)benzoate (0.711 g, 1.7 mmol) in dichloromethane (20 ml) was cooled to 0°C. Tetrabromomethane (0.694 g, 2.09 mmol) and triphenylphosphine-polymer bound (1.11 g, 3 mmol/g, 3.33 mmol) were added and the reaction was allowed to stir at 0°C for 1 hour and then allowed to warm to ambient temperature. The reaction was stirred at ambient temperature for 30 minutes then filtered and evaporated. The residue containing tert-butyl 4-(6-bromomethyl-2-(phenethyl)phenoxymethyl)benzoate was used without purification in the subsequent steps (0.82 g, quantitative).
    NMR (200 MHz, DMSO-d6): δ7.95 (d, 2H), 7.62 (d, 2H), 7.23 (m, 8H), 5.03 (s, 2H), 4.7 (s, 2H), 2.87 (s, 4H), 1.57 (s, 9H).
  • A solution of the containing tert-butyl 4-(6-bromomethyl-2-(2-phenethyl)phenoxymethyl)benzoate (0.82 g, 1.71 mmol) in DMSO (20 ml) was treated with NaCN (0.208 g, 4.24 mmol). The reaction was heated to 100°C for 10 minutes. The reaction mixture was partitioned between ethyl ether and water and the organic phase evaporated. The residue was purified by chromatography (eluant: ethyl ether/hexane) to give the title product (0.277, 38%).
    NMR (250 MHz, DMSO-d6): δ7.95 (d, 2H), 7.61 (d, 2H), 7.19 (m, 8H), 4.93 (s, 2H), 4.00 (s, 2H), 2.87 (s, 4H), 1.57 (s, 9H).
    • Reference Example 38 Preparation of tert-butyl 4-(6-methoxymethyl-2-(phenethyl)phenoxymethyl)benzoate:
  • Sodium hydride (0.1 g, 2.27 mmol) was washed with hexane (2X) and then suspended in THF (10 ml). tert-Butyl 4-(6-hydroxymethyl-2-(2-phenethyl)-phenoxymethyl)benzoate was added to this suspension (0.816 g, 1.95 mmol) as a solution in THF (5 ml). The reaction was stirred at ambient temperature for 30 minutes (until effervescence ceased). Methyl iodide (0.55 g, 3.87 mmol) was then added and the reaction stirred at ambient temperature for 1 ½ hours. The organic phase was dried (MgSO4) and evaporated and the residue purified by chromatography (eluant: ethyl ether/hexane) to give the title product.
    NMR (250 MHz, DMSO-d6): δ7.95 (d, 2H), 7.58 (d, 2H), 7.18 (m, 8H), 4.92 (s, 2H), 4.46 (s, 2H), 3.3 (s, 3H), 2.85 (s, 4H), 1.57 (s, 9H).
    • Reference Example 39 Preparation of methyl 4-(2-(2-phenethyl)-4-phenylthiomethylphenoxymethyl)benzoate:
  • Methyl 4-(4-hydroxymethyl-2-(2-phenethyl)phenoxymethyl)benzoate (0.5 g, 1.33 mmol) was dissolved in pyridine (3 ml), cooled to 0°C (under argon) and treated with PhSSPh (0.87 g, 4 mmol) and tributyl phosphine (0.8 g, 4 mmol). The mixture was allowed to warm to ambient temperature and stirred at ambient temperture overnight. The reaction was partitioned between ethyl ether and water and the etherial layer washed with water (2X), 1N HCl (2X), and brine (1X). The organic phase was dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl ether/hexane) to give the title product as a white solid (0.43 g).
    NMR (250 MHz, DMSO-d6): δ8.0 (d, 2H), 7.59 (d, 2H), 7.15 (m, 10H), 5.19 (s, 2H), 4.15 (s, 2H), 3.88 (s, 3H), 2.8 (m, 4H).
    • Reference Example 40
  • The compounds of Table XXIV were prepared using a similar method to that of Reference Example 39.
    Figure 01160001
    • Reference Example 41
  • Not used.
    • Reference Example 42 Preparation of 4-hydroxymethyl-2-(2-phenethyl)phenol:
  • a) A solution of the ethyl 4-benzyloxy-3-(2-phenethenyl)benzoate, preparation described in Reference example 44 parts a)-d), (2.6 g, 7.25 mmol) in ethanol (40 ml) was treated with 10% palladium on carbon (0.25 g). The reaction was placed under an atmosphere of hydrogen and stirred at ambient temperature until the uptake of hydrogen ceased. The reaction was filtered through Celite and evaporated to give ethyl 4-hydroxy-3-(2-phenethyl)benzoate as a colourless gum (2.2 g, 84%).
    NMR (250 MHz, DMSO-d6): δ10.21 (brs, 1H), 7.7-7.1 (complex multiplets, together 7H),6.89 (m, 1H), 4.24 (q, 2H), 2.84 (s, 4H), 1.28 (t, 3H).
  • b) To a stirred suspension of LiAlH4 (0.93 g, 24.4 mmol) in freshly distilled THF (70 ml) under argon was added dropwise ethyl 4-hydroxy-3-(2-phenethyl)benzoate (4.4 g, 12.1 mmol) as a solution in THF (25 ml). Once the addition was complete the reaction was stirred at ambient temperature for four hours. Water was added to decompose the excess LiAlH4 and the pH was adjusted to pH1-2 by the addition of 1N aqueous HCl. The reaction mixture was extracted with ethyl acetate (2X). The combined extracts were washed with brine, dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl acetate/hexane) to give the title product as a colourless solid (1.25 g, 45%).
    NMR (200 MHz, CDCl3): δ7.18 (m, 7H), 6.72 (m, 1H), 4.68 (s, 1H), 4.57 (m, 2H), 2.91 (s, 4H).
    • Reference Example 43 Preparation of methyl 4-(4-cyanomethyl-2-(2-phenethyl)phenoxymethyl)benzoate:
  • To a stirred solution of the methyl 4-(4-hydroxymethyl-2-(2-phenethyl)phenoxymethyl)benzoate (0.5 g, 1,33 mmol) in dry CH2Cl2 (16 ml) at 0°C under argon was added tetrabromomethane (0.543 g, 1.64 mmol) followed by triphenylphosphine polymer bound (3 mmol/g) (0.89 g, 266 mmol). The reaction was stirred at 0°C for 1 hour, allowed to warm to ambient temperature and stirred for 1 hour. The reaction mixture was filtered to remove the polymer and evaporated to give methyl 4-(4-bromomethyl-2-(2-phenethyl)phenoxymethyl)benzoate which was used without further purification.
    NMR (250 MHz, DMSO-d6): δ8.00 (m, 2H), 7.6 (m, 2H), 7.2 (m, 8H), 5.4 (s, 2H), 4.65 (s, 2H), 3.87 (s, 3H), 2.9 (m, 4H).
  • To a solution of the above methyl 4-(4-bromomethyl-2-(2-phenethyl)phenoxymethyl)benzoate (1.33 mmol, 0.58 g) in DMSO (15 ml) was added sodium cyanide (0.163 g, 3.32 mmol). The reaction was stirred at ambient temperature for 2 hours and then allowed to stand overnight. The reaction mixture was partitioned between ethyl ether and water and the aqueous layer was washed with ethyl ether (2x). The combined etherial extracts were washed with brine, dried (MgSO4) and evaporated. The residue was purified by chromatography to give the title product as an off-white solid (0.2 g, 38%).
    NMR (200 MHz, DMSO-d6): δ8.0 (d, 2H), 7.60 (d, 2H), 7.17 (m, 8H), 5.23 (s, 2H), 3.89 (s, 2H), 3.66 (s, 3H), 2.66 (bs, 4H).
    • Reference Example 44 Preparation of 4-(N-diethylcarbamoyl)-2-(2-phenethyl)phenol:
  • A solution of 5-bromo-2-benzyloxybenzaldehyde, prepared from commercial 5-bromosalicylicaldehyde by benzylation according to the method given in Reference example 22a), (25 g, 74.6 mmol) in toluene (250 ml) was treated with ethylene glycol (5 ml), and p-toluenesulfonic acid (0.24 g). The reaction was heated to reflux with azeotropic removal of water (Dean Stark trap). After 2.5 hrs, no further water was collected. The reaction was cooled to ambient temperature and washed with saturated aqueous NaHCO3, dried (MgSO4) and evaporated to give 2-(2-benzyloxy-5-bromophenyl)-1,3-dioxolane as a pale orange solid (26.8 g). This material was used without purification.
    NMr (200 MHz, DMSO-d6): 7.42 (m, 7H), 7.08 (m, 1H), 6.03 (s, 1H), 5.18 (s, 2H), 3.98 (m, 4H).
  • b) A solution of 2-(2-benzyloxy-5-bromophenyl)-1,3-dioxolane (7.8 g, 23.2 mmol) in freshly distilled THF (160 ml) was cooled to -75°C with stirring under an argon atmosphere. To this solution was added n-butyl lithium (25.6 ml, 1.6 M in hexane) keeping the temperature below -70°C. The reaction mixture was stirred at -70°C for 1 hour. The reaction was allowed to warm to -60°C and added to a cooled (-60°C) solution of ethyl chloroformate (5.05 g, 46.5 mmol) in freshly distilled THF (70 ml). The reaction was allowed to warm to ambient temperature and stirred overnight. The reaction mixture was diluted with ethyl ether (100 ml), washed with ice/water (1 x 50 ml), saturated aqueous NaHCO3 (1 x 35 ml), brine (1 x 35 ml) dried over MgSO4 and evaporated. The product was purified by chromatography (eluant: ethyl ether/hexane) to give 2-(2-benzyloxy-5-ethoxycarbonylphenyl)-1,3-dioxolane as a colourless gum (4.2 g, 55%).
    NMR (200 MHz, DMSO-d6): δ8.03 (d, 1H), 7.94 (dd, 1H), 7.42 (m, 6H), 6.05 (s, 1H), 5.25 (s, 2H), 4.29 (q, 2H), 4.0 (m, 4H), 1.30 (t, 3H).
  • c) A solution of the above dioxolane (1.0 g, 3.05 mmol) in ethanol (5 ml) and THF (5 ml) was treated with 2N aqueous HCl (3 ml). The reaction was allowed to stand at ambient temperature overnight then evaporated to low bulk, treated with ice, water and extracted with ethyl acetate (2x). The combined organic extracts were washed with water, saturated aqueous sodium bicarbonate and brine, dried (MgSO4) and evaporated to give ethyl 4-benzyloxy-2-formylbenzoate as a colourless gum (0.88 g). This material was used in the subsequent step without further purification.
    NMR (200 MHz, DMSO-d6): δ10.40 (s, 1H), 8.23 (m, 2H), 7.44 (m, 6H), 5.4 (s, 2H), 4.32 (q, 2H), 1.32 (t, 3H).
  • d) A suspension of benzyl triphenylphosphonium bromide (1.34 g, 31. mmol) in freshly distilled THF (15 ml) was treated with LiN(SiMe3)2 (1N in THF, 3.7 ml). After stirring for 45 minutes at ambient temperature the red solution was treated with a solution of ethyl 4-benzyloxy-2-formylbenzoate (0.88 g, 31. mmol) THF (3 ml). The reaction was stirred at ambient temperature for 24 hours, then partitioned between ethyl ether and water. The combined etherial extracts were washed with brine, dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl ether/hexane) to ethyl 4-benzyloxy-3-(2-phenethenyl)benzoate as a colourless gum (0.57 g, 51%).
    NMR (200 MHz, DMSO-d6): (mixture of cis and trans isomers) δ8.3-6.6 (series of complex multiplet taken together 15H), 5.32 and 5.22 (two singlets, together 2H), 4.3 and 4.15 (two quartets, together 2H), 1.34 and 1.19 (two triplets, together 3H).
  • e) A solution of the above ester (0.57 g, 1.6 mmol) in ethanol (8 ml) and THF (8 ml) was treated with 1N aqueous NaOH (3.5 ml) and allowed to stand at ambient temperature overnight. The reaction was partially evaporated, diluted with water, acidified with acetic acid and extracted with ethyl acetate (2x). The combined extracts were dried (MgSO4) and evaporated to give 4-benzyloxy-3-(2-phenethenyl)benzoic acid as a white solid (0.47 g).
  • f) A suspension of the above acid (0.47 g, 1.4 mmol) in dry CH2Cl2 (10 ml) was treated with oxalyl chloride (0.23 g, 1.77 mmol) and 3 drops of DMF. The reaction was stirred at ambient temperature for 3.5 hours then the solvent was evaporated to dryness, the residue taken up in dry CH2Cl2 and the solvent evaporated a second time. Finally the acid chloride was dissolved in dry CH2Cl2 (5 ml). The resultant solution of acid chloride was added to a solution of diethylamine (0.113 g, 1.54 mmol) and triethylamine (0.424 g, 4.2 mmol) in dry CH2Cl2 (5 ml) at ambient temperature. The reaction mixture was allowed to stand at ambient temperature overnight and then the solvent was evaporated. The residue was purified by chromatography (eluant: ethyl ether/hexane HOAc) to give
    N,N-diethyl-4-benzyloxy-3-(2-phenethenyl)benzamide as a colourless gum (0.3 g, 56%).
    NMR (250 MHz, DMSO-d6): (mixture of cis, trans) 67.7-6.6 (complex multiplets, together 15H), 5.26 and 5.2 (2 singlets, together 2H), 3.2 (broad multiplet, partially obscured by H2O), 1.13 (broad triplet) and 0.92 (broad singlet) (together 6H).
  • g) A solution of the above amide (0.3 g, 0.78 mmol) in ethanol (10 ml) was treated with 10% palladium on carbon (0.03 g). The reaction mixture was placed under a hydrogen atmosphere, stirred until the uptake of hydrogen ceased, filtered and evaporated to give 4-(N-diethylcarbamoyl)-2-(2-phenethyl)phenol as a colourless gum (0.227 g, 98%).
    NMR (200 MHz, DMSO-d6): δ9.71 (broad s, 1H), 7.42-7.08 (m, 5H), 7.00 (m, 2H), 6.82 (d, 1H), 3.25 (m, partially obscured by H2O), 2.83 (s, 4H), 1.05 (m, 6H).
    • Reference Example 45 Preparation of methyl 4-(4-hydroxyimino-2-(2-phenethyl)phenoxymethyl)benzoate:
  • Methyl 4-(4-formyl-2-(2-phenethyl)phenoxymethyl)benzoate (0.18 g, 0.48 mMol) was dissolved in ethanol (3 ml) and treated with hydroxylamine hydrochloride (0.040g, 0.57 mMol) and pyridine (0.1 ml). The reaction mixture was refluxed on a steam bath for 3 hours, then allowed to cool to ambient temperature. The resulting precipitate was dissolved in ethyl ether and the organic solution washed with 2N aqueous HCl (2x), water (1x) and brine (1x). The etherial layer was dried (MgSO4) and evaporated to give the title product as white solid (0.19 g, quantitative).
    NMR D1065 (200 MHz, DMSO-d6): δ11.24 (s, 1H), 8.43 (s, 1H), 8.00 (d, J=8.3 Hz, 2H), 7.65 (m, 3H), 7.21 (m, 5H), 7.02 (m, 1H), 6.88 (m, 1H), 5.29 (s, 2H), 3.88 (s, 3H), 3.01 (m, 2H), 2.85 (m, 2H).
    • Reference Example 46
  • The compounds of Table XXV were prepared using a similar method to that of Reference Example 45.
    Figure 01210001
    • Reference Example 47 Preparation of methyl 4-(4-methanesulphinyl-2-(2-phenethyl)phenoxymethyl)benzoate:
  • A solution of the methyl 4-(4-methylthio-2-(2-phenethyl)phenoxymethyl)benzoate (0.73 g, 1.79 mMol) in CH2Cl2 (25 ml) was cooled to -10°C. To this solution was added portionwise 3-chloroperoxybenzoic acid (0.586 g, 55%, 1.86 mMol). The temperature of the reaction was maintained below 8°C. Once the addition of the peracid was complete (2 hours total reaction time) no starting material could be detected by TLC (ethyl ether/hexane). The reaction mixture was washed with saturated aqueous NaHCO3, dried (MgSO4) and evaporated. The crude product was purified by chromatography (eluant: ethyl acetate/ethyl ether) to give the title product as a white solid (0.55 g, 75%).
    NMR (200 MHz, DMSO-d6): δ8.01 (d, 2H), 7.63 (d, 2H), 7.46 (m, 2H), 7.18 (m, 6H), 5.30 (s, 2H), 3.88 (s, 3H), 2.92 (m, 4H).
    • Reference Example 48
  • The compounds of Table XXVI were prepared from the appropriate thio compound using a similar method to that of Reference Example 47.
    Figure 01220001
    • Reference Example 49 Preparation of methyl 4-(4-(methylsulphonyl-2-(2-phenethyl)phenxoymethyl)benzoate:
  • A solution of methyl 4-(4-methylthio-2-(2-phenethyl)phenoxymethyl) benzoate (0.77 g, 1.96 mMol) was cooled to 0°C. 3-Chloroperoxybenzoic acid (1.23 g, 55%, 3.92 mmol in 15 ml CH2Cl2) was added keeping the temperature below 2°C. The reaction was stirred for 30 minutes to 0°C and then warmed to ambient temperature. The reaction mixture was stirred for 30 minutes at ambient temperature, then washed with saturated aqueous NaHCO3 (2x), dried (MgSO4) and evaporated. The crude product was purified by chromatography (eluant ethyl ether/hexane) to give the title product as a white solid (0.45 g, 54%).
    NMR (200 MHz, DMSO-d6): δ8.01 (d, 2H), 7.67 (m, 4H), 7.22 (m, 6H), 5.36 (s, 2H), 3.87 (s, 3H), 3.08 (s, 3H), 2.92 (m,4H).
    • Reference Example 50
  • The compounds of Table XXVII were prepared from the appropriate thio compound using a similar method to that of Reference Example 49.
    Figure 01230001
    • Reference Example 51 Preparation of 4-nitro-2-(2-phenethyl)phenol, 6-nitro-2-(2-phenethyl)phenol and 4,6-dinitro-2-(2-phenethyl)phenol:
  • Concentrated nitric acid (2.08 ml, 33 mMol] was added carefully to acetic anhydride (8.4 ml) at 0°C. The mixture was stirred at 0°C for 15 minutes, then 2-(2-phenethyl)phenol (6.2 g, 31.3 mmol in 200 ml of acetic anhydride) was added at 0°C. Once the addition was complete the yellow solution was allowed to warm to ambient temperature and to stand overnight. The reaction mixture was concentrated at reduced pressure and the residue purified by chromatography (eluant: ethyl ether/hexane) to give 6-nitro-2-(2-phenethyl)phenol (A) (2.4 g) as a bright yellow solid. An orange/yellow solid (3.8 g) was also obtained. This was purified by chromatography (eluant: ethyl acetate/hexane) to give 4,6-dinitro-2-(2-phenethyl)phenol (B) (0.70 g) as an orange solid and 4-nitro-2-(2-phenethyl)phenol (C) (1.5 g)].
  • (A) : NMR (200 MHz, DMSO-d6): δ10.54 (s, 1H), 7.86 (dd, J = 1.6, 8.4 Hz, 1H), 7.49 (dd, J = 1.6, 7.4 Hz,1H), 7.25 (m, 5H), 6.95 (dd, J = 8.4, 7.4 Hz, 1H)2.91 (m, 4H).
  • (B) : NMR (200 MHz, DMSO-d6): δ8.61 (d, J = 2.86 Hz, 1H), 8.27 (d, J = 2.86 Hz, 1H), 7.23 (m, 5H), 3.04 (m, 2H), 2.89 (m, 2H).
  • (C): NMR (200 MHz, DMSO-d6): δ11.05 (bs, 1H), 8.00 (m, 2H), 7.25 (m, 5H), 6.97 (d, J = 9.3 Hz, 1H), 2.88 (bs, 4H).
    • Reference Example 52 Preparation of 4-hexyl-2-(2-phenethyl)phenol:
  • To a suspension of pentyl triphenylphosphonium bromide (4.76 g, 11.5 mMol) in freshly distilled THF (40 ml) was added LiN(SiMe3)2 (1N in THF, 23 ml). The red solution was stirred at ambient temperature for 30 minutes then a solution of p-hydroxybenzaldehyde (1.06 g, 10 mMol) in THF (10 ml) added. The reaction was stirred at ambient temperature for 4 days, then partitioned between ethyl ether and dilute aqueous HCl (1N). The combined etherial extracts were washed with brine, dried (MgSO4) and evaporated. The crude oil was purified by chromatography (eluant: ethyl ether/hexane) to give 4-(1-hexenyl)phenol as a pale yellow solid (1.5 g, 85%).
    NMR (200 MHz, DMSO-d6) (mixture of cis and trans isomers): δ9.33 (s, 1H), 7.14 (m, 2H), 6.70 (m, 2H), 6.26 (m, 1H), 6.1-5.35 (multiplets, together 1H), 2.35-2.08 (m, 2H), 1.36 (m, 4H), 0.89 (m, 3H). 4-(1-Hexenyl)phenol in toluene (8 ml) was added to Mg(OMe)2 (7.3 ml, 8% wt/wt solution in methanol, 5.5 mMol) and the resultant red solution heated at reflux for 1 hour. The mixture was then distilled until the reaction temperature rose to 95°C. A suspension of paraformaldehyde (0.78 g, 26 mmol) in toluene (5 ml) was then added and the reaction heated at reflux for three hours. The reaction was allowed to cool to ambient temperature and to stir overnight. The reaction mixture was then diluted with toluene and washed with 2M aqueous H2SO4 (10 ml). The organic layer was washed with water (3x), dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl ether/hexane) to give 5-(1-hexenyl)-2-hydroxybenzaldehyde as a yellow/green oil (0.65 g, 38%).
    NMR (200 (MHz, DMSO-d6): (mixture of cis and trans isomers): δ10.74 (bs, 1H), 10.32 and 10.29 (2 singlets, togeher 1H), 7.66-7.44 (m, 2H), 7.02 (m, 1H), 6.5-6.33 (m, 1H), 6.3-5.6 (multiplets, together 1H), 2.24 (m, 2H), 1.43 (m, 4H), 0.95 (m, 3H).
  • To a suspension of benzyl triphenyl phosphonium bromide (4.0 g, 3.5 mmol) in freshly distilled THF (20 ml) was added as a solution of LiN(SiMe3)2 (1N, 7.0 ml). The red solution was stirred at ambient temperature for 45 minutes and then a solution of the aldehyde, from above, (0.65 g, 3.2 mmol) in THF (8 ml) was added. The resultant reaction was stirred at ambient temperature for 4 days then treated with 1N aqueous HCl (10 ml) and extracted with ethyl ether (2x). The combined extracts were washed with brine, dried MgSO4 and evaporated. The residue was purified by chromatography (eluant: ethyl ether/hexane) to give 4-(1-hexenyl)-2-(2-phenethyl)phenol as a pale yellow solid (0.5 g, 56%, mixture of cis and trans isomers of both olefins).
    NMR (200 MHz, DMSO-d6): δ9.68 (bs, 1H), 7.55-5.40 (complex multiplets, 12H), 2.4-2.0 (m, 2H), 1.33 (m, 4H), 0.85 (m, 3H).
  • To a solution of 4-(1-hexenyl)-2-(2-phenethenyl phenol (0.5 g, 1.8 mmol) in ethanol (40 ml) was added 10% palladium on carbon (0.050 g). The reaction was placed under an atmosphere of hydrogen and to stirred at STP until the uptake of hydrogen ceased. The reaction was filtered to remove catalyst. The filtrate was evaporated to leave a colourless oil which was used without purification (0.5 g, 99%).
    NMR (250 MHz, DMSO-d6): δ8.96 (bs, 1H), 7.22 (m, 5H), 6.79 (m, 2H), 6.69 (d, 1H), 2.79 (m, 4H), 2.41 (bt, 2H), 1.47 (m, 2H), 1.26 (m, 6H), 0.86 (bt, 3H).
    • Reference Example 53 Preparation of 2-hydroxy-5-methylbenzaldehyde:
  • a) To a suspension of LiAlH4 (2.5 g, 66 mmol) LiAlH4 in freshly distilled THF (8 ml) at 0°C under argon, was added dropwise with stirring a solution of 5-methylsalicylic acid (5 g, 33 mMol) in freshly distilled THF (80 ml). Addition was complete in 0.75 hours and the reaction stirred at ambient temperature overnight. Careful addition of water (5 ml) was followed by the addition of ice (10 ml) and concentrated HCl (1 ml). The solvent was decanted and the residue treated with ethyl ether and ice water. The pH of the mixture was adjusted to pH 1 with concentrated HCl and the organic layer combined with the decanted solvent, washed with brine, dried (MgSO4) and evaporated. The residue was subjected to chromatography (eluant: ethyl ether/hexane) to give 2-hydroxymethyl-4-methylphenol as a white solid (3.1 g, 68%).
    NMR: (200 MHz, DMSO-d6): δ8.96 (bs, 1H), 7.06 (bs, 1H), 6.82 (bd, 1H), 6.62 (d, 1H), 4.44 (s, 2H), 2.19 (s, 3H).
  • b) 2-Hydroxymethyl-4-methylphenol (3.1 g, 22.4 mMol) was dissolved in CHCl3 (95 ml). The solution was treated with manganese dioxide (8.7 g, 100 mmol) and the reaction stirred at ambient temperature overnight under an argon atmosphere. The reaction was then filtered through Celite and the solvent evaporated. The residue was subjected to chromatography (eluant: ethyl ether/hexane) to give 2-hydroxy-5-methylbenzaldehyde as a pale green solid (0.63 g, 20.7%).
  • NMR (200 MHz, DMSO-d6): δ10.45 (s, 1H), 10.21 (s, 1H), 7.45 (bs, 1H), 7.33 (dd, 1H), 6.89 (d, 1H), 2.45 (s, 3H).
    • Reference Example 54 Preparation of 4-hydroxy-3-(2-phenethyl)benzaldehyde:
  • A solution of 2-(2-phenethyl)phenol (5 g, 25.3 mmol) in dry dichloromethane (10 ml) under an argon atmosphere, at -5°C, was treated with a solution of TiCl4 in CH2Cl2 (1N, 56.5 ml), maintaining the temperature below -3°C (exothermic). To the deep red solution was added Cl2CHOCH3 (3.5 g, 30.4 mmol), again maintaining the temperature below -3°C. The reaction was allowed to warm to 0°C and to stir for 1 hour, then the reaction was allowed to warm to ambient temperature and to stir for 2.5 hours. The nearly black reaction mixture was poured onto ice (25 g) and HCl (1 ml) and ethyl ether (50 ml) added. After stirring for 30 minutes the mixture was extracted with ethyl acetate (2 x 100 ml) and the combined extracts washed with brine, dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl ether/hexane) to give the title product (0.18 g) as an off-white solid.
    NMR (200 MHz, DMSO-d6): δ10.27 (s, 1H), 9.34 (s, 1H), 7.81 (dd, 1H), 7.58 (dt, 1H), 7.38 (m, 2H), 6.98 (d, 2H), 6.78 (d, 1H), 6.67 (t, 1H), 3.25 (m, partially obscured by H2O), 2.78 (m, 2H).
    • Reference Example 55 Preparation of 2-hydroxy-5-pivaloyloxy-benzaldehyde:
  • To a cooled (-8°C), stirred suspension of 2,5-dihydroxybenzaldehyde (13 g, 93.6 mmol) in of CH2Cl2 (65 ml) (dried over 4A sieves) (65 ml) was added triethylamine (6.5 ml, 46.8 mmol) to give a deep red solution. Pivaloyl chloride (5.6 g, 46.8 mmol) was added portionwise keeping the temperature below 0°C. After the addition was complete the reaction was allowed to warm to ambient temperature and stirred overnight. The reaction was washed with 2N aqueous HCl, water, saturated aqueous NaHCO3 and dried (MgSO4). The organic solution was filtered and evaporated and the residue purified by chromatography (eluant: CH2Cl2/hexane) to give the title product as a colourless oil which crystallized on standing (4.7 g, 45% based on limiting reagent).
    NMR (200 MHZ, DMSO-d6): δ10.74 (bs, 1H), 10.25 (s, 1H), 7.27 (m, 2H), 7.02 (d, 1H), 1.29 (s, 9H).
    • Reference Example 56
  • Not used.
    • Reference Example 57 Preparation of tert-butyl 4-(4-N-methylcarbamoyl-2-(2-phenethyl)phenoxymethyl)benzoate:
  • A solution of the tert-butyl 4-(4-methoxycarbonyl-2-(2-phenethyl)phenoxymethyl)benzoate (1.12 g, 2.5 mmol) in THF (10 ml) and t-butanol (10 ml) was treated with 1N aqueous NaOH (10 ml). The reaction was stirred at ambient temperature for 60 hours, the solvent partially evaporated, diluted with water and acidified with acetic acid. The mixture was extracted with ethyl acetate (2x) and the combined extracts were washed with brine (2x), dried (MgSO4) and evaporated to give tert-butyl 4-(4-carboxy-2-(2-phenethyl)phenoxymethyl)benzoate as a white solid (1.0 g, 93%).
    NMR (250 MHz, DMSO-d6): δ12.5 (very broad singlet, 1H), 7.95 (d, 2H), 7.78 (m, 2H), 7.6 (d, 2H), 7.15 (m, 6H), 5.3 (s, 2H), 2.88 (m, 4H), 1.55 (s, 9H).
  • A solution of tert-butyl 4-(4-carboxy-2-(2-phenethyl)phenoxymethyl)benzoate as (1.0 g, 2.3 mmol) in freshly distilled THF (12 ml) was treated with n-methyl morpholine (0.23 g, 2.3 mmol). The solution was cooled to -20°C under argon and isobutyl chloroformate (0.32 g, 2.3 mmol) added keeping the temperature below -20°C. The reaction was allowed to warm to -10°C over 30 minutes, then to -35°C and treated with methylamine in methanol (1.3 ml of 33% w/w solution, 10 mmol) keeping the temperature below -20°C. The reaction was then allowed to warm to ambient temperature, water was added and the reaction was extracted with ethyl ether (2x). The combined etherial extracts were washed with brine, dried (MgSO4) and evaporated. The product was purified by chromatography (ethyl acetate/ethyl ether) to give the title product as a white solid (0.33 g, 32%).
    NMR (200 MHz, DMSO-d6): δ8.2 (bm, 1H), 7.93 (d, 2H), 7.63 (m, 4H), 7.2 (m, 6H), 5.27 (s, 2H), 2.88 (bs, 4H), 2.76 (d, 3H), 1.55 (s, 9H).
    • Reference Example 58 Preparation of methyl 4-hydroxy-3-(2-phenethyl)benzoate:
  • A suspension of 3-formyl-4-hydroxybenzoic acid (3.9 g, 23.5 mmol) in of methanol (50 ml) was cooled below 0°C. To the suspension was added concentrated H2SO4 (3 ml) and the reaction was allowed to warm to ambient temperature and stirred for 60 hours. The reaction was heated to reflux for 12 hours, the solvent evaporated and residue subjected to chromatography (eluant: ethyl ether/hexane) to give methyl 3-formyl-4-hydroxybenzoate as a white solid (3.55 g, 84%).
    NMR (200 MHz, DMSO-d6): δ11.53 (s, 1H), 10.30 (s, 1H), 8.25 (d, 1H), 8.06 (dd, 1H), 7.10 (d, 1H), 3.84 (s, 3H).
  • To a solution of methyl 3-formyl-4-hydroxybenzoate (3.55 g, 19.7 mmol) in DMF (20 ml) was added benzyl bromide (3.70 g, 21.67 mmol) and K2CO3 (4.1 g, 29.6 mmol). The reaction was stirred at ambient temperature overnight and the solvent evaporated to dryness (at reduced pressure). The residue was partitioned between ethyl ether and water and the aqueous layer extracted a second time with ethyl ether. The organic extracts were combined, washed with brine, dried (MgSO4) and evaporated to give methyl 3-formyl-4-benzyloxybenzoate as an off-white solid which was used without further purification.
    NMR (200 MHz, DMSO-d6): δ10.40 (s, 1H), 8.22 (m, 2H), 7.44 (m, 6H), 5.38 (s, 2H), 3.85 (s, 3H).
  • To a stirred suspension of benzyl triphenylphosphonium bromide (8.96 g, 20.6 mmol) in freshly distilled THF (80 ml) was added LiN(SiMe3)2 (1N in THF, 23.6 ml). The resultant red solution was treated with a solution of methyl 4-benzyloxy-3-formylbenzoate, (5.5 g, 19.7 mmol) in THF (20 ml). The reaction was stirred at ambient temperature for 4 days, partitioned between ethyl ether and water and the water layer extracted with ethyl ether (2x). The combined organic extracts were washed with brine, dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: ethyl ether/hexane) to give methyl 4-benzyloxy-3-(2-phenethenyl)benzoate as a colourless solid (5.1 g, 75%).
    NMR (200 MHz, DMSO-d6) (mixture of cis and trans isomers): δ8.24-6.6 (series of complex multiplets, taken together 15H), 5.31 and 5.20 (two singlets, together 2H) 3.85 and 3.72 (two singlets, together 3H).
  • To a solution of methyl 4-benzyloxy-3-(2-phenethenyl)benzoate (0.5 g, 1.45 mmol) in methanol (12 ml) was added 10% palladium on carbon (0.05 g). The reaction was placed under an atmosphere of hydrogen and stirred vigorously until the uptake of hydrogen ceased, then filtered through Celite and evaporated to give the title product as a colourless solid (0.37 g, quantitative).
    NMR (200 MHz, DMSO-d6): δ10.28 (s, 1H), 7.66 (m, 1H), 7.24 (m, 5H), 6.88 (m, 1H), 3.66 (s, 3H), 2.83 (s, 4H).
    • Reference Example 59 Preparation of 4-acetyl-2-(2-phenethyl)phenol:
  • To a stirred suspension of benzyl triphenylphosphonium bromide (7.44 g, 17.2 mmol) in freshly distilled THF (60 ml), under argon, was added a solution of LiN(SiMe3)2 (18.2 ml, 1N). The resulting red solution was allowed to stir for 30 minutes, then a solution of 5-bromo-2-benzyloxybenzaldehyde (5.0 g, 17.2 mmol) in freshly distilled THF (15 ml) added. The reaction was stirred at ambient temperature for 60 hours, treated with 1N aqueous HCl (60 ml) and extracted with ethyl ether (2x). The combined etherial extracts were washed with brine, dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant:hexane) to give β-(2-benzyloxy-5-bromophenyl)styrene as a white solid (5.5 g, 88%).
    NMR (250 MHz, DMSO-d6) (mixture of cis and trans isomers): δ7.6-6.5 (complex multiplets, taken together-15H), 5.22 and 5.14 (two singlets, together, 2H).
  • To a solution of the above olefin (5.5 g, 15 mmol) in toluene (120 ml) and ethanol (120 ml) was added Wilkinson's catalyst (0.55 g). The reaction mixture was hydrogenated at 50°C and 50 Bar for 18 hours, then evaporated. The residue was purified by chromatography (eluant: ethyl ether/hexane) to give 4-benzyloxy-3-(phenethyl)phenylbromide as a colourless oil which slowly crystallized (5.5 g, quantitative).
    NMR (200 MHz, DMSO-d6): δ7.25 (m, 1H), 5.13 (s, 2H), 2.83 (brs, 4H).
  • To a stirred solution of the 4-benzyloxy-3-(phenethyl)phenylbromide, (5.5 g, 15 mmol) in DMF (200 ml, dried) was added CuCN (3.32 g, 37 mmol). The reaction was heated to reflux and held at reflux for 20 hours, under argon. The reaction mixture was allowed to cool to ambient temperature, poured into ice water, treated with ethylene diamine (200 ml) and extracted with ethyl acetate (3 x 100 ml). The combined organic extracts were washed with brine (2 x 60 ml), dried (MgSO4) and evaporated. The crude material was purified by chromatography to give 4-benzyloxy-3-phenethylbenzonitrile as a white solid (2.0 g, 43%).
    NMR (250 MHz, DMSO-d6): δ7.38 (m, 13H), 5.25 (s, 2H), 2.85 (m, 4H).
  • A solution of the cyano benzyl ether [from above] (1.0 g, 3.2 mmol) in ethanol (100 ml) was treated with 10% palladium on carbon. The reaction was placed under an atmosphere of hydrogen, stirred until the uptake of hydrogen ceased, filtered through Celite and evaporated. The product was purified by chromatography (eluant: ethyl acetate/hexane) to give 4-cyano-2-(2-phenethyl)phenol as a white solid (0.64 g, 90%).
    NMR (250 MHz, DMSO-d6): δ10.58 (s, 1H), 7.47 (m, 2H), 7.23 (m, 5H), 6.95 (d, 1H), 2.83 (s, 4H).
  • A solution of 4-cyano-2-(2-phenethyl)phenol (0.64 g, 2.87 mmol) in THF (25 ml) under argon was cooled to -65°C. To the solution was added, over 10 minutes, a solution of methyl lithium (1.4 M in ethyl ether, 5 ml). The resultant reaction was allowed to warm to ambient temperature over 3 hours, treated with water and dilute aqueous HCl to approx pH 1. The reaction was extracted with ethyl acetate (2 x), the combined extracts washed with brine, dried (MgSO4) and evaporated and the residue purified by chromatography (eluant: ethyl acetate/hexane) to give the title product as an off-white solid (0.5 g, 72%).
    NMR (250 MHz, CDCl3): δ7.45 (m, 2H), 7.26 (m, 5H), 6.80 (m, 1H), 5.68 (s, 1H), 2.94 (s, 4H), 2.50 (s, 3H).
    • Reference Example 60
  • Not used.
    • Reference Example 61
  • Not used.
    • Reference Example 62
  • Not used.
    • Reference Example 63 Preparation of methyl 4-[6-methanesulphonyl-2-(2-phenethyl)phenoxymethyl]benzoate:
  • A solution of methyl 4-[6-methylthio-2-(2-phenethyl)phenoxymethyl]benzoate (0.38 g, 0.97 mmol) in dry CH2Cl2 (10 ml) was cooled to 0°C. To the cooled reaction was added a solution of m-CPBA (0.609 g, 55%, 1.94 mmol in 10 ml CH2Cl2), keeping the temperature below 2°C. The reaction mixture was stirred at 0°C for 20 minutes and then allowed to warm to ambient temperature over 30 minutes. The reaction mixture was washed twice with saturated NaHCO3 and the organic layer dried (MgSO4) and evaporated.
    NMR: (200 MHz, DMSO-d6) δ: 2.95 (m, 4H), 3.25 (s, 3H), 3.88 (s, 3H), 5.1 (s, 2H), 7.15 (m, 5H), 7.39 (t, 1H), 7.63 (d, 2H), 7.75 (d, 2H), 8.03 (d, 2H).
    • Reference Example 64 Preparation of methyl 4-[4-benzenesulphonylmethyl-2-(2-phenethyl)phenoxymethyl]benzoate
  • A solution of the methyl 4-[4-phenylthiomethyl-2-(2-phenethyl)phenoxymethyl]benzoate (0.43 g, 0.92 mmoles) in CH2Cl2 (5 ml) was cooled to 0°C. To this cooled solution was added portionwise, over 10 minutes, m-CPBA (0.58 g, [55%], 1.84 mmoles). The reaction was stirred at 0°C for 1.75 hours. The reaction mixture was diluted with CH2Cl2 and washed twice with saturated NaHCO3.
  • The organic phase was dried (MgSO4) and evaporated. The residue was purified by chromatography (diethyl ether/hexane) to give the title product (0.33 g, 72%).
    NMR (200 MHz, DMSO-d6): δ2.71 (m, 4H), 3.86 (s, 3H), 4.54 (s, 2H), 5.18 (s, 2H), 6.89 (bs, 1H), 6.96 (bs, 2H), 7.18 (m, 5H), 7.64 (m, 7H), 7.98 (d, 2H).
    • Reference Example 65
  • Not used.
    • Reference Example 66 Preparation of tert-butyl 4-[6-methanesulphonylmethyl-2-(2-phenethyl)phenoxymethyl]benzoate and tert-butyl 4-[6-methanesulphinylmethyl-2-(2-phenethyl)-phenoxymethyl]benzoate.
  • To a cooled (0°C) stirred solution of tert-butyl 4-[6-methylthiomethyl-2-(2-phenethyl)phenoxymethyl]benzoate (0.81, 1.8 mmol), in CH2Cl2 (30 ml) was added m-CPBA (1.13 g, (53%) 3.62 mmole) portionwise over 15 minutes. The reaction was stirred at 0°C for 30 minutes and then allowed to warm to ambient temperature. The reaction was diluted with CH2Cl2 and washed with saturated NaHCO3. The organic phase was dried (MgSO4) and evaporated and the residue was purified by chromatography (MeOH/CH2Cl2) to give the title products: tert-butyl 4-[6-methanesulphonylmethyl-2-(2-phenethyl)phenoxymethyl]benzoate (0.120 g, 14%) MS (CI+): 478 [M+NH4]+ and tert butyl 4-[6-methanesulphinylmethyl-2-(2-phenethyl)phenoxymethyl]benzoate (0.48 g, 60%) MS(CI+): 465 [M+H]+.
    • Reference Example 67 Preparation of methyl 3-(6-isopropyl-2-(2-phenethyl)phenoxymethyl)benzoate.
  • A solution of 6-isopropyl-2-(2-phenethyl)phenol (2.5 g, 19.42 mmol) in DMF (15 mL) was treated with K2CO3 (2.875 g, 20.83 mmol) and methyl 3-bromomethylbenzoate (2.62 g, 11.44 mmol). The reaction was stirred at ambient temperature overnight and then partitioned between ethyl acetate/H2O. The organic phase was washed with H2O(x4), dried (MgSO4) and evaporated. The residue was purified by chromatography (eluant: diethyl ether/hexane) to give methyl 3-(6-isopropyl-2-(2-phenethyl)phenoxymethyl)benzoate (3.3 g, 82%).
    NMR: (200 MH2, DMSO-d6): δ 8.11 (m, 1H), 7.96 (m, 1H), 7.74 (m, 1H), 7.57 (t, 1H), 7.15 (m, 8H), 4.87 (s, 2H), 3.87 (s, 3H), 3.30 (m, 1H), 2.86 (s, 4H), 1.19 (d, 6H).
    • Reference Example 68
  • Using a similar method to that of Reference Example 67, the compounds of Table XIV were prepared.
    Figure 01330001
    Figure 01340001
    • Reference Example 69 Preparation of tert-butyl 4-(6-N-methylcarbamoyl-2-(2-phenethyl)phenoxymethyl)benzoate.
  • A solution of tert butyl 4-(6-methoxycarbonyl-2-(2-phenethyl)phenoxymethyl)benzoate (0.42 g, 0.94 mmol) in methylamine (15 ml, 33% w/w in industrial methylated spirits) was placed in a carius tube and heated at 100°C for 12 hours. The reaction mixture was evaporated. The residue was purified by chromatography (dichloromethane, methanol) to give the desired product (0.29 g, 70%). MS (FAB+): 446 (M+H)+.
    The starting material was prepared according to Reference example 7 Table XVII compound 1.
    • Reference Example 70 Preparation of 3-chloro-2-hydroxybenzaldehyde.
  • a) A suspension of 3-chlorosalicylic acid (1.5 g, 8.7 mmol) in dichloromethane (10 ml) was treated with oxalyl chloride (1.59 g, 13 mmol) and 1 drop of DMF. The reaction was stirred at ambient temperature for 2 hours, evaporated to dryness and used immediatley in the next step.
  • b) 3-Chloro-2-hydroxybenzoylchloride (8.7 mmol) was dissolved in diglyme (10 ml) and cooled to -70°C under argon. Lithium tritertbutoxyaluminohydride (0.5 M, 34.8 ml 17.4 mmol) was added via syringe keeping the temperature below -60°C. The reaction was stirred at -60°C for 2½ hours. The reaction mixture was poured onto ice, acidified with concentrated HCl and extracted with ethyl acetate (2x). The organic phases were combined, dried over MgSO4 and evaporated. Flash chromatography (eluant: CH2Cl2/hexanes) gave the title product (0.2 g, 1.3 mmol).
    • MS (CI+) (M+NH4)+ 174

Claims (10)

  1. A compound of the formula (I):
    Figure 01360001
    wherein:
    A is an optionally substituted: 8- to 10-membered bicyclic heteroaryl, 5- or 6-membered heteroaryl, naphthyl or phenyl;
    provided that the -OCH(R3)- and -X- linking groups are positioned in a 1,2 relationship to one another on ring carbon atoms;
    B is an optionally substituted 5- or 6-membered heteroaryl ring system or optionally substituted phenyl;
    D is optionally substituted: pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, thienyl, furyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl or phenyl;
    X is of the formula -(CHR4)n- or -(CHR4)pCR4=CR4(CHR4)q- wherein n is 1 to 3 and p and q are either both 0 or one of p and q is 1 and the other is 0;
    R1 is positioned on ring B in a 1,3 or 1,4 relationship with the -OCH(R3)- linking group in 6-membered rings and in a 1,3 relationship with the -OCH(R3)- linking group in 5-membered rings
    and is carboxy, carboxyC1-3alkyl, tetrazolyl, tetrazolylC1-3alkyl, tetronic acid, hydroxamic acid, sulphonic acid, or R1 is of the formula -CONRaRa1 wherein Ra is hydrogen or C1-6 alkyl and Ra1 is hydrogen or optionally substituted; C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7 cycloalkyl, C3-7cycloalkylC1-6alkyl, C3-7cycloalkylC2-6alkenyl, C3-7cycloalkylC2-6alkynyl, C5-7cycloalkenyl, C3-7cycloalkenylC1-6alkyl; C5-7cycloalkenylC2-6alkenyl, C5-7cycloalkenylC2-6alkynyl, C1-3alkyl substituted by a 5- or 6-membered saturated or partially saturated heterocyclic ring, 5- or 6-membered heteroaryl C1-3alkyl, 5- or 6-membered saturated or partially saturated heterocyclic ring, or 5- or 6-membered heteroaryl; or wherein Ra and Ra1 together with the amide nitrogen to which they are attached (NRaRa1) form an amino acid residue or ester thereof; or R1 is of the formula -CONHSO2Rb wherein Rb is optionally substituted: C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl, C3-7cycloalkylC2-6alkenyl, C3-7cycloalkylC2-6alkynyl, C5-7cycloalkenyl, C5-7cycloalkenylC1-6alkyl, C5-7cycloalkenylC2-6alkenyl, C5-7 cycloalkenylC2-6alkynyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroarylC1-6 alkyl, phenyl, phenylC1-6alkyl, 5- or 6-membered saturated or partially saturated heterocyclyl or 5- or 6-membered saturated or partially saturated heterocyclylC1-6alkyl;
    R3 is hydrogen or C1-4alkyl;
    R4 is hydrogen or C1-4alkyl;
    or N-oxides thereof where chemically possible;
    or S-oxides of sulphur containing rings where chemically possible;
    or a pharmaceutically acceptable salt or an in vivo hydrolysable ester or amide thereof; excluding 4-(2-benzyl-3 -hydroxy-4-formylphenoxymethyl)-3-methoxybenzoic acid and 4-(2-(3-phenylprop-2-en-1-yl)-3-hydroxy-4-formylphenoxymethyl)-3-methoxybenzoic acid.
  2. A compound according to claim 1 wherein A is optionally substituted: phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thienyl or 1,2,3-thiadiazolyl.
  3. A compound according to either claim 1 or claim 2 wherein B is optionally substituted: phenyl, pyridyl, thiazolyl, thienyl, thiadiazolyl, pyrazinyl, pyridazinyl or pyrimidyl.
  4. A compound according to any one of claims 1 to 3 wherein D is optionally substituted phenyl.
  5. A compound according to any one of claims 1 to 4 of the formula (V).
    Figure 01380001
    wherein
    R1 and R3 are as defined in claim 1, R6 is hydrogen, halo, trifluoromethyl, nitro, hydroxy, amino, cyano, C1-6alkoxy, C1-6alkylS(O)p (p is 0, 1 or 2), phenylS(O)p (p is 0, 1 or 2), C1-6 alkyl (optionally substituted by hydroxy, amino, halo, nitro or cyano), C3-7cycloalkyl, C3-7 cycloalkylC1-3alkyl, carbamoyl, C1-4alkylcarbamoyl, di(C1-4alkyl)carbamoyl, C2-6alkenyl, C2-6alkynyl, C1-4alkoxycarbonylamino, C1-4alkanoylamino, C1-4alkanoyl(N-C1-4alkyl)amino, C1-4alkanesulphonamido,benzenesulphonamido, aminosulphonyl, C1-4 alkylaminosulphonyl, di(C1-4alkyl)aminosulphonyl, C1-4alkoxycarbonyl, C2-4alkanoyloxy, C1-6alkanoyl, formylC1-4alkyl, trifluoroC1-3alkylsulphonyl, hydroxyiminoC1-6alkyl, C1-4 alkoxyiminoC1-6alkyl or C1-6alkylcarbamoylamino, X is -(CH2)2- or -CH=CH- and B is phenyl, thiadiazolyl or pyridyl.
  6. A compound according to claim 1 which is:
    4-[6-bromo-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[5-nitro-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[4-chloro-6-methyl-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[5-bromo-6-cyano-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[5-chloro-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[4-cyanomethyl-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[6-bromo-2-(phenethyl)phenoxymethyl]-2-hydroxybenzoic acid;
    4-[5-methyl-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[2-(phenethyl)-6-phenylphenoxymethyl]benzoic acid;
    4-[6-amino-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[6-methanethio-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[4-(1-(hydroxyimino)ethyl)-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[4-methyl-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[4-bromo-2-(phenethyl)phenoxymethyl]benzoid acid;
    4-[4-methoxy-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[6-cyano-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[6-cyano-4-methyl-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[4-chloro-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[6-benzenesulphonylmethyl-2-(phenethyl)phenoxymethyl]benzoic acid; 4-[4-methanethio-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[5-bromo-2-(phenethyl)phenoxymethyl]benzoic acid;
    4-[6-isopropyl-2-(phenethyl)phenoxymethyl]benzoic acid;
    5-[4-(2-(phenethyl)-6-phenylphenoxymethyl)phenyl]tetrazole;
    5-[4-(4-hydroxy-2-(phenethyl)phenoxymethyl)phenyl]tetrazole;
    5-[4-(4-methoxy-2-(phenethyl)phenoxymethyl)phenyl]tetrazole;
    5-[4-(2-(phenethyl)phenoxymethyl)phenyl]tetrazole;
    5-[4-(4-chloro-2-(phenethyl)phenoxymethyl)phenyl]tetrazole;
    5-[4-(4-bromo-2-(phenethyl)phenoxymethyl)phenyl]tetrazole;
    5-[4-(6-bromo-2-(phenethyl)phenoxymethyl)phenyl]tetrazole; or
    5-[4-(6-isopropyl-2-(phenethyl)phenoxymethyl)phenyl]tetrazole, or
    a pharmaceutically acceptable salt or an in vivo hydrolysable ester or amide thereof.
  7. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier.
  8. The use of a compound of the formula (I), or a pharmaceutically acceptable salt or an in vivo hydrolysable ester or amide thereof, as defined in claim 1 in the manufacture of a medicament for use in the relief of pain in the animal (including human) body.
  9. A process for preparing a compound according to claim 1 which comprises deprotecting a compound of the formula (VI):
    Figure 01400001
    wherein R7 is R1 as defined in claim 1 or protected R1 ; and R3, X, A, B and D are as defined in claim 1 and any optional substituents are optionally protected and at least one protecting group is present;
    and thereafter if necessary:
    i) forming a pharmaceutically acceptable salt; and/or
    ii) forming an in vivo hydrolysable ester or amide.
  10. A process for preparing a compound of the formula (I) as defined in claim 1 or a compound of the formula (VI) as defined in claim 9 which comprises:
    a) when X is -(CHR4)n- and n is 2 or 3, by reducing a compound of the formula (VIII):
    Figure 01400002
    wherein A, B, D, R3, R4, R7, p and q are as hereinabove defined;
    b) by reacting a compound of the formula (IX) with a compound of the formula (X):
    Figure 01410001
    L-CH(R3)-B-R7 wherein A, B, D, R3, X and R7 are as hereinabove defined and L is a leaving group;
    c) when A is a activated heteroaryl ring, by reacting a compound of the formula (XI) with a compound of the formula (XII):
    Figure 01410002
    wherein A, B, D, X and R7 are as hereinbefore defined and thereafter if necessary:
    i) removing any protecting groups;
    ii) forming a pharmaceutically acceptable salt; and/or
    iii) forming an in vivo hydrolysable ester or amide.
EP95929969A 1994-08-31 1995-08-29 Ortho-substituted aromatic ether compounds and their use in pharmaceutical compositions for pain relief Expired - Lifetime EP0778821B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9417532 1994-08-31
GB9417532A GB9417532D0 (en) 1994-08-31 1994-08-31 Aromatic compounds
PCT/GB1995/002030 WO1996006822A1 (en) 1994-08-31 1995-08-29 Ortho-substituted aromatic ether compounds and their use in pharmaceutical compositions for pain relief

Publications (2)

Publication Number Publication Date
EP0778821A1 EP0778821A1 (en) 1997-06-18
EP0778821B1 true EP0778821B1 (en) 1999-10-20

Family

ID=10760629

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95929969A Expired - Lifetime EP0778821B1 (en) 1994-08-31 1995-08-29 Ortho-substituted aromatic ether compounds and their use in pharmaceutical compositions for pain relief

Country Status (8)

Country Link
US (1) US5965741A (en)
EP (1) EP0778821B1 (en)
JP (1) JPH10504836A (en)
AT (1) ATE185791T1 (en)
AU (1) AU3351995A (en)
DE (1) DE69512925T2 (en)
GB (1) GB9417532D0 (en)
WO (1) WO1996006822A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
GB9417532D0 (en) * 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
GB9420557D0 (en) * 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
TW502026B (en) 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
TW434240B (en) 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
US5834468A (en) 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
US5843983A (en) * 1996-02-15 1998-12-01 Sankyo Company, Limited Diphenylethane compounds containing a saturated heterocyclic group, their preparation, and their therapeutic use
US5919826A (en) * 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
US6242493B1 (en) 1998-03-13 2001-06-05 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
GB9903476D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
GB9919413D0 (en) * 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
JP4977297B2 (en) 1999-08-20 2012-07-18 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Composition comprising a tramadol substance and an anticonvulsant
CA2440374A1 (en) 2001-03-14 2002-09-19 Takayuki Maruyama A pharmaceutical composition for the treatment of depression comprising the ep1 antagonist as active ingredient
IL161581A0 (en) 2001-10-23 2004-09-27 Applied Research Systems Pyrazolidinone derivatives and their use
WO2003043655A1 (en) * 2001-11-19 2003-05-30 Ono Pharmaceutical Co., Ltd. Remedies for urinary frequency
ES2337887T3 (en) 2001-12-20 2010-04-30 Merck Serono Sa PIRROLIDINE DERIVATIVES IN QUALITY OF PROSTAGLANDINA MODULATORS.
CA2483555A1 (en) 2002-06-10 2003-12-18 Applied Research Systems Ars Holding N.V. Gamma lactams as prostaglandin agonists and use thereof
EP1727788B1 (en) * 2004-03-12 2010-07-28 Eli Lilly And Company Opioid receptor antagonists
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
FR2872159B1 (en) * 2004-06-28 2007-10-05 Merck Sante Soc Par Actions Si NOVEL PHENYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES
US7298297B1 (en) * 2004-08-18 2007-11-20 Mediatek Inc. Hardware-implemented Huffman decoder
US20060122222A1 (en) * 2004-11-18 2006-06-08 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids
US7696243B2 (en) 2004-12-06 2010-04-13 Merck Serono, S.A. Pyrrolidin-2-one derivatives for use as DP1 receptor agonists
JP2008525363A (en) 2004-12-23 2008-07-17 グラクソ グループ リミテッド Pyridine compounds for the treatment of prostaglandin-mediated diseases
EP1863755A1 (en) * 2005-03-21 2007-12-12 Merck & Co., Inc. Substituted aryl and heteroaryl derivatives
GB0508460D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
JP2008189549A (en) * 2005-05-12 2008-08-21 Astellas Pharma Inc Carboxylic acid derivative or its salt
JP5289046B2 (en) * 2005-05-19 2013-09-11 メルク カナダ インコーポレイテッド Quinoline derivatives as EP4 antagonists
US8283478B2 (en) 2005-05-20 2012-10-09 Janssen Pharmaceutica Nv Process for preparation of sulfamide derivatives
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
KR20130135399A (en) 2006-03-17 2013-12-10 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 Methods for preparing complex multivalent immunogenic conjugates
JP2009537525A (en) * 2006-05-16 2009-10-29 メルク エンド カムパニー インコーポレーテッド Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EA200870556A1 (en) 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. COMBINED THERAPY IN THE TREATMENT OF EPILEPSY AND RELATED DISORDERS
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders
JP5439817B2 (en) 2007-02-16 2014-03-12 小野薬品工業株式会社 Urine discharge disorder treatment
EP2125724B1 (en) 2007-03-26 2014-12-03 Merck Canada Inc. Naphthalene and quinoline sulfonylurea derivatives as ep4 receptor antagonists
EP2185534A1 (en) * 2007-08-09 2010-05-19 Merck Sharp & Dohme Corp. Process for making thiophene carboxamide derivative
US20100080786A1 (en) 2008-05-20 2010-04-01 Markus Berger Phenyl or Pyridinyl Substituted Indazoles Derivatives
PE20110060A1 (en) 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv CRYSTALLINE FORM OF (2S) - (-) - N- (6-CHLORO-2,3-DIHYDRO-BENZO [1,4] DIOXIN-2-ILMETHYL) -SULFAMIDE
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2010019796A1 (en) 2008-08-14 2010-02-18 Chemietek, Llc Heterocyclic amide derivatives as ep4 receptor antagonists
MX2012013560A (en) 2010-05-24 2013-03-05 Univ Vanderbilt Substituted-6-methylnicotinamides as mglur5 positive allosteric modulators.
JP6061373B2 (en) * 2012-07-24 2017-01-18 国立研究開発法人産業技術総合研究所 2-Hydroxybenzaldehyde compound, collagen extracellular secretion inhibitor and pharmaceutical composition containing the same
EP3036222A2 (en) * 2013-08-23 2016-06-29 Virginia Commonwealth University Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease
CN108276307A (en) * 2018-01-17 2018-07-13 常熟浸大科技有限公司 The synthetic method of 3- cyano -4- oxyl benzoic ethers
WO2020198537A1 (en) * 2019-03-28 2020-10-01 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor x4 and related products and methods

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657430A (en) * 1969-06-25 1972-04-18 Merck & Co Inc Composition and methods for treating inflammation
US3632760A (en) * 1969-06-25 1972-01-04 Merck & Co Inc Treatment of inflammation
AU510758B2 (en) * 1976-01-19 1980-07-10 The Dow Chemical Company P-benzylaminobenzoic acids
GB2041363B (en) * 1979-01-19 1982-10-06 Pfizer Ltd N-benzyl-imidazoles
US4578390A (en) * 1981-12-14 1986-03-25 Merck & Co., Inc. Hydroxybenzylamino derivatives as anti-inflammatory agents
US5105017A (en) * 1983-07-18 1992-04-14 Eli Lilly And Company Leukotriene antagonist intermediates
DE3326164A1 (en) * 1983-07-20 1985-01-31 Klinge Pharma GmbH, 8000 München NEW P-OXIBENZOESAEE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS
US4614617A (en) * 1985-02-25 1986-09-30 G. D. Searle & Co. Intermediates for 8-chlorodibenz[(b,f)][1,4]oxazepine-10(11H)-carboxylic acid, 2-(sulfinyl- and sulfonyl-containing acyl)hydrazides
WO1986005779A1 (en) * 1985-04-03 1986-10-09 Yamanouchi Pharmaceutical Co., Ltd. Phenylene derivatives
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4704386A (en) * 1985-08-29 1987-11-03 G. D. Searle & Co. 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[(phenylsulfinyl-, and phenylsulfonyl)alkanoyl]hydrazides
US5025036A (en) * 1987-10-01 1991-06-18 Hoffmann-La Roche Inc. Catechol carboxylic acids
DE3903989A1 (en) * 1989-02-10 1990-09-20 Basf Ag DIPHENYLHETEROALKYL DERIVATIVES, THEIR PREPARATION, AND MEDICAMENTS AND COSMETICS THEREOF
US5527945A (en) * 1989-02-10 1996-06-18 Basf Aktiengesellschaft Diphenylheteroalkyl derivatives, the preparation thereof and drugs and cosmetics prepared therefrom
US5262432A (en) * 1989-11-24 1993-11-16 Delalande S.A. Derivatives of 4-(hetero)arylmethyloxy phenyl diazole, a method of preparing them and use thereof in therapy
IE912956A1 (en) * 1990-09-10 1992-03-11 Abbott Lab Angiotensin ii receptor antagonists
GB9021813D0 (en) * 1990-10-08 1990-11-21 Ici Plc Tricyclic heterocycles
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ES2108120T3 (en) * 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int MONO- AND BICYCLE BIS ARYLIC AND HETEROARILIC COMPOUNDS INHIBITING EGF AND / OR PDGF TYPHOSINE KINASE.
FR2676439B1 (en) * 1991-05-13 1994-10-28 Cird Galderma NEW BI-AROMATIC COMPOUNDS DERIVED FROM A SALICYLIC PATTERN, THEIR PREPARATION PROCESS AND THEIR USE IN HUMAN AND VETERINARY MEDICINE AS WELL AS IN COSMETICS.
GB9120640D0 (en) * 1991-09-27 1991-11-06 Ici Plc Tricyclic heterocycles
US5324743A (en) * 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
DE4241632A1 (en) * 1992-12-10 1994-06-16 Thomae Gmbh Dr K New (aza)aromatic or alicyclic carboxylic acid cpds. - used e.g. for treating thrombosis, inflammation, osteoporosis, cardiac infarct or tumour metastasis
KR0161553B1 (en) * 1993-09-28 1999-05-01 사또오 아키오 Immunological detection method of pyrethroid compound, haptenic compound, intermediate for the haptenic compound, imunogen and antibody
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5552420A (en) * 1994-05-13 1996-09-03 Sterling Winthrop Inc. Therapeutic phenoxyalkylazoles and phenoxyalkylazines
US5441950A (en) * 1994-06-09 1995-08-15 G. D. Searle & Co. Substituted dibenzoxazepine and dibenzthiazepine carbamate compounds, pharmaceutical compositions and methods of use
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
GB9417532D0 (en) * 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
GB9420557D0 (en) * 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
TW434240B (en) * 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
TW502026B (en) * 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
US5834468A (en) * 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists

Also Published As

Publication number Publication date
JPH10504836A (en) 1998-05-12
AU3351995A (en) 1996-03-22
DE69512925D1 (en) 1999-11-25
GB9417532D0 (en) 1994-10-19
ATE185791T1 (en) 1999-11-15
US5965741A (en) 1999-10-12
WO1996006822A1 (en) 1996-03-07
EP0778821A1 (en) 1997-06-18
DE69512925T2 (en) 2000-05-04

Similar Documents

Publication Publication Date Title
EP0778821B1 (en) Ortho-substituted aromatic ether compounds and their use in pharmaceutical compositions for pain relief
EP0752421B1 (en) Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
EP0733033B1 (en) Pharmaceutically active substituted aromatic compounds
JP3949166B2 (en) Aromatic compounds and pharmaceutical compositions containing the compounds
EP0773930B1 (en) Aromatic amino ethers as pain relieving agents
JP3992666B2 (en) Carboxylic acid derivatives
US6043284A (en) Anti-atherosclerotic diaryl compounds
US7446222B2 (en) Phenyl compounds
JP3895404B2 (en) Chalcone derivative and pharmaceutical containing the same
US6313148B1 (en) Aromatic amine compounds that antagnoize the pain enhancing effects of prostaglandins
CA2017376C (en) Diarylstyrylquinoline diacids
JPH0592956A (en) Nitrogenous heterocyclic compound
JPH0390063A (en) Disubstituted(quinoline-2-yl-methoxy) phenylacetic acid derivative
US20050239802A1 (en) (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives
JPH033658B2 (en)
JPH07119188B2 (en) Chalcone derivative
JP2021534251A (en) 1-Methyl-4-[(4-phenylphenyl) sulfonylmethyl] cyclohexanol compounds and 1-methyl-4-[[4- (2-pyridyl) phenyl] sulfonylmethyl] cyclohexanol compounds and their therapeutic uses
JPH03157376A (en) Thiazole based compound and use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 970401;LV PAYMENT 970401;SI PAYMENT 970401

17Q First examination report despatched

Effective date: 19971205

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 19970401;LV PAYMENT 19970401;SI PAYMENT 19970401

LTIE Lt: invalidation of european patent or patent extension
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19991020

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991020

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991020

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19991020

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991020

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991020

REF Corresponds to:

Ref document number: 185791

Country of ref document: AT

Date of ref document: 19991115

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

REF Corresponds to:

Ref document number: 69512925

Country of ref document: DE

Date of ref document: 19991125

ITF It: translation for a ep patent filed

Owner name: BIANCHETTI - BRACCO - MINOJA S.R.L.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000120

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000120

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

ET Fr: translation filed
NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000829

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20000831

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: ZENECA LIMITED TRANSFER- ASTRAZENECA AB

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Ref country code: FR

Ref legal event code: CD

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20060706

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20060707

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20060803

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060831

Year of fee payment: 12

Ref country code: DE

Payment date: 20060831

Year of fee payment: 12

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20070829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070831

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20080430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070829